Lewis Au^{1,2,22}, Emine Hatipoglu^{2,3,4,22}, Marc Robert de Massy^{3,4,22}, Kevin Litchfield^{5,22}, Andrew Rowan^{5,22}, Rachael
Thompson⁶, Desiree Schnidrig¹, Fiona Byrne¹, Gordon Beattie^{3,4}, Stuart Horswell⁷, Ni Thompson", Desiree Schnidrig⁺, Fiona Byrne⁺, Gordon Beattie^{-3,}", Stuart Horswell', Nicos Fotiadis", Steve
Hazell⁹, David Nicol¹⁰, Scott Thomas Colville Shepherd^{1,2}, Annika Fendler¹, Robert Mason², Jan Atti Yang²¹, Tom Lund²², Kim Dhillon²⁴, Marcos Duran Vasquez^{3,4}, Ehsan Ghorani^{3,4}, Hang Xu², José Ignacio López²²,
Anna Green¹³, Ula Mahadeva¹³, Elaine Borg¹¹, Miriam Mitchison¹¹, David Moore^{4,11}, Ian Pr Anna Green¹³, Ula Mahadeva¹³, Elaine Borg¹¹, Miriam Mitchison¹¹, David Moore^{4,11}, Ian Proctor¹¹, Mary
Falzon¹¹, Andrew Furness², Lisa Pickering², James L. Reading^{3,4}, Roberto Salgado^{14,15}, Teresa Mara Falzon¹¹, Andrew Furness², Lisa Pickering², James L. Reading^{3,4}, Roberto Salgado^{14,23}, Teresa Marafioti¹¹,
Mariam Jamal-Hanjani^{4,16,17} on behalf of the PEACE Consortium, George Kassiotis⁶, Benny Chain^{18,19} Mariam Jamal-Hanjani^{4,25,17} on behalf of the PEACE Consortium, George Kassiotis⁹, Benny Chain^{2,21,21}, James
Larkin^{2,21}, Charles Swanton^{4,5,18,21,21}, Sergio A Quezada^{3,4,21}, Samra Turajlic^{1,2,21*} on behalf of Larkin^{2,21}, Charles Swanton^{4,5,18,21,21}, Sergio A Quezada^{344,22}, Samra Turajlic^{2,212} on behalf of the TRACERx Renal
Consortium.
*Lead Contact
Samra.turajlic@crick.ac.uk

Consortium.
*Lead Contact
Corresponding authors -
samra.turajlic@crick.ac.us
s.quezada@ucl.ac.uk $rac{1}{2}$ Corresponding

<u>samra.turajlic@</u>

<u>s.quezada@ucl</u>

1. Cancer Dyi Samra.turajlic@crick.ac.ux

s.quezada@ucl.ac.uk

1. Cancer Dynamics Lal

2. Renal and Skin Units same and the control of the same control of the capacity
1. Cancer Dynamics Labo
2. Renal and Skin Units, T
3. Cancer Immunology

-
-
- Example
1. Cancer Dynamics
2. Renal and Skin UI
3. Cancer Immunol
Institute, London $\begin{bmatrix} 1 & 1 \\ 1 & 1 \\ 1 & 1 \end{bmatrix}$ 1. Cancer Primitive Laboratory, The Francis Laboratory, The Francis Crick Institute, London SW3 6
1. Cancer Immunology Unit, Research Department of Haematology, University
Institute, London WC1E 6DD, UK
1. Cancer Research 2. Cancer Immunology Unit, Research Department of Haematology, University Co
Institute, London WC1E 6DD, UK
4. Cancer Research UK Lung Cancer Centre of Excellence, University College London Car
WC1E 6DD, UK
5. Cancer Evolu
- 3. Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
3. Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London
3. Cance Cancer Research UK Lung Cancer
WC1E 6DD, UK
Cancer Evolution and Genome In:
Retroviral Immunology, The Fran
Department of Bioinformatics an
-
-
-
- 4. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK
6. Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
7. Department of Bioinformatics and Biostatis Cancer Evolution

Retroviral Immi

Department of

Cancer Researc

Research and R 5. Retroviral Immunology, The Francis Crick Institute, London NW1 1AT, UK
5. Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, UK.
8. Cancer Research UK Cancer Imaging Centre, Div Francis Crick Institute 1. The Francis Crick Institute

8. Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and

Research and Royal Marsden Hospital, London SW3 6JJ, UK

9. Department of Pathology, the Ro 7. Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute
1. Research and Royal Marsden Hospital, London SW3 6JJ, UK
10. Department of Pathology, the Royal Marsden NHS Foundation Trus
-
-
-
- Research and Royal Marsden Hospital, London SW3 6JJ, UK
9. Department of Pathology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
10. Department of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6 Research and Research and Royal Marsden NHS Foundation
Department of Pathology, the Royal Marsden NHS Foundation
Department of Cellular Pathology, University College Londo
Department of Pathology, Cruces University Hospita 9. Department of Urology, the Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
11. Department of Cellular Pathology, University College London Hospital, London NW1 2BU,
12. Department of Pathology, Cruces University 11. Department of Cellular Pathology, University College London Hospital, London NW1 2BU
12. Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute,
Bizkaia, Spain
13. Department of Cellular Patho 12. Department of Pathology, Cruces University Hospital, Biocruces-Bizkaia Institute, 4890
Bizkaia, Spain
13. Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hos
14. Division of Resear
- Bizkaia, Spain
13. Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, St Thomas' Hospital, London
14. Division of Research, Peter MacCallum Cancer Centre, Melbourne VIC300, Australia Bizantin, Spain
Bepartment of
SE1 7EH, UK
Division of Res
Department of
-
-
- 16. Cancer Metastasis Laboratory, University College London Cancer Institute, London WC1E 6DD, UK
17. Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK
- Division of Ro
Department
Cancer Meta
Department
Division of In 15. Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Antwerp, Belgium.
16. Cancer Metastasis Laboratory, University College London Cancer Institute, London V
17. Department of Medical Oncology, University College Londo 16. Cancer Metastasis Laboratory, University College London Cancer Institute
17. Department of Medical Oncology, University College London Hospitals, Lc
18. Division of Infection and Immunity, University College London, Lo 17. Department of Medical Oncology, University College London Hospitals, London NW1 2BU, UK
18. Division of Infection and Immunity, University College London, London WC1E 6BT, UK
19. University College London Cancer Instit
- 17. Department of Medical Oncology, University College London, London WC1E 6BT, UK
18. Division of Infection and Immunity, University College London, London WC1E 6BT, UK
19. University College London Cancer Institute, Lond
- 18. Division College London Cancer Institute, London WC1E 6DD, UK
19. University College London Cancer Institute, London WC1E 6DD, UK
20. Equal Contributions
21. Equal Contributions
- 20. Equal contributions
21. Equal Contributions
- 20. Equal contributions
21. Equal Contributions
21. Equal Contributions 21. Equal Contributions

Summary
Summary
Antigen recognition and T-cell mediated cytotoxicity in clear-cell renal cell ca
incompletely understood. To address this knowledge gap, we analysed 115 mu
collected from 15 treatment-naïve patients pre- an Antigen

incomplet

collected f

We perfor

analyses Incompletely understood. To address this knowledge gap, we analysed 115 multiregion tumour samples

collected from 15 treatment-naïve patients pre- and post-nivolumab therapy, and at autopsy in three patients.

We performe incollected from 15 treatment-naïve patients pre- and post-nivolumab therapy, and at autopsy in three patients.
We performed whole-exome sequencing, RNAseq, TCRseq, multiplex immunofluorescence and flow cytometry
analyses collected whole-exome sequencing, RNAseq, TCRseq, multiplex immunofluorescence and flow cytometry
analyses and correlated with clinical response. We observed pre-treatment intratumoural TCR clonal
expansions suggesting pre analyses and correlated with clinical response. We observed pre-treatment intratumoural TCR clonal
expansions suggesting pre-existing immunity. Nivolumab maintained pre-treatment expanded, clustered TCR
clones in responder expansions suggesting pre-existing immunity. Nivolumab maintained pre-treatment expanded, clustered TCR
clones in responders, suggesting ongoing antigen-driven stimulation of T-cells. T-cells in responders were
enriched fo expansions in responders, suggesting ongoing antigen-driven stimulation of T-cells. T-cells in responders were
enriched for expanded TCF7⁺CD8⁺ T-cells and upregulated GZMK/B upon nivolumab-binding. By contrast,
nivolum enriched for expanded TCF7⁺CD8⁺ T-cells and upregulated GZMK/B upon nivolumab-binding. By contrast, nivolumab promoted accumulation of new TCR clones in non-responders, replacing pre-treatment expanded clonotypes. In t enriched for expanded TCF7*CD8*
nivolumab promoted accumulation
clonotypes. In this dataset, mutati
endogenous retrovirus expression
responses in ccRCC by binding pre-e notypes. In this dataset, mutational features did not correlate with response to nivolumab and human
endogenous retrovirus expression correlated indirectly. Our data suggests that nivolumab potentiates clinical
responses i endogenous retrovirus expression correlated indirectly. Our data suggests that nivolumab potentiates clinical
responses in ccRCC by binding pre-existing expanded CD8⁺ T-cells to enhance cytotoxicity.
Keywords: clear ce

responses in ccRCC by binding pre-existing expanded CD8⁺ T-cells to enhance cytotoxicity.
 Keywords: clear cell renal cell carcinoma, nivolumab, immunotherapy, cytotoxicity, TCR clonal maintenance,

TCR clonal replacem responses in ccRCC by binding pre-existing expanded CD8⁺ T-cells to enhance cytotoxicity.
 Keywords: clear cell renal cell carcinoma, nivolumab, immunotherapy, cytotoxicity, TCR

TCR clonal replacement, human endogenou ו
ד TCR clonal replacement, human endogenous retrovirus, longitudinal sampling, multiregion sampling, autopsy
TCR clonal replacement, human endogenous retrovirus, longitudinal sampling, multiregion sampling, autopsy TCR clonal replacement, human endogenous retrovirus, longitudinal sampling, multiregion sampling, autopsy

Introduction
Clear-cell renal cell carcinoma (ccRCC) is the most common histological subtype of ki
global incidence². Instances of spontaneous regression³⁻⁵, efficacy of interleukin-2^{6,}
inhibitors (CPI)⁸⁻¹¹ conf Clear-cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer¹ with a rising
global incidence². Instances of spontaneous regression³⁻⁵, efficacy of interleukin-2^{6, 7} and immune c global incidence². Instances of spontaneous regression³², efficacy of interleukin-2^{5, 7} and immune checkpoint
inhibitors (CPI)⁸⁻¹¹ confirm ccRCC as an immunogenic tumour type, but the nature of the antigenic stimul inhibitors (CPI)⁸⁻¹¹ confirm ccRCC as an immunogenic tumour type, but the nature of the antigenic stimulus is
unknown. ccRCC carries a modest tumour mutational burden (TMB) (median of 1.42 mutations per megabase
(mut/mb (mut/mb))¹², ten-fold lower than melanoma and comparable to immune 'cold' tumours¹³. In contrast to melanoma¹⁴, non-small cell lung cancer^{15, 16}, bladder¹⁷, and colorectal cancers¹⁸, TMB does not associate wit (mut/mb))¹², ten-fold lower than melanoma and comparable to immune 'cold' tumours¹³. In contrast to melanoma¹⁴, non-small cell lung cancer^{15, 16}, bladder¹⁷, and colorectal cancers¹⁸, TMB does not associate wit melanoma¹⁴, non-small cell lung cancer^{15, 16}, bladder¹⁷, and colorectal cancers¹⁶, TMB does not associate with
CPI response in ccRCC¹⁹⁻²¹. Kidney tumours are enriched for frameshift insertion and deletions (fsIND CPI response in ccRCC¹⁹⁻²¹. Kidney tumours are enriched for frameshift insertion and deletions (fsINDELs)²², which can generate novel open-reading frames triggering a large number of highly distinct neoantigens.
Howev However, fsINDEL burden has so far not been shown to predict benefit from CPI in patients with ccRCC^{20, 21}, again in contrast to other tumour types^{22, 23}. Mutations in *PBRM1* are reported to be enriched in responders However, fsINDEL burden has so far not been shown to predict benefit from CPI in patients with ccRCC^{20, 21}, again in contrast to other tumour types^{22, 23}. Mutations in *PBRM1* are reported to be enriched in responders

again in contrast to other tumour types^{22, 23}. Mutations in *PBRM1* are reported to be enriched in responders to
CPI in ccRCC^{19, 24, 25}, though this has not been observed consistently^{20, 21, 26, 27}.
Large-scale, pan CPI in ccRCC^{19, 24, 25}, though this has not been observed consistently^{20, 21, 26, 27}.
Large-scale, pan-cancer transcriptional analyses have shown ccR
immune-infiltrated solid tumour types^{1, 28}. However, in contrast Infiltrated solid tumour types^{1, 28}. However, in contrast to other cancers, immune infiltration
In s with poorer prognosis in ccRCC²⁹. The baseline composition of the infiltrate has been linked to CPI
with high T-cell immune-infiltrated solid tumour types², ∞ . However, in contrast to other cancers, immune infiltration correlates with poorer prognosis in ccRCC²⁹. The baseline composition of the infiltrate has been linked to CPI benefit, with high T-cell/low myeloid infiltration and high B-cell abundance enriched in responders to atezolizumab (anti-PD1)²⁰ and nivolumab (anti-PD1)³⁰, respectively.

Intratumour heterogeneity (ITH) can impact th

benefit) in the myeloid infinite interaction and high B-cell abundance entities in response in a
atezolizumab (anti-PDL1)²⁰ and nivolumab (anti-PD1)³⁰, respectively.
Intratumour heterogeneity (ITH) can impact therapy r atezolizumab (anti-PDL1)²⁰ and nivolumab (anti-PD1)³⁰, respectively.
Intratumour heterogeneity (ITH) can impact therapy resporesistance mechanisms, loss of HLA heterozygosity, and loss of c
feature of ccRCC that associ Intratumour heterogeneity (ITH) can impact therapy response in cancer in called 3³¹⁻³³. ITH is a frequent
of ccRCC that associates with outcomes following surgery, but its impact on therapy response is
 $^{34-36}$. Further resistance mechanisms, loss of HLA heterozygosity, and loss of clonal neoantigens³¹⁻³³. ITH is a frequent
feature of ccRCC that associates with outcomes following surgery, but its impact on therapy response is
unknown³⁴

unknown³⁴⁻³⁶. Furthermore, ITH complicates evaluation of prognostic and predictive biomarkers in all settings.
ADAPTeR (NCT02446860) is a phase II, single-arm, open-label study of nivolumab in treatment-naive
metastatic ADAPTeR (NCT02446860) is a phase II, single-arm, open-label study of nivolumab in treatment-naive
metastatic ccRCC. Patients underwent multiregional fresh tumour sampling of primary and/or metastatic sites
at baseline, wee TRACERx Renal (TRAcking Cancer Evolution through therapy [Rx]; NCT03226886), and the PEACE (Posthumous at baseline, week-9, at surgery (if performed), and disease progression. Key aim of the study was to evaluate
genomic and tumour immune microenvironment features, throughout therapy. Patients were co-recruited to
TRACERx R at baseline, week-9, at surgery (if performed), and disease progression. By aim of the studies in genomic and tumour immune microenvironment features, throughout therapy. Patients were co-recruited to TRACERx Renal (TRAcki TRACERX Renal (TRAcking Cancer Evolution through therapy. RX); NCT03226886), and the PEACE (Posthumous
Evaluation of Advanced Cancer Environment; NCT03004755) studies to expand the spatial and temporal
breadth of profiling TRACERTR RENAL (TRACKING CANCERT EVOLUTION INTERPTON) TO CONSUMIT THERMAN EVALUATION EVALUATION EVALUATION EVA
Breadth of profiling. We present an integrated analysis of clinical features and whole-exome and RNA
sequencing breadth of profiling. We present an integrated analysis of clinical features and whole-exome and RNA sequencing, TCR profiling and multiplex immunohistochemistry/immunofluorescence (mIHC/IF); and high dimensional flow cytometry across longitudinal, multiregion fresh tumour samples in this cohort (Figure 1A). dimensional flow cytometry across longitudinal, multiregion fresh tumour samples in this cohort (Figure 1A).

Patient
15 patie
shown i
Metasta
(Decem Patient characteristics are shown in **Table S1A**. 13 (87%) patients had intermediate- or poor-prognostic risk disease (by International Metastatic RCC Database Consortium risk categorisation; IMDC) (**STAR Methods**)³⁷. At Metastatic RCC Database Consortium risk categorisation; IMDC) (**STAR Methods**)³⁷. At clinical datalock (December 2018), median follow up was 12.5 months. Six deaths occurred, all due to progressive disease. The median p (December 2018), median follow up was 12.5 months. Six deaths occurred, all due to progressive disease. The median progression-free (PFS) and overall survival (OS) were 4.1 and 12.5 months, respectively. For translational $37.$ At clinical datalock
progressive disease. The
onths, respectively. For
se (PR) or stable disease
Methods) for ≥ 6 months Median progression-free (PFS) and overall survival (OS) were 4.1 and 12.5 months, respectively. For
translational analyses, we defined 'responders' as patients who had a partial response (PR) or stable disease
(SD) as meas enrolment regardless of best-response (ten patients). By these criteria, five patients (33%) had a PR, where transference analyses, we defined 'responders' as patients who had a partial responder (SD) as measured by Response Evaluation Criteria In Solid Tumours criteria (STAR Methods) for ≥ 6 months of (five patients). 'Non-r (SD) as measured by Responders' were classified as patients with progressive disease (PD) within 6 months of
enrolment regardless of best-response (ten patients). By these criteria, five patients (33%) had a PR, where
one one patient (ADR005) had short-lived PR (<6 months, non-responder). Six patients (40%) had SD, where one
patient (ADR011) had durable response (>6 months SD, responder) (**Figure S1A and Table S1A**). Two patients
underwent patient (ADR011) had durable response (>6 months SD, responder) (**Figure S1A and Table S1A**). Two patients underwent a cytoreductive nephrectomy during the course of the study. We observed no associations patient a cytoreductive nephrectomy during the course of the study. We observed no associations
between age, sex, IMDC risk category, and presence of sarcomatoid/rhabdoid features (n=2) and response to
nivolumab (Table S1A between age, sex, IMDC risk category, and presence of sarcomatoid/rhabdoid features (n=2) and response to
nivolumab (**Table S1A**). Overall, these clinical outcomes data are consistent with a larger phase II (n=110)
cohort nivolumab (Table S1A). Overall, these clinical outcomes data are consistent with a larger phase II (n=110)

nivolumation (Table S1A). Overally mode annual outcomes and are considered in the stager phase II (n=110).

Cohort study of first-line pembrolizumab in patients with mRCC³⁸.

All patients underwent image-guided percutane Molecular features do not correlate with nivolumab response
All patients underwent image-guided percutaneous tumour biopsies with additional archived and fresh $\frac{1}{t}$ Molecular features are correlate the non-terminal response
All patients underwent image-guided percutaneous tumour
samples collected via TRACERx Renal and PEACE studies. 15
treatment samples. In total, 115 tumour samples (samples collected via TRACERx Renal and PEACE studies. 15 patients had baseline samples, and 13 post-
treatment samples. In total, 115 tumour samples (fresh and archived) were available for translational analyses
(Figure S were excluded due to low tumour purity as expected with image-guided biopsies. 59 tumour samples from 13 (Figure S1A for consort diagram; Supplemental Data Table 1 for sample characteristics). 81 fresh tumour samples and matched germline DNA underwent whole-exome sequencing (WES). Subsequently, 21 samples
were excluded due to samples and matched germline DNA underwent whole-exome sequencing (WES). Subsequently, 21 samples
were excluded due to low tumour purity as expected with image-guided biopsies. 59 tumour samples from 13
patients were of su

patients were of sufficient quality for downstream analyses (STAR Methods).
Median sequencing depth was 199x (range 130-359x) (Supplemental Data Table 1). Neither pre-
treatment TMB (median 0.9 mut/mb; range 0.4-11.1), nor Median sequencing depth was 199x (range 130-359x) (Supplement treatment TMB (median 0.9 mut/mb; range 0.4-11.1), nor fsINDEL load (m with response to nivolumab (Figure S1B). Reduction of nsSNVs and fsINDI baseline has been and subsequent elimination of tumour cells under CPI. To explore the contribution of neoantigens to anti-PD1
response, we asked whether mutations which have undergone genomic contraction post-treatment were The response to nivolumab (Figure S1B). Reduction of nsSNVs and fsINDELs post-treatment compared to baseline has been referred to as "genomic contraction"³⁹, and may reflect immune recognition of neoantigens and subseque baseline has been referred to as "genomic contraction"³⁹, and may reflect immune recognition of neoantigens
and subsequent elimination of tumour cells under CPI. To explore the contribution of neoantigens to anti-PD1
res baseline has been referred to as "genomic contraction"³⁹, and may reflect immune recognition of neoantigens
and subsequent elimination of tumour cells under CPI. To explore the contribution of neoantigens to anti-PD1
res and subsequent elimination of tumour cells under elimination of the contraction post-treatment were
enriched for mutations which encoded neoantigens (STAR Methods). We found no significant difference in
contraction of neoa reponsive of the sponse, which encoded neoantigens (**STAR Methods**). We found no significant difference in contraction of neoantigen-encoding mutations compared to the remaining non-synonymous mutations (**Figure S1C**).
S1

entraction of neoantigen-encoding mutations compared to the remaining non-synonymous mutations (Figure

SIC).

Molecular features of this cohort were typical of ccRCC^{1, 35}, including mutations in *VHL* (77%, and *VHL*

m S1C).

Molecular features of this cohort were typical of ccRCC^{1, 35}, including mutations in *VHL* (77%, and *VHL*

methylation in additional 15%), *PBRM1* (62%), *SETD2* (38%), *BAP1* (15%), and *KDM5C* (38%) (**Figure 1B** S1C). Molecular features of this cohort were typical of ccRCC^{1, 35}, including mutations in *VHL* (77%, and *VHL*
methylation in additional 15%), *PBRM1* (62%), *SETD2* (38%), *BAP1* (15%), and *KDM5C* (38%) (**Figure 1B**) Increased sensitivity of multiregion sampling revealed the presence of subclonal driver events in most
Increased sensitivity of multiregion sampling revealed the presence of subclonal driver events in most
4 Increased sensitivity of multiregion sampling revealed the presence of subclonal driver events in most

patients. Instances of composite mutations (two or more nonsynonymous somatic mutations in the same gene
and tumour sample⁴⁰) involving *SETD2*, *KDM5C*, and *TSC2* were detected. There was no association between
any mu and tumour sample³⁰) involving *SETD2, KDM5C,* and *TSC2* were detected. There was no association between
any mutations, regardless of their clonality, and response to nivolumab, including *PBRM1* (*P*>0.05, Fisher's
ex any mutations, regardless of their clonality, and response to involuntab, including PBRM1 (P>0.05, Fisher's exact test). Copy number landscape was also typical of ccRCC with clonal loss of 3p25.3 detected in all tumours an and 9p21.3 and/or 14q31.1 loss observed in 12/13 patients, consistent with our previous findings in metastatic
ccRCC³⁶ (Figure 1B). In agreement with other studies, weighted genome instability index (wGII) as a global
m and 9p21.3 and 9p21.3 and 9p21.1 and 9p3.1 a
measure of chromosomal complexity was not predictive of nivolumab response (median 0.29, range 0.04-0.71;
P=0.0 ccRCC³⁶ (Figure 1B). In agreement with other studies, weighted genome instability index (wGII) as a global
measure of chromosomal complexity was not predictive of nivolumab response (median 0.29, range 0.04-0.71;
P=0.076 $P=0.076$) (Figure S1B; STAR Methods)^{19, 20}. No driver SCNAs associated with response while loss of 10q23.31, previously reported to associate with benefit from nivolumab¹⁹, showed only a trend towards enrichment in r previously reported to associate with benefit from nivolumab¹⁹, showed only a trend towards enrichment in
responders (P=0.07, Fisher's exact test). However, the small cohort size was likely statistically underpowered
to

responders (P=0.07, Fisher's exact test). However, the small cohort size was likely statistically diderpowered
to robustly detect response associations of these mutational events.
through post-mortem sampling. ADR015 had s Intermetastatic heterogeneity can underpin differential the
through post-mortem sampling. ADR015 had stage IV disease at en
bed recurrence, mixed lytic/sclerotic bone, and nodal disease. A
treatment. PFS was 8.4 months und Intermetastatic heterogeneity can underpin differential therapy response⁴⁴⁻⁴⁴, which we evaluated
post-mortem sampling. ADR015 had stage IV disease at enrolment into ADAPTeR, including surgical
urrence, mixed lytic/scler bed recurrence, mixed lytic/sclerotic bone, and nodal disease. A tonsillar metastasis was resected pre-
treatment. PFS was 8.4 months under nivolumab (best response: PR), patient progressed with multiple brain
metastases a which progressed (brain) and responded (nodal metastases) under nivolumab. Mutational profile of a thyroid metastasis incidentally found at autopsy reflected lesions which responded under treatment (Figures 1B and metastastas and whole exome sequenced. We found evidence of genetic divergence between disease sites
which progressed (brain) and responded (nodal metastases) under nivolumab. Mutational profile of a thyroid
metastasis inc metastasis incidentally found at autopsy reflected lesions which responded under treatment (**Figures 1B and**
 S2B). Significantly higher median TMB (10.8 mut/Mb) and fsINDEL load (166) was evident in the progressive

bra **S2B**). Significantly higher median TMB (10.8 mut/Mb) and fsINDEL load (166) was evident in the progressive brain and resected tonsillar metastases, consistent with a hypermutant genotypic background in these sites, compa Sammann, migher median TMB (10.8 mun, 10.8 mutatement (10.9) was enterted in these sites,

compared with treatment-responsive disease sites (median TMB 1.3 mut/Mb; fsINDEL load 8). Accordingly, we

observed higher neoanti compared higher neoantigen load in brain and tonsillar metastases (**Figure S2B**). Excess mutations carried the
signature of C>T at GpCpN trinucleotides (Signature 15) associated with defective DNA mismatch repair¹³. We
o observed a pathogenic mutation in *MLH1*⁴⁵ with loss of heterozygosity (LOH; biallelic inactivation through canonical 3p loss), in the sites with excess TMB (**STAR Methods**), as well as a beta-2-microglobulin (*B2M*) mut observed a pathogenic mutation in *MLH1⁴³* with loss of heterozygosity (LOH; biallelic inactivation through canonical 3p loss), in the sites with excess TMB (**STAR Methods**), as well as a beta-2-microglobulin (*B2M*) mut canonical 3p loss), in the sites with excess TMB (STAR Methods), as well as a beta-2-microglobulin (B2M) mutation with LOH (biallelic inactivation through 15q loss) (Figure S2B; STAR Methods). Functional *MLH1* mutations r mutation with LOH (biallelic inactivation through 15q loss) (Figure 32B; STAR Methods). Functional MEH1
mutations result in mismatch repair-deficiency (MMRd) and high immunogenicity driven by accumulation of
neoantigens ac neoantigens across MMRd tumours⁴⁰. *B2M* encodes a protein subunit integral for major histocompatibility
complex class I (MHC-I) endogenous peptide presentation⁴⁷. Taken together, our findings suggest that in this
case complex class I (MHC-I) endogenous peptide presentation⁻'. Taken together, our findings suggest that in this case somatic loss of *MLH1* led to accumulation of an uncharacteristically high number of neoantigens in the co case somatic loss of *MLH1* led to accumulation of an uncharacteristically high number of neoantigens in the
context of ccRCC, and subsequent loss of antigen presentation via *B2M* and immune escape, as observed
during niv context of center, and subsequent loss of antigen presentation via B2M and immune escape, as observed
during nivolumab treatment. MMRd in ccRCC has been reported but is rare⁴⁸, and B2M loss as a mechanism of
immunotherap during nivolumab treatment. MMRd in ccRCC has been reported but is rare⁴⁶, and *B2M* loss as a mechanism of
immunotherapy resistance⁴⁹ has not to date been described in ccRCC.
Ma**jority of HERVs detected in ccRCC tumou**

immunotherapy resistance³⁵ has not to date been described in ccRCC.
Majority of HERVs detected in ccRCC tumour samples are expressed l
In light of reports associating intratumoural cytotoxic T-cells²⁸ or respo
human en $\frac{1}{1}$ In light of reports associating intratumoural cytotoxic T-cells²⁸ or response to nivoluma
human endogenous retroviruses (HERVs) in ccRCC, we examined previously published
human endogenous retroviruses (HERVs) in ccRCC, w human endogenous retroviruses (HERVs) in ccRCC, we examined previously published HERV signatures in the human endogenous retrovirus, we examined previously published HERVs, we examined the HERVs signatures in the s
S

(week-9), representing 14 patients (**Figures S1A**; **STAR Methods**).
Two of the previous reports of HERV associations^{28, 50} used 66 HERV loci annotated by Mayer et al.⁵³,
and another study⁵¹ selected 3,173 HERV loci (we exactly representing 14 patients (Figure s 14, 2011) and the previous reports of HERV associations^{28, 50} us
and another study⁵¹ selected 3,173 HERV loci annotated by Varging
repeat region annotation which we descr and another study⁵¹ selected 3,173 HERV loci annotated by Vargiu et al.⁵⁴. We mapped these loci to a custom
repeat region annotation which we described previously⁵⁵ (**STAR Methods**). First, we observed discrepancies and another study⁻⁺ selected 3,173 HERV loci annotated by Vargiu et al.⁵⁴. We mapped these loci to a custom
repeat region annotation which we described previously⁵⁵ (**STAR Methods**). First, we observed discrepancies
 repeat region annotation which we described previously³⁵ (STAR Methods). First, we observed discrepancies
between our HERV loci annotations with those in Mayer et al. and/or Vargiu et al., including HERV loci that
were c were considered as a single integration in our annotation that appeared fragmented in the Mayer et al. and/or
Vargiu et al. annotations, and vice versa (**Supplemental Data Table 2**). Further, we found HERV annotations in
b integrations to include exons of adjacent genes belonging to separate transcription units (**Figure S3A**). We
note that these discrepancies affected HERV integrations previously associated with cytotoxic T-cell presence both Mayer et al. and Vargiu et al. that were either incomplete or extended beyond the boundaries of integrations to include exons of adjacent genes belonging to separate transcription units (**Figure S3A**). We note that th integrations to include exons of and the separate genes belonging to separate transcription units (Figure 120, 110
note that these discrepancies affected HERV integrations previously associated with cytotoxic T-cell presen

or ccRCC response to immunotherapy, such as ERV3-2 and ERVK-10²⁰²² (**Figure S3A**). The previously annotated
66 and 3,173 HERVs finally corresponded to 7,989 repeat annotations by our method⁵⁵.
We evaluated previously r We evaluated previously reported HERV signatures^{28, 50, 51, 56} in our cohort and did not observe a
le between responders and non-responders, nor significant change in their expression levels following
ab (**Figure 2A**). F nivolumab (Figure 2A). Further, we found that the HERVs with the highest expression and, therefore, strongest
contribution to previously described signatures^{28, 50, 51, 56}, such as ERV3-2 and ERVK-10, were not specific t nontribution to previously described signatures^{28, 50, 51, 56}, such as ERV3-2 and ERVK-10, were not specific to ccRCC, but were highly expressed in purified immune cell subsets (Figure S3B; STAR Methods). Therefore, it s ccRCC, but were highly expressed in purified immune cell subsets (**Figure S3B; STAR Methods**). Therefore, it
seems likely that their reported association with response to CPI is underpinned by immune infiltration (which
in

seems likely that their reported association with response to CPI is underpinned by immune infiltration (which
in itself is linked to response^{20, 21}) and high HERV expression in immune cells.
Next, to examine a possible in itself is linked to response^{20, 21}) and high HERV expression in immune cells.
Next, to examine a possible correlation with HERVs that we
expression of 570 transcripts previously identified through *de novo* transcr
L Next, to examine a possible correlation with HERV that were criter possibly to overlap with
nents and with high specificity to $ccRCC^5$ (**STAR Methods**). Most $ccRCC$ -specific LTR elements were
d (≥0.5 TPM) in the majority of samples in this study and 12 ccRCC-specific LTR elements, from nine
loci, were differentially expressed (≥2-fold change, qLTR elements and with high specificity to $ccRCC⁵⁷$ (STAR Methods). Most $ccRCC$ -specific LTR elements were expressed (≥ 0.5 TPM) in the majority of samples in this study and 12 $ccRCC$ -specific LTR elements, from LTR elements and with high specificity to ccRCC²⁷ (**STAR Methods**). Most ccRCC-specific LTR elements were expressed (≥0.5 TPM) in the majority of samples in this study and 12 ccRCC-specific LTR elements, from nine disti expression levels were significantly altered following nivolumab (Figure 2B). These transcripts included
members of the HERV-E group (ERVE-4⁵³ and HERV4700⁵¹) that were previously associated with
immunotherapy response members of the HERV-E group (ERVE-4⁵³ and HERV4700⁵¹) that were previously associated with
immunotherapy response in ccRCC⁵¹⁻⁵³. However, we found that these transcripts were expressed
predominantly in pre-treatment immunotherapy response in ccRCC³¹⁻³³. However, we found that these transcripts were expressed
predominantly in pre-treatment non-responders (**Figure 2B**). Tumour purity in pre-treatment samples was
significantly higher i predominantly in pre-treatment non-responders (rigate 2B). Famour punty in pre-treatment samples was
significantly higher in non-responders compared to responders (reflecting lower levels of immune infiltration)
(Figure 2C Figure 2C). Consequently, the level of HERV expression correlated with tumour purity (Figure 2D), explaining
higher expression in non-responders. Post-treatment, we observed that the expression of ccRCC-specific LTR
transc (Figure 2C). Consequently, the level of HERV expression correlation in non-responders. Post-treatment, we observed that the expression of ccRCC-specific LTR transcripts in non-responders normalised relative to responders (

nivolumab-induced immune infiltration lowering tumour purity, which in turns lowered the abundance of
tumour-specific LTR transcripts in the biopsies.
In summary, although we did observe correlations between expression of the the biology is the biology of the biology were indirect. Firstly, certain HERVs, such as In summary, and sign we did one correlations as the observe correlations of certain of certain HERVs and FRVS-2 and FRVK-10, were associated with immunotherapy linest. Firstly, certain HERVs, such as ERV3-2 and ERVK-10, we were indirect. Firstly, certain HERVs, such as ERV3-2 and ERVK-10, were associated with immunotherapy were indirect. Firstly, certain HERVs, such as ERVs, such as ERV3-2 and ERVK-10, were associated with immunotherapy ϵ

abundance of ccRCC-specific HERV transcripts, such as ERVE-4 and HERV4700, reflected tumour purity and
correlated with response to immunotherapy indirectly as the least infiltrated tumours responded the least to
therapy. abundance of critic specific HERV transcripts, such as ERVE-4 and HERV470, reflects tament purity and
correlated with response to immunotherapy indirectly as the least infiltrated tumours responded the least to
Nivolumab i therapy.
Nivolumab induces T-cell activation and upregulation of TCR signalling in responders
Next, we evaluated the composition of the immune infiltrate in the bulk transcriptome of tumour samples pre-

Nivolumab induces T-cell activation and upregulation of TCR signalling in responders
Next, we evaluated the composition of the immune infiltrate in the bulk transcriptome of tumour samples pre-
and post-nivolumab. We perfo |
|
|
| (Next, we evaluated the composition of the immune infiltrate in the bulk transcriptome
and post-nivolumab. We performed differential gene expression, gene set enrichme
immune subset deconvolution⁵⁸ (STAR Methods). Immune compared to non-responders ($P=0.031$ and $P=0.017$, respectively), and higher post-treatment compared to immune subset deconvolution⁵⁸ (STAR Methods). Immune infiltration and cytotoxicity signatures were observed in all timewous and all time points, but their expression was significantly higher in responders compared to no immune subset deconvolution³⁶ (STAR Methods). Immune infiltration and cytotoxicity signatures were
observed in all tumours and all time points, but their expression was significantly higher in responders
compared to non pre-treatment in both groups (Figures 3A-3D). Treatment-induced enrichment of "immune-activation" and the
"TCR signalling" pathways was evident in responders but not in non-responders (Figures 3E and 3F).
Specifically, usi TCR signalling" pathways was evident in responders but not in non-responders (Figures 3E and 3F).

Specifically, using the Danaher signature⁵⁸, the T-cell score expression was significantly higher in responders at

pre- Specifically, using the Danaher signature⁵⁸, the T-cell score expression was significantly higher in responders at
pre- and post-treatment timepoints (*P*=0.019 and *P*=0.038 respectively) (**Figure S4**). We also observe Specifically, using the Danaher signature³⁸, the T-cell score expression was significantly higher in responders at
pre- and post-treatment timepoints (*P*=0.019 and *P*=0.038 respectively) (**Figure S4**). We also observe

pre- and post-treatment timepoints (P=0.019 and P=0.038 respectively) (Figure 34). We also observe a trend
towards higher B-cell expression scores in responders pre-treatment, but not post-treatment (Figure S4).
Finally, Finally, we evaluated the association between previously published associations between
expression signatures and CPI response in metastatic ccRCC (STAR Methods). IMmotion150 study
signature²⁰, but not T_{eff}^{high}/Myel Finally, the evaluation are associated previously published association assumed to the $r_{\text{eff}}^{\text{high}}$
and $P=0.038$ at pre- and post-treatment timepoints, respectively) (Figure S4). The 26-gene Javelin101
and $P=0.038$ a signature²⁰, but not T_{eff}^{high}/Myeloid^{low} signature was enriched in responders compared to non-responders (*P*=0.042 and *P*=0.038 at pre- and post-treatment timepoints, respectively) (**Figure S4**). The 26-gene Jav _{mgn}
ers
.01
nd
A), $(P=0.042$ and $P=0.038$ at pre- and post-treatment timepoints, respectively) (Figure S4). The 26-gene Javelin101 "^{6"}/Myeloid["]" signature was enriched in responders compared to non-responders
pre- and post-treatment timepoints, respectively) (**Figure S4**). The 26-gene Javelin101
iched in responders compared to non-responders (*P* (P=0.042 and P=0.038 at pre- and post-treatment timepoints, respectively) (Figure 34). The 20-gene Javelin101
signature²¹ was also enriched in responders compared to non-responders (P=0.028 and P=0.038 at pre- and
postsignature²¹ was also enriched in responders compared to non-responders (*P*=0.028 and *P*=0.038 at pre- and post-treatment timepoints, respectively). Individual marker genes for T-cell infiltration (CD3E, CD8A), activat activation (GZMB), and TCF7 expression (reported as predictive of CPI response⁵²), were consistently higher in
responders compared to non-responders, particularly post-treatment (**Figure S4**). Overall, previously publish responders compared to non-responders, particularly post-treatment (Figure S4). Overall, previously published
signatures of response validate in our cohort in spite of inherent differences in treatment regimens, and tissue responders compared to non-response validate in our cohort in spite of inherent differences in treatment regimens, and tissue
type used for transcriptome profiling.
CD8⁺ T-cells upregulate GZMB following nivolumab in res

the accordination
CD8⁺ T-cells upregulate GZMB followi
Following antigen stimulation CD8⁺ T-
killing. To investigate the phenotype l
|
|
| CD8
Follo
killing
immu
tumc
antib T-cells undergonal comparison in the species wing antigen stimulation CD8⁺ T-cells undergo cytotoxic difference g. To investigate the phenotype of the T-cells in the tumo
unoblistochemistry (mIHC) and immunofluorescence Following antigen stimulation CD8⁺ T-cells undergo cytotoxic differentiation in order to mediate tumour cell
killing. To investigate the phenotype of the T-cells in the tumours under study, we performed multiplex
immunoh immunohistochemistry (mIHC) and immunofluorescence (mIF) on 61 formalin-fixed paraffin-embedded
tumour samples (41 pre-treatment; 20 post-treatment) from 14 patients (**Figure S1A**). We applied bespoke
antibody panels (3 ma tumour samples (41 pre-treatment; 20 post-treatment) from 14 patients (**Figure S1A**). We applied bespoke
antibody panels (3 markers for mIHC, 6 markers for mIF) to quantify and characterise infiltrating immune cells
(STAR

antibody panels (3 markers for mIHC, 6 markers for mIF) to quantify and characterise infiltrating immune cells

(STAR Methods).

We observed no difference in T-cell number (CD8⁺, CD4⁺, CD8⁺CD4⁺, or Tregs), or CD8⁺ We observed no difference in T-cell number (CD8⁺, CD4⁺, CD8⁺CD4⁺, or Tregs), or CD8⁺/Treg and
CD4⁺effector/Treg between response groups, either pre- or post-treatment (**Figures 4A and S5A-C**). Total PD1
expres expression did not differ in the two groups (**Figures 4B**). Overall quantified GZMB expression (*P*=0.024) and
GZMB expression on CD8⁺ T-cells (*P*=0.047) were significantly higher in responders compared to noneffector, Treg between response of Figures 4B). Overall quantified GZMB expression (P=0.024) and
B expression on CD8⁺ T-cells (P=0.047) were significantly higher in responders compared to non-
7 GZMB expression on $CD8^+$ T-cells ($P=0.047$) were significantly higher in responders compared to non-
 7 GZMB expression on CD8+ T-cells (P=0.047) were significantly higher in responders compared to non-

samples were available, we observed a trend for upregulation of GZMB expression on CD8⁺ T-cells in
responders but not in non-responders, following nivolumab (Figure S5D). CD163⁺ myeloid cell level alone or as
a ratio t responders but not in non-responders, following nivolumab (**Figure S5D**). CD163⁺ myeloid cell level alone or as
a ratio to T-cells (CD3⁺/CD163⁺ and CD8⁺/CD163⁺) did not associate with response (**Figures 4A and S5** a ratio to T-cells (CD3⁻/CD163⁻ and CD8⁻/CD163⁻) did not associate with response (**Figures 4A and S5C**).
Compared to non-responders we observed significantly more B-cells in responders pre- but not post-
treatment

data. For example, increased B-cells and higher GZMB expression in responders evident by mIHC/mIF were treatment (*P*=0.02 and 0.96, respectively) (**Figures 4A**). There were no differences in the number of plasma
cells between response groups (*P*=0.23 and 0.54 pre- and post-treatment, respectively) (**Figures 4A and S5A**). cells between response groups (P=0.23 and 0.54 pre- and post-treatment, respectively) (Figures 4A and 35A).
We note a certain number of discrepancies in our observations made from bulk RNAseq and mIHC/IF
data. For example, non-significant trends by RNAseq (Figure S4), and the opposite trend was observed for CD4⁺/8⁺ T-cell numbers
and PD-1 expression. These findings likely reflect the known weak correlation between protein and mRNA
levels non-significant trends by RNAseq (**Figure S4**), and the opposite trend was observed for CD4⁻/8⁻ T-cell numbers
and PD-1 expression. These findings likely reflect the known weak correlation between protein and mRNA
leve /8
rot
ssif and Porels for many genes, as well as sensitivity limitations of immune deconvolution and classification by bulk
ANAseq⁶⁰ as compared to the single-cell resolution afforded by histology-based methods.
Maintenance of TCR

RNAseq⁶⁰ as compared to the single-cell resolution afforded by histology-based methods.
Maintenance of TCR clonal expansion and clustering support ongoing antigen-driven stimulation of T-cells in
responders RNAseq[∞] as compared to the single-cell resolution afforded by histology-based methods.
Maintenance of TCR clonal expansion and clustering support ongoing antigen-driven stil
responders
Next, we sequenced the β-chain TCR

|
|
| Maintenance of TCR clonal expansion and clustering support ongoing antigen-driven stimulation of Terminia

Next, we sequenced the β -chain TCR repertoires from 64 tumour and 29 peripheral blood mononuclear cell

(PBMCs) Rext, we sequenced the β-chain TCR repertoires from 64 tumour and 29 peripheral blood mononuclear cell
(PBMCs) samples from 14 patients pre- and post-treatment (**Figure S1A; STAR Methods**). To mitigate against
effects of

effects of intratumour TCR heterogeneity⁶¹⁻⁶³ (Figures S6A and S6B), we pooled TCR sequences from multiple
tumour regions for each patient at different timepoints.
Cohort-wide median number of unique β-chain transcripts effects of intratumour TCR heterogeneity³²⁵³ (**Figures S6A and S6B**), we pooled TCR sequences from multiple
tumour regions for each patient at different timepoints.
Cohort-wide median number of unique β-chain transcript tumour regions for each patient at different timepoints.

Cohort-wide median number of unique β-chain transcripts in tumour and blood samples was 3,644

and 21,370, respectively. For each pooled sample, we quantified TCR Cohort-wide meaning median number of unique β-chain transcripts in tumour and blood camples median of the score
Score (low scores correlate with more diverse repertoire and high scores with dominant clones) (STAR
S). TCR c clonality score (low scores correlate with more diverse repertoire and high scores with dominant clones) (STAR
Methods). TCR clonality was overall higher in tumour samples compared to PBMCs (Figure 5A), potentially
reflect significantly different between tumour and PBMCs, irrespective of response (Figures 5B and S6C,E).
Contraction and expansion of CDR3s present in pre- and post-treatment samples was not associated with
response. This was tr Methods). The intertumoural expansion of specific TCR clones. T-cell clonal contraction and expansion was not
significantly different between tumour and PBMCs, irrespective of response (Figures 5B and S6C,E).
Contraction a Expansion and expansion of CDR3s present in pre- and post-treatment samples was not associated with
response. This was true for tumour and PBMC samples (Figures 5C and S6D). To examine the maintenance of
expanded clonotype expanded clonotypes, we computed a cosine score which reflects degree of TCR repertoire similarity
comparing pre- and post-treatment timepoints (STAR Methods). Compared to non-responders, intratumoural,
but not PBMC TCR re comparing pre- and post-treatment timepoints (**STAR Methods**). Compared to non-responders, intratumoural, but not PBMC TCR repertoire similarity was significantly greater in responders ($P=0.024$, **Figures 5D and S6F**). I but not PBMC TCR repertoire similarity was significantly greater in responders (P=0.024, **Figures 5D and S6F**).
In responders, intratumoural clones expanded pre-treatment were more likely to be maintained compared to non-r

In responders, intratumoural clones expanded pre-treatment were more likely to be maintained compared to non-responders, where they were frequently replaced by new clones $(P=0.024$, **Figures 5E and S7A**).
Antigen specific non-responders, where they were frequently replaced by new clones (P=0.024, Figures 5E and S7A).

Similar CDR3 peptide binding sequences^{64, 65}. To investigate if maintained expansion of TCR clonetypes is

driven by a sha driven by a shared and persistent antigen, we performed clonotype clustering analysis (STAR Methods). In
responders, expanded TCR clones exhibited a trend towards increased clustering of similar CDR3 sequences (or driven by a shared and performed imagen, we performed clustering analysis (STAR Methods), in
responders, expanded TCR clones exhibited a trend towards increased clustering of similar CDR3 sequences (or
'cluster structure') responders both pre- and post-treatment (P=0.06 and 0.07, respectively)
8 'cluster structure') compared to non-responders both pre- and post-treatment (P=0.06 and 0.07, respectively) (Figure 5F and S7F). Expanded-maintained TCRs displayed significantly more cluster structure than expanded-

metastatic lesions at the time of death. While primary tumour and lung metastases in this case maintained a expanded due to a shared antigen and were maintained presumably due to persistent antigen stimulation.

Finally, we performed TCRseq in a patient who underwent post-mortem sampling (ADR005), allowing

greater resolution of Finally, we performed TCR constrained in a patient of the sequence of
ic lesions at the time of death. While primary tumour and lung metastases in this case maintained a
esponse to nivolumab until death, new brain, bone, a greater resolution of spatial and temporal ayrithment of temporal diamped and insight into surveillance of metastatic lesions at the time of death. While primary tumour and lung metastases in this case maintained a partial metastatic lesions at the time of death. Here, primary tumour and thoraco-nodal metastases emerged on
nivolumab, presenting sites of immune-escape (Figure S2C). Five TCR clones that were expanded pre-
nivolumab were mainta nivolumab, presenting sites of immune-escape (**Figure S2C**). Five TCR clones that were expanded pre-
nivolumab were maintained post-treatment at week-9. Three of these five clones remained expanded in non-
progressive dise progression (brain, bone and thoraco-nodal metastases) (Figures S2D and S2F).
Responder CD8⁺ T-cells express TCF7
TCR stimulation drives T-cell differentiation states which impact effector function^{66.68} and response to

Responder CD8⁺ T-cells express TCF7
.

progress of the section of the section of the sequence of the sequence of the sequence of the S2D and TCR stimulation drives T-cell differentiation states which impact effector func
We derived single-cell suspensions of tu ו
י
) Responder CD8 1-cells express TCF7
TCR stimulation drives T-cell differen
We derived single-cell suspensions of
nephrectomy specimen and analysed
(STAR Methods). Due to large amou
underwent cytoreductive nephrectom We derived single-cell suspensions of tumour-infiltrating lymphocytes from six spatially distinct regions of the nephrectomy specimen and analysed CD8⁺ T-cell differentiation states via high dimensional flow cytometry (nephrectomy specimen and analysed CD8[.] T-cell differentiation states via high dimensional flow cytometry

(**STAR Methods**). Due to large amounts of fresh tissue required, this was only feasible in the patients who

under

TCF7 is associated with progenitor-like phenotype and preserved effector function of dysfunctional T-(STAR Methods). Due to large amounts of fresh tissue required, this was only feature in the patient inter-

ICF7 is associated with progenitor-like phenotype and preserved effector function of dysfunctional T-

cells durin effector function⁷²⁻⁷⁵. More TCF7⁺TOX⁺CD8⁺ T-cells were detected in ADR013 compared to ADR001 (4.56% vs. cells during prolonged antigen stimulation^{97, 70, 71}. A higher frequency of CD8⁺ T-cells expressed TCF7 in the
responder ADR013 (27.5%) compared to non-responder ADR001 (4.64%). TOX expression is linked with
dysfunctio dysfunction, but also appears critical for epigenetic programming of progenitor-like CD8⁺ T-cell towards
effector function⁷²⁻⁷⁵. More TCF7⁺TOX⁺CD8⁺ T-cells were detected in ADR013 compared to ADR001 (4.56% vs.
0. dysfunction, but also appears critical for epigenetic programming of progenitor-like CD8' T-cell towards
effector function⁷²⁻⁷⁵. More TCF7⁺TOX⁺CD8⁺ T-cells were detected in ADR013 compared to ADR001 (4.56% vs.
0.96 effector function¹²⁵³. More TCF7⁺TOX⁺CD8⁺ T-cells were detected in ADR013 compared to ADR001 (4.56% vs.
0.96%, respectively) (**Figures 6A-C**). CD39 associates with antigen stimulation and tumour reactivity^{76,77}. 0.96%, respectively) (Figures 6A-C). CD39 associates with antigen stimulation and tumour reactivity^{19, 79}. CD39 expression was higher in ADR013 (35.7%) compared to ADR001 (2.29%) (Figures 6A-C). Expressed markers of dysf expression was majoritative treated (1980), compared to Markers (2012%), TIM3 (13.1% and 1.35%), and CD38 (33.9% and 19.7%), respectively (Figures 6B-C). The markers differentiating ADR013 from ADR001 were reflected in the (33.9%), and 19.7% and 19.7% (Figures 6B-C). The markers americanism, one constraints and the bulk RNAseq cohort-level data, which showed a trend towards higher expression of TCF7, CD39, and TOX in responders compared to n

Expanded CD8⁺ T-cells are drug-binding and cytotoxic during nivolumab induced responses
Next, we asked if characterising intratumoural, nivolumab-bound cells and comparing responder and no
responder populations would pro |
|
|
| Expanded CD8 T-cells are drug-binding and cytotoxic during nivolumab induced responses

Next, we asked if characterising intratumoural, nivolumab-bound cells and comparing res

responder populations would provide further $|{\tt g}$ G4 identified T-cells bound to pembrolizumab (anti-PD1 antibody), consistent with prior reports responder populations would provide further resolution on CD8' T-cells which exhibit features of antigen
engagement. IgG4 has previously been shown as a robust surrogate marker for PD-1 receptor occupancy by
anti-PD1 antib engagement. Ig a root previously as a receptor of the shown as a rounded in a competition assay where
IgG4 identified T-cells bound to pembrolizumab (anti-PD1 antibody), consistent with prior reports
(Supplemental Data Fig anti-PD1 antibodies^{80, 81}. We established the technical feasibility of this method in a competition assay where
IgG4 identified T-cells bound to pembrolizumab (anti-PD1 antibody), consistent with prior reports
(**Suppleme** Igaar included T-cells bound to pembrolizumab (and the district), y consistent with prior reports. (Supplemental Data Figure 1; Star Methods).

Supplemental Data Figure 1; Star Methods).

We performed flow cytometry analysis on IgG4*CD8* T-cells from ADR0013 (responder) and ADR001
oonder). Expression of the following markers were all higher in ADR013 compared to ADR001: GZMB
s 8.75%), TCF7 (19.5% and 2.17%) (38.9% vs 8.75%), TCF7 (19.5% and 2.17%), CD39 (54.6% vs 3.25%), TOX (14.5% vs 4.10%), and TIM3 (35.4% vs
3.52%), respectively (Figure 6C). This suggested drug-bound CD8⁺ T-cells in the responder were cytotoxic and
proge (3.52%), respectively (Figure 6C). This suggested drug-bound CD8⁺ T-cells in the responder were cytotoxic and
progenitor-like, despite upregulating markers of dysfunction. We detected unbound PD-1 on IgG⁺CD8⁺ T-cells 3.52%), respectively (**Figure 6C**). This suggested drug-bound CD8' T-cells in the responder were cytotoxic and
progenitor-like, despite upregulating markers of dysfunction. We detected unbound PD-1 on IgG⁺CD8⁺ T-cells
 progenitor-like, despite upregulating markers of dysfunction. We detected unbound PD-1 on IgG'CD8' T-cells
despite expected receptor occupancy by nivolumab, higher in ADR013 (20.9%) than ADR001 (0.78%) (**Figure**
6C). Det despite expected receptor occupancy by nivolutions, higher in terms (20.9%) than terms (19.0%) (Figure 6C). Detection of unbound PD-1 on $|gG4^*CD8^*|$ T-cells possibly indicates further PD-1 upregulation after drugbinding

6C). Detection of unbound PD-1 on IgG4*CD8*
binding and TCR stimulation, as a marker of act
this case.
Next, we performed paired single-cel
cells (**STAR Methods**). The scRNA datasets wer
and followed by UMAP projection. cells (STAR Methods). The scRNA datasets were annotated with their corresponding VDJ information, merged, binding and TCR stimulation, as a marker of activation^{92, 83}, rather than incomplete receptor-drug occupancy in
this case.
Next, we performed paired single-cell RNA and TCRseq (scRNA/TCRseq), on lgG4⁺ and lgG4⁻ CD3⁺ this case.
A
cells (**STA**
and follov
Treg (CD8 Next, we performed paired single-cell RNA and TCRseq (scRNA/TCRseq), on IgG4' and IgG4 CD3'
AR Methods). The scRNA datasets were annotated with their corresponding VDJ information, merge
wed by UMAP projection. Cells wer ent
. and followed by UMAP projection. Cells were classed as CD8 (CD8⁺CD4-FOXP3⁻), CD4 (CD8⁻CD4⁺FOXP3⁻) and
Treg (CD8⁻FOXP3⁺) (Figure S9A; STAR Methods). We observed similar levels of CD8⁺ T-cells, but lower
prop Treg (CD8FOXP3⁺) (Figure S9A; STAR Methods). We observed similar levels of CD8⁺ T-cells, but lower
proportions of Tregs in ADR013 (responder) compared with ADR001 (Figure S8B). Differential gene enrichment
and gene se and gene set enrichment analyses of IgG4⁺CD8⁺ T-cells showed upregulated pro-inflammatory cyto/chemokine
genes and T-cell activation pathways in both patients, indicating drug-binding CD8⁺ cells had similar
transcrip genes and T-cell activation pathways in both patients, indicating drug-binding CD8' cells had similar
transcriptional characteristics irrespective of clinical response (**Figures 7A and S9C**). TCRseq revealed
hyperexpanded transcriptional characteristics interperties in annual response virtual response of the clinical revealed to t
hyperexpanded CD8⁺ T-cells (defined as 200-1000 clones (Figures 7B and 7C). We observed that the more
pronoun Pronounced the clonal expansion, the higher the proportion of IgG4⁺ compared to IgG4⁻ CD8+ T-cells, suggesting drug-binding led to clonal expansion (Figure 7D). Expanded IgG4⁺CD8⁺ clones were characterised by cytot suggesting drug-binding led to clonal expansion (**Figure 7D**). Expanded IgG4⁺
cytotoxic activation in ADR013, including higher expression of GZMK tha
Analysis with a portfolio of publicly available gene signatures for Tcytotoxic activation in ADR013, including higher expression of GZMK than ADR001 (**Figures 7E and S9D**).
Analysis with a portfolio of publicly available gene signatures for T-cell states demonstrated expression of
signature Analysis with a portfolio of publicly available gene signatures for T-cell states demonstrated expression of Analysis with a portfolio of publicly available gene signatures for T-cell states demonstrated expression of signatures associated with T-cell activation / dysfunction in drug-bound cells from both patients, higher in ADR0 Signature SPE; STAR Methods). scRNAseq data also confirmed flow cytometry findings, with higher expression of (Figure S9E; STAR Methods). scRNAseq data also confirmed flow cytometry findings, with higher expression of GZMB ADROIS THAN ADDED AND MATCHEST TERRIFUM IN THE REPERTHEM IN THIS SEMILETIES.
(Figure S9E; STAR Methods). scRNAseq data also confirmed flow cytometry findings, with higher expression of
GZMB, TCF7, TIM3, and CD39 expression

(Figure S9E; Time Methods). SCAR Methods and CD39 expression on $|gG4^*CD8^*T\text{-cells}$ in ADR013 compared to ADR001 (Supplemental
Data Figure 2).
Next, combining bulk-TCRseq and scTCRseq datasets, we asked if post-treatment ex GZMB, TCF7, TIM3, and CD39 expression on IgG4'CD8' T-cells in ADR013 compared to ADR001 (**Supplemental**
 Data Figure 2).

Next, combining bulk-TCRseq and scTCRseq datasets, we asked if post-treatment expanded clones in
 Next, combining bulk-TCRseq and scTCRseq datasets, we asked if post-treatment expanded clones in
each patient 1) displayed cluster structure (shared antigen recognition); 2) if clustered clones were drug-
bound; and 3) if Finally, we used pre/post-treatment bulk-TCRseq data for ADR013 and ADR001 to derive 'novel' or 'prebound; and 3) is cluster networks for ADR013 and ADR001 according to CDR3 amino acid triplet sharing (STAR
Methods). Then, we defined each TCR clone within the networks by drug-binding status (IgG4⁺ or IgG4).
Finally, we Methods). Then, we defined each TCR clone within the networks by drug-binding status (IgG4⁺ or IgG4).
Finally, we used pre/post-treatment bulk-TCRseq data for ADR013 and ADR001 to derive 'novel' or 'pre-
existing' labels Methods). Then, we defined each TCR clone within the networks by drug-binding status (IgG4' or IgG4
Finally, we used pre/post-treatment bulk-TCRseq data for ADR013 and ADR001 to derive 'novel' or 'pre
existing' labels for ,
h
ed TCR clusters contained both novel and pre-existing TCRs (Figure 7F). By contrast, the salient finding in ADR001 expanded clones annotated for drug-binding and 'novel' versus 'pre-existing' status, for each patient (Figure

7F). In ADR013 (responder), expanded clones were clustered and mostly (89%) drug-bound. These clustered expanded clones and the drug-binding and there is even procedure, the same patient (Figure

7F). In ADR013 (responder), expanded clones were clustered and mostly (89%) drug-bound. These clustered

TCR clusters contained bo TCR clusters contained both novel and pre-existing TCRs (Figure 7F). By contrast, the salient finding in ADR001
TCR clusters contained both novel and pre-existing TCRs (Figure 7F). By contrast, the salient finding in ADR00 T CR clusters contained both novel and pre-existing TCRs (Figure 7F). By contrast, the salient finding in A D B with the post-treatment bulk-level data (Figure 7F). This limited any inference on the relationship between
clustering and drug-binding at single-cell level in this non-responder patient.
Overall, while the scRNA/TCRseq da

clustering and drug-binding at single-cell level in this non-responder patient.
Coverall, while the scRNA/TCRseq data were derived from only two patients, not only were the
findings in agreement with the bulk, cohort-level In agreement with the bulk, cohort-level data, showing maintenance and reinvigoration of pre-
progenitor-activated CD8⁺ T-cells underpinned nivolumab response; but these data provided direct
that intratumoural T-cells in responder (Figure 8). existing, progenitor-activated CD8⁺ T-cells underpinned nivolumab response; but these data provided direct
evidence that intratumoural T-cells in a responding patient were expanded, PD1 expressing and nivolumabbinding, and had a more activated phenotype. These features were not observed in T-cells from a nonresponder (Figure 8).

We present a multi-omic analysis of advanced stage ccRCC through treatment which sheds light on the
mediators of anti-PD1 response and resistance, and in particular the nature of the CD8⁺ T-cells that contribute
to anti-

mediators of anti-PD1 response and resistance, and in particular the nature of the CD8⁺ T-cells that contribute
to anti-tumour immunity.
Our WES data showed that no single mutation, SCNA, nor TMB and INDEL load associate Our WES data s

response in accordance w

SCNA events to anti-tumo

case with excessively hig Fig. 1922 and the mutation mutation, Senaton and TMB and INDEL load association in the secondance with prior studies^{19-21, 27}, although the question about the contribution of mutations or ents to anti-tumour immunity in response in accordance with prior studies³⁹-21, although the question about the contribution of mutations or
SCNA events to anti-tumour immunity in ccRCC remains incompletely understood. A notable exception was a
case wi case with excessively high TMB mediated by MMRd where immune editing was evident with subsequent
immune escape via loss of B2M. Decreased MHC-I expression associates with reduced PFS with avelumab plus
axitinib in ccRCC²¹ immune escape via loss of *B2M*. Decreased MHC-I expression associates with reduced PFS with avelumab plus axitinib in ccRCC²¹, but the frequency and impact of loss of antigen presentation remains unclear. With respect t immune escape via loss of *B2M*. Decreased MHC-I expression associates with reduced PFS with avelumab plus
axitinib in ccRCC²¹, but the frequency and impact of loss of antigen presentation remains unclear. With respect
t axitinib in ccRCC²¹, but the frequency and impact of loss of antigen presentation remains unclear. With respect
to HERV expression signatures, we show that HERVs, such as ERV3-2 and ERVK-10, most frequently associated
wi with T-cell infiltration in bulk tumour biopsies^{28, 50, 51, 56} are highly expressed in immune cells, which offers a
more parsimonious explanation for previously described associations. However, we confirmed ERVE-4 and
H with T-cell infiltration in bulk tumour biopsies^{29, 50, 51, 55} are highly expressed in immune cells, which offers a
more parsimonious explanation for previously described associations. However, we confirmed ERVE-4 and
HE HERV4700 are ccRCC-specific consistent with studies demonstrating direct T-cell reactivity to these specific
HERVs⁵⁶. While they did not associate with nivolumab response in this cohort, we note that T-cell responses
tar HERVs⁵⁶. While they did not associate with nivolumab response in this cohort, we note that T-cell responses
targeting these HERVs are HLA-A*02 restricted^{51,84} and, consequently, a positive correlation with the outcome
 HERVs³⁶. While they did not associate with nivolumab response in this cohort, we note that T-cell responses
targeting these HERVs are HLA-A*02 restricted^{51,84} and, consequently, a positive correlation with the outcome

targeting these HERVs are HLA-A*02 restricted^{31, 84} and, consequently, a positive correlation with the outcome
of immunotherapy would only be expected in patients with this HLA allele.
While the source of antigen(s) stim While the source of antigen(s) stimulus in ccRCC remains elusive,
findings of a population of pre-existing, expanded CD8⁺ T-cells in respond
quality of T-cells were comparable between patients at baseline, but the al
mai While the source of antigen(s) stimulus in ccRCC remains elusive, their existence is supported by our findings of a population of pre-existing, expanded CD8⁺ T-cells in responders. Moreover, our data show the quality of findings of a population of pre-existing, expanded CD8⁺ T-cells in responders. Moreover, our data show the quality of T-cells were comparable between patients at baseline, but the ability of expanded CD8⁺ T-cells to b quality of T-cells were comparable between patients at baseline, but the ability of expanded CD8⁺ T-cells to be
maintained underscores response to nivolumab in ccRCC. We show that on-treatment change in GZMB
expression i expression is a dynamic biomarker of nivolumab in ccRCC, which has also demonstrated predictive utility for
neoadjuvant avelumab in bladder cancer⁸⁵. Increase in TCF7⁺CD8⁺ T-cells and B-cells also correlated with
res expression is a dynamic increase in TCF7⁺CD8⁺ T-cells and B-cells also correlated with
response in our cohort. We note a prior report has shown TCF7⁺CD8⁺ T-cell can be activated *in vitro*, and could
maintain a pro neoadjuvant avelumab in bladder cancer⁹⁵. Increase in TCF7⁺CD8⁺ T-cells and B-cells also correlated with
response in our cohort. We note a prior report has shown TCF7⁺CD8⁺ T-cell can be activated *in vitro*, and response in our cohort. We note a prior report has shown TCF7'CD8' T-cell can be activated *in vitro,* and could
maintain a progenitor-like state when located within antigen presentation niches in ccRCC⁸⁵. Higher CD8⁺ maintain a progenitor-like state when located within antigen presentation niches in ccRCC⁸⁵. Higher CD8⁺ T-cell
density at tumour invasive margin has been reported to associate with longer PFS with avelumab plus axitin density at tumour margin has been reported to associate marking to a minimize parameter in $\text{c}c^{21}$. As such, further work to characterise the interaction between co-located B- and T-cells, especially at tumour margin

in ccRCC²¹. As such, further work to characterise the interaction between co-located B- and T-cells, especially
at tumour margins will be critical.
There are limitations to our study. First, the small number of patients There are limitations to complement in the critical phase of the critical metastatic site biopsies) and lone (TIME) changes under therapy. There are for discovery was afforded by a broadened sampling frame (multiregion and multi-
ic site biopsies) and longitudinally tracking of molecular and tumour immune microenvironment
hanges under therapy. Only two patien relationship with other immune cells was not evaluable. Looking forward, spatial transcriptomic profiling (TIME) changes under therapy. Only two patient samples underwent multiparameter flow cytometry and
scRNA/TCRseq analyses in our study. While this facilitated high-resolution cellular characterisation, spatial
relationship scRNA/TCRseq analyses in our study. While this facilitated high-resolution cellular characterisation, spatial
relationship with other immune cells was not evaluable. Looking forward, spatial transcriptomic profiling
techni scrutionship with other immune cells was not evaluable. Looking forward, spatial transcriptomic profiling
techniques with single-cell sensitivity^{87,88} will be valuable in studying TIME evolution in ccRCC.
In conclusion,

relationship with single-cell sensitivity^{87,88} will be valuable in studying TIME evolution in ccRCC.
In conclusion, in this prospective study we reveal features of anti-PD1 response and resistance in
ccRCC. We identified techniques with single-cell sensitivity^{97, 88} will be valuable in studying TIME evolution in ccRCC.
In conclusion, in this prospective study we reveal features of anti-PD1 response a
ccRCC. We identified antigen-specific In conclusion, in this prospective study in the statute of anti-PD1 reponse and resistance in
Ne identified antigen-specific T-cells with cytotoxic features in ccRCC, which hold promise for
nent of adoptive cellular therap development of adoptive cellular therapy for this cancer⁸⁹. While the treatment landscape has evolved to
12 development of adoptive cellular therapy for this cancer⁸⁹. While the treatment landscape has evolved to the treatment landscape has evolved to the treatment landscape has evolved to the treatment of adoptive cellular th

include combination therapies¹¹, this dissection of immune changes under nivolumab provides the foundation
for understanding response to combination therapies. Finally, our multi-omic analysis framework provides a template and highlights challenges for future immuno-oncology biomarker studies in ccRCC. template and highlights challenges for future immuno-oncology biomarker studies in ccRCC.

We thank the ADAPTeR trial team and the Skin and Renal Unit Research Team at The Royal Marsden NHS
Foundation Trust, including Lyra Del Rosario, Karla Lingard and Mary Mangwende, as well as Kim Edmonds,
Sarah Sarker, Charl Foundation Trusteen, Charlotte Lewis, Fiona Williams, Hamid Ahmod, Eleanor Carlyle, Tara Foley, Dilruba Kabir, Justine
Forteweg, Aida Murra, Nahid Shaikh, Kema Peat, Sarah Vaughan and Lucy Holt. We acknowledge the valuable Sarah Sarah Sarah Sarah Sarah Sarah Sarah and Lucy Holt. We acknowledge the valuable
Support of the PEACE consortium. We also thank Lavinia Spain, Irene Lobon, Daqi Deng, Katja De Paepe, Andy
Georgiou, Carmella Beastall, N Korteg, Andersale, Aida Murra, Aida Peat, Angleh, Kema Peat, Aida Deng, Katja De Paepe, Andy
Seorgiou, Carmella Beastall, Nagina Mangal, Katey Enfield, and Dhruva Biswas for their input. Most
importantly, we thank the pati Support of the PEACE consortion of the PEAC main Lavinia Spain, Irene Lobon, Daqi Deng, Maybettempt, Most
Seorgiou, Carmella Beastall, Nagina Mangal, Katey Enfield, and Dhruva Biswas for their input. Most
importantly, we t

importantly, we thank the patients and their families.
The ADAPTeR study (CA209-129) is sponsored by The Royal Marsden NHS Foundation Trust, and
partly funded by National Institute for Health Research (NIHR) Biomedical Res Bristol-Myers Squibb was the drug provider. The Francis Crick Institute, which receives its core funding from The ADAPTER study (CA209-129) is sponsored by National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Hospital and Institute of Cancer Research (ICR) (A80), and Cancer Research UK (CRUK) partly funded by Health Biothermann (NTM) and Cancer Research UK (CRUK) (17767).
Bristol-Myers Squibb was the drug provider. The Francis Crick Institute, which receives its core funding from
CRUK (FC010110), the UK Medical Bristol-Myers Squibb was the drug provider. The Francis Crick Institute, which receives its core funding from
CRUK (FC010110), the UK Medical Research Council (FC010110), the Wellcome Trust (FC010110). For the
purpose of O CRUK (FC010110), the UK Medical Research Council (FC010110), the Wellcome Trust (FC010110). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted
Manuscript version arising from this submission. TRACERx Renal is funded by NIHR BRC at the Royal Marsden
Hospital and purpose of Open Accepts. The authors of Open Access of Open Manuscript version arising from this submission. TRACERx Renal is funded by NIHR BRC at the Royal Marsden
Hospital and Institute of Cancer Research (A109).
Author Manuscript version arising from this submission from this submission. This submission is funded by Alman submi
Manuscript and Institute of Cancer Research (A109).
Conceptualisation, J.L, C.S., S.T. and S.A.Q.; Trial conduc

Author Contributions
Conceptualisation, J.L, C.S., S.T. and S.A.Q.; Trial c
T.M., M.M., E.H., G.K., K.L., D.S., L.A. and R.T.; Fo Conceptualisation, J.L,
T.M., M.M., E.H., G.K.,
Investigation, A.R., F.B
N.F., S.Hazell., D.N. K.J
contribution and inter T.M., M.M., E.H., G.K., K.L., D.S., L.A. and R.T.; Formal Analysis, M.M., E.H., G.K., D.S., R.T., L.A., K.L. and G.B.;
Investigation, A.R., F.B., E.H., I.U., L.A. and M.M; Resources, S.T., J.L., C.S., S.A.Q., M.J-H., A.R., Investigation, A.R., F.B., E.H., I.U., L.A. and M.M; Resources, S.T., J.L., C.S., S.A.Q., M.J-H., A.R., L.A., E.H., F.B.,
N.F., S.Hazell., D.N. K.J., I.U., P.B., M.S.W., A.A., I.P., W.Y., T.L., K.D. and M.D.V.; Data Curati N.F., S.Hazell., D.N. K.J., I.U., P.B., M.S.W., A.A., I.P., W.Y., T.L., K.D. and M.D.V.; Data Curation: L.A., R.M.; Data contribution and interpretation: all; Writing - original draft, L.A., E.H. and M.M.; Writing - review and editing,
L.A., S.T., E.H., and M.M.; Visualisation, M.M., E.H., G.K., L.A., G.B. and R.T.; Supervision, S.T., S.A.Q. contribution and M.M.; Visualisation, M.M., E.H., G.K., L.A., G.B. and R.T.; Supervision, S.T., S.A.Q., B.C., T.M.,
J.L., C.S.; Project Administration, S.T., J.L., L.A., E.H. and S.A.Q.; Funding Acquisition, J.L, C.S., S.T

Declaration of Interests
L.A. is funded by the Royal Marsden Cancer Charity. J.A. is a full-time employee of Hoffmann-La Roche AG J.L., C.S.; Project Administration, S.T., J.L., L.A., E.H. and S.A.Q.; Funding Acquisition, J.L, C.S., S.T. and S.A.Q. |
|
|
| L.A. is funded by the Ro
(Basel, Switzerland). L.P
Bristol-Myers Squibb, an
Institute for Health Rese
of Cancer Research (A10 L.A. Is funded by the Royal Marsden Cancer Charley, Charles Charlins Charley Constraining an increase (Basel, Switzerland). L.P. has received research funding from Pierre Fabre, and honoria from Pfizer, Ipsen,
Bristol-Myer (Bristol-Myers Squibb, and EUSA Pharma. S.T. is funded by Cancer Research UK (C50947/A18176), the National
Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute
of Canc Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (A109), the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, The Rosetrees Institute for Health Research (A109), the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, The
Rosetrees Trust (A2204), Ventana Medical Systems Inc (10467/10530), the National Institute of Health (US)
a of Cancer Research Alliance. R.S. has received non-financial support from Merck and Bristol Myers
Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol
Myers Squibb; and pe and the Melanoma Research Alliance. R.S. has received non-financial support from Merck and Bristol Myers
Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol
Myers Squibb; Squibb; research support from Merck, Puma Biotechnology, and Roche; and advisory board fees for Bristol
Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project; all
related to b Myers Squibb; and personal fees from Roche for an advisory board related to a trial-research project; all related to breast cancer research projects. R.S. reports no conflict of interests related to this project. G.K.
receives core funding from the Francis Crick Institute (FC0010099). M.J.H. is a Cancer Research UK (CRUK)
14 receives core funding from the Francis Crick Institute (FC0010099). M.J.H. is a Cancer Research UK (CRUK) receives core funding from the Francis Crick Institute (FCO).
14

Research, Rosetrees Trust, UKI NETs and NIHR University College London Hospitals Biomedical Research
Centre. M.J.H. is a member of the Scientific Advisory Board and Steering Committee for Achilles Therapeutics.
J.L. has re Research, Research, Rosettrees Trust, UKI NETS and Trust, UKI 2012, UKI 2012, Control Prepartic Trusters Therapeutics.

T.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therap J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics,
Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo, and served as a consultant to
Achilles Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo, and served as a consultant to
Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen,
Imugene, I Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen,
Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech,
Secarna, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna, and Vitaccess. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb, Roche-Ventana Impleme, Incyte and Vitaccess. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb,

Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing

tech Secarna, and Vitation of the anti-mologol grant support from Pfizer, Containing esidual disease sequencing
Rechnologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for
the MeRmai Rochnologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for
The MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb,
Celgene, technologies) and Ono Pharmaceutical, is an AstraZeneca Advisor, Journal and Ono Pharmaceutical, the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol-Myers Squibb,
Celgene, AstraZe The Merman Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the
Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and h Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has
stock options and is co-founder of Achilles Therapeutics. Patents: C.S. holds European patents relating to assay stock options and is co-founder of Achilles Therapeutics. Patents: C.S. holds European patents relating to assay
technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens
(PCT/EP2016/059401), ide determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer
(PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifyin (PET/EPECT/EPP2016/052018/052004), predicting survival rates of patients with cancer
(PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US
patent relating to detecting tumour m determining HLA LOH (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US
patent relating to detecting tumour mutations (PCT/US2017/28013) and both a European and US patent
rel (PCT/US2017/28013) and both a European and US patent

related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). C.S. is Royal Society Napier

Research Professor (RP150154). His work is supported by th related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). C.S. is Royal Society Napier
Research Professor (RP150154). His work is supported by the Francis Crick Institute, which receives its core
fund Research Professor (RP150154). His work is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169), and the Wellcome Trust (F Funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169), and the
Wellcome Trust (FC001169). C.S. is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer
Immunotherapy Catalyst Network Funding Trust (FC001169), C.S. is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer
Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust,
Butterfield and Ston Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust,
Butterfield and Stoneygate Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorship
Enhanceme Immunote Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorship
Inhancement Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK-UCL
Centre, Experimental Cancer Medici Butterfield and Stoneygate Trusts, Novo Christman Foundation (ID1614), Novo Christials, the CRUK-UCL
Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation, USA (BCRF). His
research is suppor Enhancement Award (RP/EA/2000), the Tamilton are at Enhancement Architects, the Enhancement Control Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation, USA (BCRF). His research is support Centre, Experimental Cancer Medicine Centre and the Breast Centre Accessor (Superior, Centre Cancer Interception Dream Team Translational Research Grant (SU2C-AACR-DT23-17). Stand Up To Cancer is a program of the Entertain Interception Dream Team Translational Research Grant (SU2C-AACR-DT23-17). Stand Up To Cancer is a
program of the Entertainment Industry Foundation. Research grants are administered by the American
Association for Cancer Re program of the Entertainment Industry Foundation. Research grants are administered by the American
Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding from the European
Research Coun Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding from the European
Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013)
Consolidator Grant Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013)
Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet 607722), an ERC
Advanced Grant (PROTEUS) from th Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet 607722), an ERC
Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020
The European And innovatio Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020

Fesearch and innovation programme (835297) and Chromavision from the European Union's Horizon 2020

Fesearch and innovati Research and innovation programme (835297) and Chromavision from the European Union's Horizon 2020
Thesearch and innovation programme (665233). ST has received speaking fees from Roche, Astra Zeneca,
Novartis and Ipsen. ST research and innovation programme (665233). ST has received speaking fees from Roche, Astra Zeneca,
Novartis and Ipsen. ST has the following patents filed: Indel mutations as a therapeutic target and predictive
Novartis an Novartis and Ipsen. ST has the following patents filed: Indel mutations as a therapeutic target and predictive
Example: Astra Zeneca, Ast
 Nova and Ipsen. State filed: Independent filed: Independent as a therapeutic target and predictively and predictively
15

P113326GB.
T<mark>he TRACERx Renal Consortium</mark>
The members of TRACERx Renal Consortium are: Lewis Au, Ben Challacombe, Ashish Chandra, Simon

THE TRACER:
The TRACER:
The membe
Chowdhury, ד
ז
ז The members of TRACERx Ren
Chowdhury, William Drake, Arc
Harrison-Phipps, Steve Hazell, P
David Nicol, Tim O'Brien, Jonatho
Scott Shepherd, Charles Swantor The members of TRACERR Renal Constraint are Lewis Any Lewis Chandrenally Pandin Channey Charactery
Chowdhury, William Drake, Archana Fernando, Nicos Fotiadis, Andrew Furness, Emine Hatipoglu, Karen
Harrison-Phipps, Steve H Chowday, Ministre Branch, Ministre Fotianus, Archana Fernando, Archana Fernando, Archana Fernando, Archana Fer
Harrison-Phipps, Steve Hazell, Peter Hill, Catherine Horsfield, James Larkin, Jose I. Lopez, Teresa Marafioti,
 David Nicol, Tim O'Brien, Jonathon Olsburgh, Lisa Pickering, Alexander Polson, Sergio Quezada, Sarah Rudman,
Scott Shepherd, Charles Swanton, Samra Turajlic, Mary Varia, Hema Verma.
The PEACE Consortium

The members of PEACE Consortium are: Chris Abbosh, Kai-Keen Shiu, John Bridgewater, Daniel Hochhauser, Scott Shepherd, Shepherd, Charles Swanton, Samra Turajlic, Mary Journal Turania
The Members of PEACE Consortium are: Chris Abbosh, Kai-Keen Shiu, Johr
Martin Forster, Siow-Ming Lee, Tanya Ahmad, Dionysis Papadatos-Pastos, ד
ו
ו The members of PEACE Consortium are: Chris Abbosh, Kai-Keen Shiu, John Bridgewater, Daniel Hochhauser,
Martin Forster, Siow-Ming Lee, Tanya Ahmad, Dionysis Papadatos-Pastos, Sam Janes, Peter Van Loo, Katey
Enfield, Nichola Enfield, Nicholas McGranahan, Ariana Huebner, Sergio Quezada, Stephan Beck, Peter Parker, Henning
Walczak, Tariq Enver, Rob Hynds, Mary Falzon, Ian Proctor, Ron Sinclair, Chi-wah Lok, Zoe Rhodes, David
Moore, Teresa Marafi Walczak, Tariq Enver, Rob Hynds, Mary Falzon, Ian Proctor, Ron Sinclair, Chi-wah Lok, Zoe Rhodes, David
Moore, Teresa Marafioti, Elaine Borg, Miriam Mitchison, Reena Khiroya, Giorgia Trevisan, Peter Ellery, Mark
Linch, Seb Moore, Teresa Marafioti, Elaine Borg, Miriam Mitchison, Reena Khiroya, Giorgia Trevisan, Peter Ellery, Mark
Linch, Sebastian Brandner, Crispin Hiley, Selvaraju Veeriah, Maryam Razaq, Heather Shaw, Gert Attard, Mita
Afroza Moore, Teresa Maramon, Taline Borg, Miriam Miriam Miriam Miriam, Peregia Morrelin, Perecarity, Milin
Linch, Sebastian Brandner, Crispin Hiley, Selvaraju Veeriah, Maryam Razaq, Heather Shaw, Gert Attard, Mita
Afroza Akther, Afroza Akther, Cristina Naceur-Lombardelli, Lizi Manzano, Maise Al-Bakir, Simranpreet Summan, Nnenna Kanu,
Sophie Ward, Uzma Asghar, Emilia Lim, Faye Gishen, Adrian Tookman, Paddy Stone, Caroline Stirling, Lewis Au,
Andrew Sophie Ward, Uzma Asghar, Emilia Lim, Faye Gishen, Adrian Tookman, Paddy Stone, Caroline Stirling, Lewis Au, Sophie Ward, Camaraghar, Emilia Lin, Faye Gistran, Mahar Memilia, Many Memili Camara, Emilia China Byrne, Addi
Sophia Spain, Scott Shepherd, Haixi Yan, Ben Shum, Eleanor Carlyle, Steve Hazell, Annika Fendler, Fiona Byrne,
 Andrew Furness, Andrew Furness, Andrew Furness, Senator Angless, Alar, Analy Prancy Prace Engers,
Lavinia Spain, Scott Shepherd, Haixi Yan, Ben Shum, Eleanor Carlyle, Steve Hazell, Annika Fendler, Fiona Byrne,
Nadia Yousaf Nadia Yousaf, Sanjay Popat, Olivia Curtis, Gordon Stamp, Antonia Toncheva, Emma Nye, Aida Murra, Justine
Korteweg, Nahid Sheikh, Debra Josephs, Ashish Chandra, James Spicer, Ula Mahadeva, Anna Green, Ruby
Stewart, Lara-Ros Karapagniotou, Elias Pintus, Andrew Tutt, Sarah Howlett, Vasiliki Michalarea, James Brenton, Carlos Caldas,
Rebecca Fitzgerald, Merche Jimenez-Linan, Elena Provenzano, Alison Cluroe, Grant Stewart, Colin Watts, Kortewart, Lara-Rose Iredale, Tina Mackay, Ben Deakin, Debra Enting, Sarah Rudman, Sharmistha Ghosh, Lena
Karapagniotou, Elias Pintus, Andrew Tutt, Sarah Howlett, Vasiliki Michalarea, James Brenton, Carlos Caldas,
Rebecca Stepangniotou, Elias Pintus, Andrew Tutt, Sarah Howlett, Vasiliki Michalarea, James Brenton, Carlos Caldas,
Rebecca Fitzgerald, Merche Jimenez-Linan, Elena Provenzano, Alison Cluroe, Grant Stewart, Colin Watts,
Richard Gil Rebecca Fitzgerald, Merche Jimenez-Linan, Elena Provenzano, Alison Cluroe, Grant Stewart, Colin Watts,
Richard Gilbertson, Ultan McDermott, Simon Tavare, Emma Beddowes, Patricia Roxburgh, Andrew Biankin,
Anthony Chalmers, Richard Gilbertson, Ultan McDermott, Simon Tavare, Emma Beddowes, Patricia Roxburgh, Andrew Biankin, Anthony Chalmers, Sioban Fraser, Karin Oien, Andrew Kidd, Kevin Blyth, Matt Krebs, Fiona Blackhall, Yvonne
Summers, Carol Richard Ghartertson, Ultan McDermott, Simon Terras, Simon Termotters, Carter McDermott, Anthony Chalmers, Sioban Fraser, Karin Oien, Andrew Kidd, Kevin Blyth, Matt Krebs, Fiona Blackhall, Yvonne
Summers, Caroline Dive, Ric Anthony Chalmers, Sioban Fraser, Matherston, Finland, Anthony, Matherston, Thene Stammers, Caroline Dive, Richard Marais, Fabio Gomes, Mat Carter, Jo Dransfield, John Le Quesne, Dean
Fennell, Jacqui Shaw, Babu Naidu, Shobh Fennell, Jacqui Shaw, Babu Naidu, Shobhit Baijal, Bruce Tanchel, Gerald Langman, Andrew Robinson, Martin
Collard, Peter Cockcroft, Charlotte Ferris, Hollie Bancroft, Amy Kerr, Gary Middleton, Joanne Webb, Salma
Kadiri, Pet Fellard, Peter Cockcroft, Charlotte Ferris, Hollie Bancroft, Amy Kerr, Gary Middleton, Joanne Webb, Salma
Kadiri, Peter Colloby, Bernard Olisemeke, Rodelaine Wilson, Ian Tomlinson, Sanjay Jogai, Christian
Ottensmeier, Davi Collard, Peter Colloby, Bernard Olisemeke, Rodelaine Wilson, Ian Tomlinson, Sanjay Jogai, Christian Ottensmeier, David Harrison, Massimo Loda, Adrienne Flanagan, Mairead McKenzie, Allan Hackshaw, Jonathan Ledermann, Kitty Ottensmeier, David Harrison, Massimo Loda, Adrienne Flanagan, Mairead McKenzie, Allan Hackshaw, Jonathan
Ledermann, Kitty Chan, Abby Sharp, Laura Farrelly, and Hayley Bridger. Ottensmann, Kitty Chan, Abby Sharp, Laura Farrelly, and Hayley Bridger.
Ledermann, Kitty Chan, Abby Sharp, Laura Farrelly, and Hayley Bridger. Ledermann, Kitty Chan, Abby Sharp, Laura Farrelly, and Hayley Bridger.

Figure 1. Experimen
ADAPTeR cohort
(A) Overview of experiments are shown
alterations annotated Figure 1. Experimental workflow, Number (n) of patients contributing to sample collection at different

(A) Overview of experimental workflow, Number (n) of patients contributing to sample collection at different

timepoin (A) Overview of e
timepoints are sk
alterations annot
Composite mutat
insertion chr3:52 (A) The time points are shown. (B) Heatmap of WES analysis demonstrating TMB, INDEL burden, and somatic driver
alterations annotated by pre/post-treatment, tumour site, IMDC risk category, and nivolumab response.
Composite alterations annotated by pre/post-treatment, tumour site, IMDC risk category, and nivolumab response.
Composite mutations are annotated with dual colours. Complex mutations in ADR002: *PBRM1* frameshift
insertion chr3:5258 alterations annotated by pre/post-treatment, tumour site, IMDC risk category, and nivolumab response.
Composite mutations are annotated with dual colours. Complex mutations in ADR002: *PBRM1* frameshift
insertion chr3:5258 Insertion chr3:52584573:->T and non-frameshift deletion chr3:52584576:TAT>-; TP53 missense mutation
chr17:7572969:A>T and frameshift insertion chr3:7572962:->CT. * (Asterix) denotes two distinct fslNDEL
mutations in one tu insertion chr3:52584573:->T and non-frameshift deletion chr3:52584576:TAT>-; TP53 missense mutation
chr17:7572969:A>T and frameshift insertion chr3:7572962:->CT. * (Asterix) denotes two distinct fsINDEL
mutations in one tu

christian christian christian institution christian christian (Asterix) and the analysis in christian
Tigure 2. Expression of human endogenous viruses (HERVs) and LTR-overlapping transcripts in ccRCC
according to tumour pu mutations in one tumour sample in ADR013.
Figure 2. Expression of human endogeno
according to tumour purity
(A) Hierarchical clustering patient samples ad

 $\frac{1}{2}$ **Expressed (STA)**
Expression of HERVs previously associated
(A) Hierarchical clustering patient samples according to the relative expression of HERVs previously associated
With cytotoxic T-cell presence, response to (A) Hierarchical clustering p.
with cytotoxic T-cell prese
Hierarchical clustering patie
expressed (\geq 2-fold change,
Comparisons of tumour pur with cytotoxic T-cell presence, response to immunotherapy or the provision of antigenic epitopes. (B)
Hierarchical clustering patient samples according to the 12 LTR-overlapping transcripts that were differentially
expres Hierarchical clustering patient samples according to the 12 LTR-overlapping transcripts that were differentially
expressed (22-fold change, q≤0.05) between responders and non-responders or affected by nivolumab. (C)
Compar comparisons of tumour purity between non-responders and responders. Per-sample values are represented.
Median values are shown. ****P<0.0001, ***P=0.001; Mann-Whitney U test. (D) Distribution plot of significant Spearman's Median values are shown. The 1980-1, Theory is also the set. (D) Distribution plot of
significant Spearman's rank-order correlation between tumour purity and transcript per million (TPM)
expression of the 12 HERVs differen significant Spearman's rank-order correlation between tumour purity and transcript per million (TPM)
expression of the 12 HERVs differentially expressed between responders and non-responders. NR - nonresponders; R - responders

Figure 3. GSEA and immune deconvolution by RNAseq shows higher levels of immune infiltration and
activation in responders compared to non-responders under nivolumab

 $\begin{array}{c} \n\bullet \\
\bullet \\
\bullet\n\end{array}$ activation in responders compared to non-responders under nivolumab

(A) Transcripts differentially regulated Pre-treatment between responders and non-responders (n=33 samples,

14 patients, negative binomial Wald test, Be (A) Transcripts differentially regulated Pre-treatment between responder:
14 patients, negative binomial Wald test, Benjamini–Hochberg correcte
differentially regulated (FDR<0.05), the ones that overlap with the Di
labelle (A) Transcripts anterementy regulated Free treatment a entertrement between responders (n=23 samples, 14 patientially regulated (FDR<0.05), the ones that overlap with the Danaher immune score gene list are labelled. (B) He 14 patients, negative binomial wald test, benjamini Hochberg corrected P values). 3,382 transcripts were
differentially regulated (FDR<0.05), the ones that overlap with the Danaher immune score gene list are
labelled. (B) differentially regulated (FDR state), the ones that overlap with the Danaher immune score gene interestion (as
differentially regulated post-treatment between responders and non-
responders (n=27 samples, 10 patients, nega Pre-treatment samples. (C) Transcripts differentially regulated post-treatment between responders and non-
responders (n=27 samples, 10 patients, negative binomial Wald test, Benjamini–Hochberg corrected P values).
7,975 t Presponders (n=27 samples, 10 patients, negative binomial wald test, benjamini–Hochberg conected P values).

7,975 transcripts were differentially regulated (FDR<0.05), the ones that overlap with the Danaher immune

score France gene list are labelled. (D) Heatmap showing the relative expression (z scores) of genes from 8 Danaher
immune modules in post-treatment samples. (E) GOBP pathway analysis of genes preferentially upregulated
and down immune modules in post-treatment samples. (E) GOBP pathway analysis of genes preferentially upregulated
and downregulated pre-treatment in responders, Overlap (n), number of significant genes from a pathway
(hypergeometric immune modules in post-treatment in responders, Overlap (n), number of significant genes from a pathway
(hypergeometric test). (F) GOBP pathway analysis of genes preferentially upregulated and downregulated
post-treatment (hypergeometric test). (F) GOBP pathway analysis of genes preferentially upregulated and downregulated
post-treatment in responders, Overlap (n), number of significant genes from a pathway (hypergeometric test). (hypergeometric test). (F) GOBP pathway analysis of genes procedurated and downregulated post-treatment in responders, Overlap (n), number of significant genes from a pathway (hypergeometric test).
17 post-treatment in responders, Overlap (n), number of significant genes from a pathway (hypergeometric test).

Figure 4. The Community of the Community of the Community of the Community of the Community Community (A) Community community (A) Community samples in responders (n=5) and non-responders (n=9) is shown on the left. On the IHC and minital
Iteatment na
Iteatment na
Iteation betwee
Iteation cell simages of re (A) Comparison of T-cell subset (out of total T-cells), CD163⁺ myeloid cells, B-cell and plasma cell infiltration in
treatment naïve samples in responders (n=5) and non-responders (n=9) is shown on the left. On the right ratio between CD3 (total T-cells) and CD163 myeloids cells and CD8 and CD163 cells at baseline. B-cell and
plasma cell scoring was done by using immunohistochemistry. Other markers were scored by using IF. IHC
images of re ratio between CD 3 (total T-cells) and CDD 3 (plans CD 163 my plans CD 8 and CD 8 and CD 8 and 8 plasma cells
images of representative responder and non-responder patients pre-treatment showing B-cell (blue), PD-1⁺
cells plasma cell scores in the corresponder and non-responder patients pre-treatment showing B-cell (blue), PD-1⁺
cells (yellow) and plasma cells (magenta) infiltration. **(B)** Level of overall GZMB, GZMB⁺CD8⁺, and overall images of representative responder and non-responder patients pre-treatment showing B-cell (blue), PD-1⁺
cells (yellow) and plasma cells (magenta) infiltration. **(B)** Level of overall GZMB, GZMB⁺CD8⁺, and overall PDcells (yellow) and plasma cells (magenta) infiltration. **(B)** Level of overall GZMB, GZMB⁺
expression in responders and non-responders in treatment naïve and on treatment sataining was performed with immunohistochemistry CD8⁺
ampl_'
with
nt at
n-Wł From PD-1
IF. (C) mIF images
baseline and on
iitney U statistical expression in responder and non-responders in a sequence in treatment samples is in treatment in responders showing GZMB⁺CD8⁺ cells in a representative responder and non-responder patient at baseline and on Nivolumab t showing GZMB⁺CD8⁺ cells in a representative responder and non-responder patient at baseline and on
Nivolumab treatment. Median values were used for each patient and a two-sided Mann-Whitney U statistical
test was used showing GZMB*CD8* cells in a representative responder and non-responder patient at baseline and on
Nivolumab treatment. Median values were used for each patient and a two-sided Mann-Whitney U statistical
test was used for

Nest was used for the analysis.
Nigure 5. TCR sequencing demonstrates maintained clonal expansion through persistent antigenic
Stimulation associate with nivolumab response test was used for the analysis.
Figure 5. TCR sequencing
stimulation associate with niv
(A) The intratumoural and p

 $\frac{1}{3}$ Figure 1. The Expansion associate with nivolumab response
(A) The intratumoural and peripheral TCR repertoire clonality score is shown for each patient at each
timepoint. (B) Correlated clone sizes in tumour samples. Scatt (A) The intratumoural and peripheral TCR representing the intratumoural and peripheral TCR representing before treatment are shown for all patients.
Methods). (C) The intratumoural TCR repertoire each patient. Patients are (A) The intratumoural and peripheral TCR repertoire Treman, 1999 is shown clone size after treatment and before treatment are shown for all patients. Clones are colored by expansion/contraction status (STAR Methods). (C) T the tore treatment are shown for all patients. Clones are colored by expansion/contraction status (STAR
 Methods). (C) The intratumoural TCR repertoire clonality score pre-treatment and on-treatment is shown for

each pa **Before treatment are shown for all patients.** Performant are contraction, in patients, contraction status (status
 Methods). **(C)** The intratumoural cosine score between responders and non-responders. Mixed-effect model Methods). (C) The intratumoural TCR repertoire clonality score pre-treatment and on-treatment and p-value shown.

(D) The intratumoural cosine score between pre-treatment and on-treatment is shown for each patient (n=12).
 each patient. Patients are split between responders and non-responders. Mixed-effect model p-value shown.
 (D) The intratumoural cosine score between pre-treatment and on-treatment is shown for each patient (n=12).

Pat Patients are split between responders and non-responders. Responding patients exhibit greater cosine score,
with the two-sided Mann–Whitney test P value shown. (E) The frequency distribution of the intratumoural
expande expanded TCRs pre-treatment (red circles; $n = 469$ individual TCRs combined from 12 patients) and post-
treatment (blue circles). Only TCRs that were detected post-treatment were included. (F) The clustering
algorithm was algorithm was run on all patients, and the pre-treatment normalised number of clusters for the networks
containing expanded sequences is shown. Two-sided Mann-Whitney test P value shown; n=14 patients.
Figure 6. Flow cytom

algorithm was run on all patients, and the pre-treatment normalised number of clusters for the networks.

containing expanded sequences is shown. Two-sided Mann-Whitney test P value shown; n=14 patients.

Figure 6. Flow cy containing expanded sequences is shown. Two-sided Mann–Whitney test P value shown; n=14 patients.
Figure 6. Flow cytometry-based analysis of ADR013 (responder) and ADR001 (non-responder) eval
post-treatment total and nivol

 Figure 1. Flow consists the CDS of the CDS of the CDS of the CDS

Figure 6. Flow cytoscope in a representative patient who had ≤6 months response to Nivolumab treatment (ADR001_T tumour tissue) and a

representative patien post-treatment total and nivolumab-bound CD8 T-cells

(A) Expression of T cell differentiation focused mark

representative patient who had ≤6 months response to N

representative patient who had had ≥6 months respons

an (A) Expression of T cell differentiation focused markers on CD8⁺ tumour infiltrating lymphocytes in a representative patient who had ≤ 6 months response to Nivolumab treatment (ADR001_T tumour tissue) and a represen representative patient who had had ≥6 months response to Nivolumab treatment (ADR013_T tumour tissue
and ADR013_N tumour adjacent normal kidney tissue) is shown in the heatmap. Relative expression level of
each heatmap cl representative patient who had had 26 months response to Nivoluma Technical (ADR013_N tumour adjacent normal kidney tissue) is shown in the heatmap. Relative expression level of each heatmap cluster for each sample is show and ADR013. The ADR013 H tumour adjacent normal kidney tissue in the heatmap cluster expression constrained by
a each heatmap cluster for each sample is shown in the percentage bar graph and UMAP. 920 CD8⁺ cells were
inf each heatmap cluster for each sample is shown in the percentage bar graph and UMAP. 920 CD8' cells were
used per sample for the analysis. **(B)** Expression of T cell checkpoint focused markers on CD8⁺ tumour
infiltrating used per sample for the analysis. **(B)** Expression of T cell checkpoint focused markers on CD8⁺
infiltrating lymphocytes in a representative responder and a non-responder patient is shown in the h
infiltrating lymphocyte infiltrating lymphocytes in a representative responder and a non-responder patient is shown in the heatmap.
18 infiltrating lymphocytes in a representative responder and a non-responder patient is shown in the heatmap.

UMAP. 990 CD8⁺ cells were used per sample. **(C)** FACS plots show the co-expression of markers on CD8⁺ and
IgG4⁺CD8 cells in ADR001_T tumour, ADR013_T tumour tissue and ADR013_N tumour-adjacent normal kidney
tissue. UMAP. 990 CD8" cells were used per sample. (C) FACS plots show the co-expression of markers on CD8" and
|gG4*CD8 cells in ADR001_T tumour, ADR013_T tumour tissue and ADR013_N tumour-adjacent normal kidney
tissue.
<mark>Figure 7</mark>

IgG4"CD8 cells in ADR001_T tumour, ADR013_T tumour tissue and ADR013_N tumour-adjacent normal kidney
tissue.
Figure 7. Nivolumab binding correlates with upregulation of T-cell activation genes and clones expanded
through p Figure
throug
(A) GO

|
|
| Figure 7. Nivolution and interesting correlation

(A) GOBP pathway analysis of genes preferentially upregulated in drug bound CD8 cells in ADR001 (non-

responder) and ADR013 (responder), circle size indicative of number o through persistent antigenic stimulation

(A) GOBP pathway analysis of genes preferentially upregulated in drug bound CD8 cells in ADR001 (non-

responder) and ADR013 (responder), circle size indicative of number of genes of cells in each expansion class which are Nivolumab bound or unbound. **(E)** Heatmaps showing top genes
which positively correlated (Pearson's correlation, CD8⁺ cells only) with TCR expansion in the responder. **(F) UMAP** of scRNA Seq data from non-responder and responder coloured by frequency of clone. (C) Clonal proportion plot of CD8, CD4 effector and Treg compartments in non-responder and responder. (D) Proportion of cells in e proportion plot of CD8, CD4 effector and Treg compartments in non-responder and responder. (D) Proportion
of cells in each expansion class which are Nivolumab bound or unbound. (E) Heatmaps showing top genes
which positiv proportion plane in each expansion class which are Nivolumab bound or unbound. (**E)** Heatmaps showing top genes
which positively correlated (Pearson's correlation, CD8⁺ cells only) with TCR expansion in the responder. (which positively correlated (Pearson's correlation, CD8⁺ cells only) with TCR expansion in the responder. (F)
Representative network diagrams of post-treatment intratumoural CDR3 β-chain sequences for ADR001 and
ADR013. Representative network diagrams of post-treatment intratumoural CDR3 β-chain sequences for ADR001 and
ADR013. Clustering was performed within the bulk TCR-seq data around expanded intratumoural TCRs,
subdivided between clo ratumoural CDR3 β-chain sequences for ADR001 and
CR-seq data around expanded intratumoural TCRs,
ost-treatment repertoire exclusively (blue circles) and
sircles). The network shows clusters for which at least
gG4 negativ ADR013. Clustering was performed within the bulk TCR-seq data around expanded intratumoural TCRs, subdivided between clones that were expanded in the post-treatment repertoire exclusively (blue circles) and clones that wer ADROIS THE PERSONS WAS PERSONS WANDED WITH THE BULK TERR IN EXPANDED WELKNEED AND THE PRODUCED STANDARD WAS SU
ADROIS that were also expanded Pre-treatment (orange circles). The network shows clusters for which at least
on subdivided between clones that were expanded Pre-treatment (orange circles). The network shows clusters for which at least
one CDR3 was also detected in the scTCR repertoire. IgG4 negative clones that were detected in the clones CDR3 was also detected in the scTCR repertoire. IgG4 negative clones that were detected in the scTCR repertoire but not expanded in the bulk TCR repertoire and are represented (yellow circle). The network was then s repertoire but not expanded in the bulk TCR repertoire and are represented (yellow circle). The network was
then split between clones that were mapping to a majority of IgG4 negative cells (top panel) or a majority of
IgG4 repertoire but not expanded in the bulk TCR repertoire and are represented (yellow circle). The network then
then split between clones that were mapping to a majority of IgG4 negative cells (top panel) or a majority of
IgG then split between clones that were mapping to a majority of IgG4 negative clone (top panel) or a majority or
IgG4 positive cells (bottom panel) in the single-cell data. Clustering network derived from bulk post-treatment

tissue (grey circles) as also shown in Figure S7G.
Figure 8. Longitudinal profiling by bulk and single-cell RNA/TCRseq reveal dynamic immune correlates of
response and resistance to nivolumab

Figure 8. Longitudinal profiling by bulk and singure 8. Longitudinal profiling by bulk and singures
The response and resistance to nivolumab
(1) Clonally expanded CD8⁺ T-cells pre-treatment
Maintenance of pre-existing cl |
|
| Figure 8. Longitudinal response and resistance to nivolumab

(1) Clonally expanded CD8⁺ T-cells pre-treatment in ADR013 (responder). TCR clonotypes are highly similar. (2)

Maintenance of pre-existing clonally expanded a (1) Clonally expanded $CD8^+$ T-cells pre-t
Maintenance of pre-existing clonally e
binding activates tumour-specific $CD8^+$
cells pre-treatment in ADR001 (non-ree
expanded $CD8^+$ T-cells under nivolumal (1) Clonally expanded CD8⁺
Maintenance of pre-existir
binding activates tumour-s
cells pre-treatment in ADR
expanded CD8⁺ T-cells und
progression ensues. T-cells pre-treatment in ADR001 (non-responder). TCR repertoire clonality is limited clonal expansion of CD8⁺ T-cells pre-treatment in ADR001 (non-responder). TCR repertoire clonality is limited. (4) Clonal replacement o binding activates tumour-specific CD8' T-cells during therapy response. **(3)** Limited clonal expansion of CD8'
cells pre-treatment in ADR001 (non-responder). TCR repertoire clonality is limited. **(4)** Clonal replacement
ex expanded CD8⁺ T-cells under nivolumab. Drug-binding occurs on non-tumour specific CD8⁺ T-cells and tumour
progression ensues.
The progression ensues. progression ensues. T-cells under nivolumab. Drug-binding occurs on non-tumour specific CD8⁺
|
|
| progression ensues.

Key resources table in separate files
RESOURCE AVAILABILITY
Lead Contact
Further information and requests fo $\begin{array}{c} \text{I} \\ \text{I} \\ \text{F} \end{array}$ Lead Contact
Further information and r
Lead Contact, Samra Tura
Materials Availability Further inform
Further inform
Lead Contact,
Materials Ava
This<mark>p</mark>study dic Further information and requests for resources and reagents should be directed to and will be fulfilled by the
Lead Contact, Samra Turajlic <u>(samra.turajlic@crick.ac.uk)</u>.
This $\mathbb B$ study did not generate new unique reagen

$\begin{array}{c} 1 \\ 7 \end{array}$

Materials Availability
This as Availability.
This as adding the senerate new unique reagents. Materials Availability
This astudy did not gen
Data and code availab
EXPERIMENTAL MODI This \boxtimes study did not generate new unique reagents.
Data and code availability
EXPERIMENTAL MODEL AND SUBJECT DETAILS

 $\frac{1}{2}$)
EXPERIMENTAL MODEL AN
Clinical studies
ADAPTeR (NCT02446860)
therapy in metastatic ccR $\frac{1}{t}$ **Clinical studies**
ADAPTeR (NCT02446860) is a single-arm, oper
therapy in metastatic ccRCC. Planned interim
enrolled had their first Response Evaluation Cr
response assessment. ADAPTeR was initially a_l EDAPTER (NCT02446860) is a single-arm, open-label, phase 2 study of nivolumab therapy as pre-operative
therapy in metastatic ccRCC. Planned interim analysis took place after six months after the last patient
enrolled had t therapy in metastatic correct contract metastatic correct planned interim analysis to the last patient encoded

enrolled had their first Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) defined objective
 response assessment. ADAPTeR was initially approved by NRES Committee London Fulham on 01/12/2014.
ADAPTeR is performed in accordance with the ethical principles in the Declaration of Helsinki, Good Clinical
Practice and a ADAPTeR is performed in accordance with the ethical principles in the Declaration of Helsinki, Good Clinical
Practice and applicable regulatory requirements.

infusion every 2-weeks. Eligible patients were 18 years of age or older, had histologic confirmation of Nivolumab was administered at a dose of 3mg per kilogram of body weight as a 60-minute intravenous
infusion every 2-weeks. Eligible patients were 18 years of age or older, had histologic confirmation of
advanced or metasta $\frac{1}{3}$ Infusion every 2-weeks. Eligible patients were 18 years of age or older, had histologic confirmation of
advanced or metastatic renal-cell carcinoma (RCC) with predominantly clear cell component with at least one
site of di infusion every 2-weeks. The distanced or metastatic renal-cell carcinoma (RCC) with predominantly clear cell component with at least one
site of disease outside the kidney measurable according to the RECIST version 1.1, wi and the disease outside the kidney measurable according to the RECIST version 1.1, with no prior systemic
therapy for ccRCC. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
1. Key e site of disease or another condition requiring systemic disease or another condition of disease or another condition requiring systemic treatment with either corticosteroids (>10mg daily prednisolone equivalent) or other i therapy for concerning patients had an Eastern Cooperative Oncology Cooperative Oncology 1.
1. Key exclusion criteria were need for immediate nephrectomy, any active, known or suspected autoimmune
disease or another condit disease or another condition requiring systemic treatment with either corticosteroids (>10mg daily
prednisolone equivalent) or other immunosuppressive medications within 14-days of study drug
administration (excluding viti prednisolone equivalent) or other immunosuppressive medications within 14-days of study drug
administration (excluding vitiligo, Type 1 diabetes mellitus, residual hypothyroidism due to autoimmune
condition only requiring condition only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not
expected to recur in the absence of an external trigger). During the course of the study, inclusion expanded to
tho condition only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger). During the course of the study, inclusion expanded to tho expected to recur in the absence of an external trigger). During the course of the study, inclusion expanded to
those who have had a prior nephrectomy but are suitable for on treatment biopsies. The prognostic factors
asse those who have had a prior nephrectomy but are suitable for on treatment biopsies. The prognostic factors
assessed for the risk categorisation are as per the published IMDC criteria³⁷: time to systemic therapy (<1
year), assessed for the risk categorisation are as per the published IMDC criteria³⁷: time to systemic therapy (<1
year), performance status, anaemia, hypercalcaemia, neutrophilia and thrombocytosis. Presence of zero
(favourabl year), performance status, anaemia, hypercalcaemia, neutrophilia and thrombocytosis. Presence of zero (favourable-risk), one (intermediate-risk), and two or three (poor-risk) factors provides the categorisation.
20
20 (favourable-risk), one (intermediate-risk), and two or three (poor-risk) factors provides the categorisation.

The progression free survival (PFS), and overall survival (OS). Exploratory endpoints were overall response rate (ORR), progression free survival (PFS), and overall survival (OS). Exploratory endpoints pertain to biomarker metastatic corresponsible complementary estimately subplementary entries response rate (statistically progression free survival (PFS), and overall survival (OS). Exploratory endpoints pertain to biomarker analyses.
Patient providents deemed clinically suitable for nephrectomy at baseline were scheduled for surgery after the fourth
cycle of treatment. Patients not deemed clinically suitable for nephrectomy at baseline would undergo surgery
if repries of treatment. Patients not deemed clinically suitable for nephrectomy at baseline would undergo surgery
If an excellent clinical response is observed and if surgery was clinically appropriate. Nivolumab treatment w cycle of treatment. Patient in the second clinical method is upper to the phrectomy of treatment was recommenced post-operatively upon sufficient recovery, and until disease progression. Patients who remained clinically un if an excellent clinical response is observed and it supply that and it is observed and it also remained clinically unsuitable for nephrectomy continued nivolumab treatment until disease progression.
For translational stud

recommenced post-operations commenced post-operative recoversion.
For translational study sample collection, baseline tumour biopsy via appropriate guidance (ultrasound or
computer tomography [CT]) at least 3 days and up t For translational study sample collection, baseline tumour biopsy via appropriate guidance
computer tomography [CT]) at least 3 days and up to 14 days prior to starting nivolumab
Tumour multiple regions of nephrectomy spec $\frac{1}{2}$ For transiemal study study studies and up to 14 days prior to starting nivolumab was obtained.
Tumour multiple regions of nephrectomy specimen were sampled, as well as image guided biopsy of
regressing lesions or at diseas Tumour multiple regions of nephrectomy specimen were sampled, as well as image guided biopsy of
regressing lesions or at disease progression either at site of progression or, if not possible, percutaneous
primary renal tum Tumor multiple regressing lesions or at disease progression either at site of progression or, if not possible, percutaneous
primary renal tumour biopsy, prior to commencement of any subsequent treatment. Blood samples were primary renal tumour biopsy, prior to commencement of any subsequent treatment. Blood samples were
collected at each tumour sampling timepoint.

Autopsy samples from ADR001, ADR005, and ADR015 were obtained through the PEACE Study (NIHR 18422;
NCT03004755), where samples are harvested within ~48 hours from death. All patients were co-recruited to concern at each tumour sampling intependent
Autopsy samples from ADR001, ADR005, and
NCT03004755), where samples are harvested
the TRACERx Renal study (NCT03226886; s ノーセ Autor Caupter Memberse from ADR001, Manus and ADR001, ADR001, MCT03004755), where samples are harvested within \sim 48 hours from death. All patients were co-recruited to the TRACERx Renal study (NCT03226886; see secondary NCTO3004886; see secondary author list for the full list of TRACERx Renal
Consortium investigators). Patient and sample metadata (i.e. age a diagnosis, sex, clinical response, biopsy site)
are provided as Table S1 and Sup consortium investigators). Patient and sample metadata (i.e. age a diagnosis, sex, clinical response, biopsy site)
are provided as Table S1 and Supplemental Data Table 1. All the patients provided written informed consent. are provided as Table S1 and Supplemental Data Table 1. All the patients provided written informed consent. are provided as Table S1 and Supplemental Data Table 2.1 and the patients provided interferent method of the protocols, amendments and informed consent forms were approved by the institutional review board or independent e

METHOD DETAILS
Sample collection. Tumour and normal tissue were collected via image-guided percutaneous biopsies, ex vivo independent ethical
Independent ethic of the Sample collected
Sampling at nephrectomy, and at autopsy. Multiregion sample
Sampling at nephrectomy, and at autopsy. Multiregion sample |
|
|
| Sample collection.

sampling at nephre

obtained at neph

multiregion sampled fr Sample concerion. Tumour and normal tissue were concered via mage-guided percutaneous biopsies, ex vivo
sampling at nephrectomy, and at autopsy. Multiregion samples were obtained with all modalities. For samples
obtained a obtained at nephrectomy, and at autopsy. Multimage of autopsy. The substitute with all modeling obtained at nephrectomy, resected specimens were reviewed macroscopically by a pathologist to guide multiregion sampling for t multiples sampled from the "tumour slice" using a 6mm punch biopsy needle. The punch was changed between
samples to avoid contamination. The total number of samples obtained reflects the tumour size with a
minimum of 3 bio samples to avoid contamination. The total number of samples obtained reflects the tumour size with a
minimum of 3 biopsies that are non-overlapping and equally spaced. Areas which are obviously fibrotic or
haemorrhagic are recorded. Normal kidney tissue was sampled from areas distant to the primary tumour and labelled N1. For all minimum of 3 biomateum of 3 biology and the statement is made to reflect macroscopically
heterogeneous tumour areas. Primary tumour regions are labelled as R1, R2, R3.Rn and locations are
recorded. Normal kidney tissue was heterogeneous tumour areas. Primary tumour regions are labelled as R1, R2, R3.Rn and locations are
recorded. Normal kidney tissue was sampled from areas distant to the primary tumour and labelled N1. For all
samples collec heterogeneous tumour areas. Primary tumour regions are labelled as R1, R1, R2, R3.Rn and locations are
recorded. Normal kidney tissue was sampled from areas distant to the primary tumour and labelled N1. For all
samples co recorded. Normal kidney areas distant to the principle in the primary tumour and labelled the recorded samples collected, each were split into two for snap freezing and formal in fixing respectively, such that the fresh fr samples constants and were spin the two formal metals and formalin many freperties, and that the
fresh frozen sample has its mirror image in the formalin-fixed sample which is subsequently paraffin
embedded. Fresh samples from firstness samples were placed in a 1.8 ml cryotube and immediately snap frozen in liquid nitrogen for
embedded. Fresh samples were placed in a 1.8 ml cryotube and immediately snap frozen in liquid nitrogen for
21 embedded. Fresh samples were placed in a 1.8 ml cryotube and immediately snap frozen in liquid nitrogen for

processed to separate buffy coat and peripheral blood mononuclear cells (PBMCs).
30 Nucleic acid extraction, DNA and RNA library preparation and sequencing. DNA and RNA were co-extracted
19 from fresh-frozen tumour tissue processed to separate buffy coat and peripheral blood mononuclear cells (PBMCs).

Nucleic acid extraction, DNA and RNA library preparation and sequencing. DNA and RNA were co-extracted

from fresh-frozen tumour tissue usi From fresh-frozen tumour tissue using AllPrep DNA/RNA mini kit (Qiagen). RNA from peripheral blood
Mononuclear cells (PBMC) were extracted from blood stored in Tempus tubes using the Tempus™ Spin RNA
Isolation Kit (Invitr from fresh-from frame in the lange of the period, that the transmitted period is mononuclear cells (PBMC) were extracted from blood stored in Tempus tubes using the Tempus™ Spin RNA
Isolation Kit (Invitrogen). Germline DN mononuclear cells (PBMC). Germline DNA was isolated from whole blood using the DNeasy Blood and Tissue kit
(Qiagen). DNA yield and quality were assessed on TapeStation4200 (Agilent) and Qubit Fluorometric
quantification (T ISOL (Qiagen). DNA yield and quality were assessed on TapeStation4200 (Agilent) and Qubit Fluorometric
Invitrition (ThermoFisher Scientific). Samples were normalised to either 3 ug or 200ng and sheared to 150-
Invitrition (Congris). DNA yield and quality were arrested on TapeStationally (Consist) and Charlent Presenting
quantification (ThermoFisher Scientific). Samples were normalised to either 3 ug or 200ng and sheared to 150-
200bp using quantification (Thermortication Chemoty) Camples international to either 2 ug or 2000p using a Covaris-E220 or LE220-plus. Agilent SureSelectXT enriched libraries were constructed following
the manufacturer's manual or aut 2006 nanufacturer's manual or automated (using the Agilent Bravo liquid handling platform) SureSelectXT Target Enrichment System for Illumina Paired-end Multiplexed Sequencing Library protocol. Hybridisation and capture we Target Enrichment System for Illumina Paired-end Multiplexed Sequencing Library protocol. Hybridisation and
capture were performed using the Agilent SureSelectXT Human All Exon v5 capture library. Final libraries were
sequ Target Irreprend In the Agilent SureSelectXT Human All Exon v5 capture library. Final libraries were
Sequenced to a target coverage of 250x with 101bp paired-end reads multiplexed on the Illumina HiSeq4000
Sequencing platf sequenced to a target coverage of 250x with 101bp paired-end reads multiplexed on the Illumina HiSeq4000
sequencing platform. The extracted RNA was normalised to 100ng for library construction using RNA-Ribozero
(ribodeple sequencing platform. The extracted RNA was normalised to 100ng for library construction using RNA-Ribozero
(ribodeplete) Library Preparation Kits. The prepared libraries were multiplexed and QC'ed before paired-end
sequenc requencing plant that the extracted RNA was normalized to 100 ng method. The extracted and QC'ed before paired-end
sequencing with target coverage of 50 million reads per sample on HiSeq4000 sequencing platforms (Illumina) (ribodeplete) Library Preparation Kits. The preparation Kits. The prepared and QC'ed before pairs of the sequencing with target coverage of 50 million reads per sample on HiSeq4000 sequencing platforms (Illumina).
RNA was sequencing with target coverage of 50 million reads per sample on HiSeq or equencing platforms (Mahmma).
RNA was extracted from blood for TCR sequencing from the following cases and timepoints: all cases (n=15)
SNV, and IN

pre- and post-treatment.
RNA was extracted from an interval on the sequencing from and time format
SNA was equenced by Hiseq were aligned to the reference human genome (build hg19), using the Burrows-Wheeler SNV, and INDEL calling
SNV, and INDEL calling
sequenced by Hiseq were
Aligner (BWA) v0.7.15. w the second for the second second to the second second to the second second second to the second second second to the second SCRIPT THE CALLING THE CONDUCT CONDUCT CALLING FROM THE CALLING FROM SEQUENCES SEQUENCES Aligner (BWA) v0.7.15. with seed recurrences (-c flag) set to 10000⁹⁰. Intermediate processing of Sam/Bam files was performed using Aligner (BWA) v0.7.15. with seed recurrences (-c flag) set to 10000³⁵. Intermediate processing of Sam/Bam
files was performed using Samtools v1.3.1 and deduplication was performed using Picard 1.81
(http://broadinstitute filttp://broadinstitute.github.io/picard/). Single Nucleotide Variant (SNV) calling was performed using Mutect
1.1.7 and small scale insertion-and-deletions (INDELs) were called running VarScan v2.4.1 in somatic mode
1.1.7 (http://broadinationstitute.github.io/problems/). Single Nucleotide Variant (SNV) calling VarScan v2.4.1 in somatic mode
with a minimum variant frequency (--min-var-freq) of 0.005, a tumour purity estimate (--tumour-purit with a minimum variant frequency (--min-var-freq) of 0.005, a tumour purity estimate (--tumour-purity) of 0.75 and then validated using Scalpel v0.5.3 (scalpel-discovery in --somatic mode) (intersection between two caller 0.75 and then validated using Scalpel v0.5.3 (scalpel-discovery in --somatic mode) (intersection between two callers taken) $91-93$. SNVs called by Mutect were further filtered using the following criteria: i) \leq 5 alte callers taken) $91-93$. SNVs called by Mutect were further filtered using the following criteria: i) \leq 5 alternative reads supporting the variant and variant allele frequency (VAF) of \leq 1% in the corresponding germl reads supporting the variant and variant allele frequency (VAF) of \leq 1% in the corresponding germline sample, ii) variants falling into mitochondrial chromosome, haplotype chromosome, HLA genes or any intergenic region one sample, vi) sequencing depth need to be ≥20 and ≤3000 across all samples. Dinucleotide substitutions ing the mitochondrial chromosome of both forward and reverse strand reads supporting the variant, iv) >5
reads supporting the variant in at least one sample, v) variants were required to have a VAF of 0.01 in at least
one reads supporting the variant in at least one sample, v) variants were required to have a VAF of 0.01 in at least
one sample, vi) sequencing depth need to be \geq 20 and \leq 3000 across all samples. Dinucleotide substitut one sample, vi) sequencing depth need to be \geq 20 and \leq 3000 across all samples. Dinucleotide substitutions (DNV) were identified when two adjacent SNVs were called and their VAFs were consistently balanced (based on ONV) were identified when two adjacent SNVs were called and their VAFs were consistently balanced (based
on proportion test, P≥0.05). In such cases the start and stop positions were corrected to represent a DNV and
freque (DNV) were reconsigned when the suppose on the sum of the NNV summer corrected to represent a DNV and frequency related values were recalculated to represent the mean of the SNVs. Variants were annotated using Annovar⁹⁴ on proportion test, P≥0.05). In such cases the start and stop positions were corrected to represent a DNV and
frequency related values were recalculated to represent the mean of the SNVs. Variants were annotated using
Anno Annovar⁹⁴. Individual tumour biopsy regions were judged to have failed quality control and excluded from
22 Annovar⁹⁴. Individual tumour biopsy regions were judged to have failed quality control and excluded from
22
2 and that copy number calling failed. Driver variants are manually reviewed and predicted for variant effect, and
variant annotations on the heatmap are only for confident driver events.
Methylation specific PCR. Methylatio

that copy number calling failed. Driver called the manually reviewed and predicted of calling theory, and
variant annotations on the heatmap are only for confident driver events.
Methylation specific PCR. Methylation of th Methylation specific PCR. Methylation of the VHL promoter was detecte
of patient DNA using the EZ DNA Methylation-Direct kit (Zymo Res
amplified in the PCR using methylation specific oligonucleotides follo $\frac{1}{c}$ of patient DNA using the EZ DNA Methylation-Direct kit (Zymo Research). Bisulphite treated DNA was amplified in the PCR using methylation specific oligonucleotides followed by Big Dye terminator Sanger sequencing. Methylat amplified in the PCR using methylation specific oligonucleotides followed by Big Dye terminator Sanger

Neoantigen calling. Neoantigen predictions were derived by first determining the 4-digit HLA type for each sequencing. Methylation protected CpG sequences.
The methylation protected CpG sequences.
Neoantigen calling. Neoantigen predictions were derived by first determining the 4-digit HLA type for each
patient, along with mutat For methylation protected open upper
Neoantigen calling. Neoantigen prediction
patient, along with mutations in class | HI
mutant peptides were computed, based of |
|
|
| patient, along with mutations in class | HLA genes, using POLYSOLVER⁹⁵. Next, all possible 9, 10 and 11-mer
mutant peptides were computed, based on the detected somatic non-synonymous SNV and INDEL mutations
in each sam mutant peptides were computed, based on the detected somatic non-synonymous SNV and INDEL mutations
in each sample. Binding affinities of mutant and corresponding wildtype peptides, relevant to the
corresponding POLYSOLVE in each sample. Binding affinities of mutant and corresponding wildtype peptides, relevant to the corresponding POLYSOLVER-inferred HLA alleles, were predicted using NetMHCpan (v3.0)⁹⁶ and NetMHC (v4.0)⁹⁷. Neoantigen corresponding POLYSOLVER-inferred HLA alleles, were predicted using NetMHCpan (v3.0)⁹⁶ and NetMHC corresponding POLYSOLVER-inferred HLA alleles, were predicted using NetMHCpan (v3.0)⁹⁷ and NetMHC
(v4.0)⁹⁷. Neoantigen binders were defined as strong binders if their %rank was below <0.5 for the mutant and
>0.5 for th

(v4.0)". Neoantigen binders were defined as strong binders if their %rank was below <0.5 for the mutant and
>0.5 for the wildtype protein.
TMB, fsINDEL burden, neonatigen burden, wGII. To calculate sample-level TMB, fsIN TMB, fsINDEL burden, neor
neoantigen burden, variants
sequencing but on a per samp - 「
「
「 THE STANDER STATIST TERRATION IS THE CONDUCTED THE STATIST THE STATIST REGION OF THE STATIST ARE REGULATED SUR

Sequencing but on a per sample-basis. Variants were restricted to positions falling inside the targeted captur neoantigen burden, variants were multi-region burden as described above for multi-region the sequencing but on a per sample-basis. Variants were restricted to positions falling inside the targeted capture range (±50bp padd sequencing but on a per sample-basis. The frameshift (TMB) was calculated as the number of exonic non-
synonymous SNVs per mega base. The frameshift (NDEL (fs)NDEL) burden was calculated as the total number
of exonic frame weighted on each of the 22 autosomal chromosomes, was estimated as the weighted genome instability index synonic frameshift INDELs per sample. The neoantigen burden was calculated as the total number of predicted strong binders per sample. The average proportion of the genome with aberrant copy number, weighted on each of the predicted strong binders per sample. The average proportion of the genome with aberrant copy number,
weighted on each of the 22 autosomal chromosomes, was estimated as the weighted genome instability index
(wGII).

SNP calling. Single nucleotide polymorphisms (SNPs) were called in the germline sample using Platypus v0.8.1 weighted on each of the 22 autosomal chromosomal chromosomes as the weighted genome instability index.
With calling. Single nucleotide polymorphisms (SNPs) were called in the germline sample using Platypus v0.8.1
With defa (weight)
SNP ca
with de
based $\begin{array}{c} \frac{4}{\pi} \\ \frac{1}{\pi} \end{array}$ With default parameters apart from --genindels=0 and --minMapQual=40. Tumour regions were genotyped
based on the variants identified in the germline (parameters set to --minPosterior=0 --
getVariantsFromBAMs=0). SNPs with based on the variants identified in the germline (parameters set to --minPosterior=0 --
getVariantsFromBAMs=0). SNPs with a minimum coverage of 50x in the germline and the tumour sample were
used for allele-specific copy n based on the variants increasing to the variants in the germine (parameters set to ---------------------------
getVariantsFromBAMs=0). SNPs with a minimum coverage of 50x in the germline and the tumour sample were
used for

get used for allele-specific copy number segmentation.
Figure of 50 x in the specific copy number segmentation.
The fault parameters on paired tumour-normal sequencing data⁹⁸. Outliers of the derived log2-ratio (logR) ca Used only alleled someon
Copy number analysis. CNVkit v0.7.3 was used with
Absolute Deviation Winsorization before case-spec $\begin{array}{cc} 1 & 1 \ 1 & 1 \end{array}$ Copy number analysis. Coutliers of the derived log2-ratio (logR) calls from CNVkit were detected and modified using Median
Absolute Deviation Winsorization before case-specific joint segmentation of fresh-frozen samples to Absolute Deviation Winsorization Before case-specific joint segmentation of fresh-frozen samples to identify
genomic segments of constant $logR^{99}$. Formalin-fixed and paraffin-embedded (FFPE) samples were segmented
23 genomic segments of constant logR⁹⁹. Formalin-fixed and paraffin-embedded (FFPE) samples were segmented
23
23 were called as losses or gains relative to overall sample wide estimated ploidy. Driver copy number was
identified by overlapping the called somatic copy number segments with putative driver copy number regions
identified identified by overlapping the called somatic copy number segments with putative driver copy number regions
identified by Beroukhim et al.¹⁰⁰. Allele-specific segmentation was performed using the paired PSCBS method
after identified by Beroukhim et al.¹⁰⁰. Allele-specific segmentation was performed using the paired PSCBS method
after removal of single-locus outliers (R package PSCBS v0.61.0¹⁰¹).
Purity and ploidy estimate. Tumour samp

identified by Beroukhim et al.²⁰⁰. Allele-specific segmentation was performed using the paired PSCBS method
after removal of single-locus outliers (R package PSCBS v0.61.0¹⁰¹).
Purity and ploidy estimate. Tumour samp after removal of single-locus outliers (R package PSCBS v0.61.0 ²⁰²).
Purity and ploidy estimate. Tumour sample purity, average plo
segment were estimated using ABSOLUTE v1.2 in allelic mode¹⁰². I
ABSOLUTE solutions segment were estimated using ABSOLUTE v1.2 in allelic mode¹⁰². In line with recommended best practice all
ABSOLUTE solutions were reviewed by 3 researchers, with solutions selected based on majority vote. Purity
assigned ABSOLUTE solutions were reviewed by 3 researchers, with solutions selected based on majority vote. Purity assigned 0.1 for samples below ABSOLUTE estimate thresholds for comparison analysis of samples between assigned 1.1 for samples below ABSOLUTE estimate an entities for comparison analysis of samples below ABS
 Subclonal deconstruction. To estimate the CCF of a mutation, we used the following formula:

responders and non-responders and supply to the Subdivident Subdivident Subdivident Subdivident Subdivident Su
The Subdivident Subdivident Subdivident Subdivident Subdivident Subdivident Subdivident Subdivident Subdividen

$$
VAF = \frac{CN_{mut} * CCF * p}{CN_n * (1 - p) + CN_t * p}
$$

 $VAR = \frac{CN_{mut} * CCF * p}{CN_n * (1-p) + CN_t * p}$
Where VAF is the variant allele frequency of the mutation, p the estimated tumour purity, CN_n
copies carrying the mutation and CN, the local copy number in the tumour cells. CN_n is the l $\frac{1}{2}$ \
(
i copies carrying the mutation and CN_t the local copy number in the tumour cells. CN_n is the local copy number
in the non-tumour proportion of the sample which was assumed to be 2. The CN_{mut} and CCF were estimated
thr in the non-tumour proportion of the sample which was assumed to be 2. The CN_{mut} and CCF were estimated
through iteration of all possible combinations of CCF (range 0.01 to 1, by 0.01) and CN_{mut} (range 1 to CN_t, by 1 through iteration of all possible combinations of CCF (range 0.01 to 1, by 0.01) and CN_{mut} (range 1 to CN_t, by 1)
using the formula above to identify the best fit CCF.
Genomic contraction, persistence and expansion a

using the formula above to identify the best fit CCF.
Genomic contraction, persistence and expansion analysis. For each patient with matched pre- and post-
treatment WES data (N=8 patients), the pre-treatment CCF was compa samples. In patients with multiple pre-treatment samples, the median pre-treatment CCF was used. In each t
S
S
C categories: "Genomic contraction", "Genomic persistence", "Genomic expansion"³⁹. A mutation was defined
to have undergone genomic contraction if the CCF decreased by ≥10% from pre- to post-treatment or if the
mutation w samples. In patients with multiple pre-treatment samples, the median pre-treatment CCF was used. In each
post-treatment sample, all nonsynonymous SNVs and fsINDELs were assigned to one of the following
categories: "Genomi post-treatment sample, all nonsynonymous SNVs and fsINDELs were assigned to one of the following
categories: "Genomic contraction", "Genomic persistence", "Genomic expansion"³⁹. A mutation was defined
to have undergone g categories: "Genomic contraction", "Genomic persistence", "Genomic expansion"³⁹. A mutation was defined
to have undergone genomic contraction if the CCF decreased by ≥10% from pre- to post-treatment or if the
mutation w mutation was present in the pre-treatment but not the post-treatment sample; genomic expansion if the CCF increased by ≥10% from pre- to post-treatment or if the mutation was present in the post-treatment but not the preincreased by \geq 10% from pre- to post-treatment or if the mutation was present in the post-treatment but not
the pre-treatment sample; genomic persistence if the CCF in the post-treatment sample was within the range
of the pre-treatment sample; genomic persistence if the CCF in the post-treatment sample was within the range
of ±10% of the pre-treatment CCF. The proportion of mutations falling into each category was calculated for
nonsyno of ±10% of the pre-treatment CCF. The proportion of mutations falling into each category was calculated for
nonsynonymous SNVs and fsINDELs and repeated with only neoantigen encoding mutations. An enrichment
test (Fisher's nonsynonymous SNVs and fsINDELs and repeated with only neoantigen encoding mutations. An enrichment
test (Fisher's exact test) was performed to determine whether mutations which encode neoantigens were
more likely to under nonsynonsynony is the repeat of the remain in the remaining more the field repeating more likely to undergo genomic contraction than the remaining nonsynonymous SNVs and fsINDELs.
Mutational signature analysis. Mutational

the state of the state of the performance of a seconder mutation mutation in the state is and forming the more
more likely to undergo genomic contraction than the remaining nonsynonymous SNVs and fsINDELs.
Mutational signa more likely to undergo set of the Mutational Signatures of the restimated using the deconstructSigs p
R¹⁰³. Sample specific mutational signature analysis was restricted to samples with at least 50 mutation
M¹⁰³. Sample |
|
| R^{103} . Sample specific mutational signature analysis was restricted to samples with at least 50 mutations.
24 R¹⁰³. Sample specific mutational signature analysis was restricted to samples with at least 50 mutations.
R¹⁰³.
Sample specific mutational signature analysis was restricted to samples with at least 50 mutations.
R¹⁰³

 $\frac{1}{1}$ Analysis for mismatrich repair definitions, Champed Co. Mindeletter, M. M. Champed generations genes into performed: POLD3, MLH3, MSH6, RPA4, LIG1, MLH1, MSH2, MSH3, PCNA, PMS2, POLD1, POLD2, POLD4, RFC1, RFC2, RFC4, RFC5, RFC2, RFC3, RFC4, RFC5, RPA1, RPA2, RPA3, SSBP1, EXO1.

Analysis for mutations associated with defective antigen presentation rand, its mutations in the following nominated genes was performed: B2M, CIITA, IRF1, PSME1, PSME2, PSME3, ERAP1, ERAP2, HSPA, PSMA7, HSPC, HSPBP1, TAP1 following nominated genes was performed: B2M, CINA, INT, TSME1, TSME2, TSME3, ERAP1, ERAP2, HSTA,
PSMA7, HSPC, HSPBP1, TAP1, TAP2, TAPBP, CALR, CNX, CANX, PDIA3.
Detection of B2M mutations by Sanger sequencing
Validation o PSMA7, HSPC, HSPBP1, TAP1, TAP2, TAPBP, CALR, CNX, CANX, PDIA3.

|
|
|
| Validation of the *B2M* mutation was performed using
the ABI 3700. 20ng of patient DNA was a
B2M:c.42_45delTCTT:p.S14fs. PCR conditions inve
oligonucleotide primer annealing at 55oC and sequence
reagents. Oligonucleotide on the ABI 3700. 20ng of patient DNA was amplified for exon 1 of *B2M*, to enable detection of *B2M*:c.42_45delTCTT:p.S14fs. PCR conditions involved 35 cycles of denaturation at 950C, followed by oligonucleotide primer ann B2M:c.42_45delTCTT:p.S14fs. PCR conditions involved 35 cycles of denaturation at 950C, followed by oligonucleotide primer annealing at 55oC and sequence extension at 720C using Qiagen Taq polymerase and
reagents. Oligonucleotide sequences used are: Forward: aacgggaaagtccctctctc; Reverse: agatccagccctggactagc.
Bulk RNAse

oligonucleotide sequences used are: Forward: aacgggaaagtccctctctc; Reverse: agatccagccctggactagc.
 Bulk RNAseq data processing. RNAseq data were mapped to the hg19 reference human genome using the

STAR¹⁰⁴ algorithm, a Rulk RNAseq data processing. RNAseq data were mapped to the hg19 reference human genome using the STAR¹⁰⁴ algorithm, and transcript and gene abundance were estimated by RSEM¹⁰⁵ with default parameters.
Samples were exc $\frac{1}{2}$ Bulk RNA¹⁰⁴ algorithm, and transcript and gene abundance were estimated by RSEM¹⁰⁵ with default parameters.
Samples were excluded if they had less than 15,000 genes detected.
Human endogenous retrovirus (HERV) analys

Samples were encanced if they had less than 15,000 genes detected.

Human endogenous retrovirus (HERV) analysis. Expression of p

analysed. HERV loci used in these three studies^{28, 50, 51} were taken fr

66 and 3173 loci Human endogenous retrovirus (HERV) analysis. Expression of previously annotated HERVs^{28, 50, 51} was Human endogenous retrovirus (HERV) analysis. Expression of previously annotated HERVs^{28, 30}, ³¹ was
analysed. HERV loci used in these three studies^{28, 50, 51} were taken from Mayer et al. ⁵³ and Vargiu et al. ⁵⁴ 66 and 3173 loci respectively. BLASTn was used to match example sequences from HERVs in Mayer et al. to GRCh38, chromosome coordinates with the greatest homology over the greatest length were taken as the best match. The L GRCh38, chromosome coordinates with the greatest homology over the greatest length were taken as the best
match. The Lift Genome Annotations tool from UCSC (https://genome.ucsc.edu/cgi-bin/hgLiftOver) was used
to convert a Figure 2.1 Coordinates with the Lift Genome Annotations tool from UCSC (https://genome.ucsc.edu/cgi-bin/hgLiftOver) was used
to convert annotated GRCh37 HERV loci coordinates from Vargui et al. to GRCh38 coordinates. Compa matrix the Lift Centric Chift Centric Condinates from Vargui et al. to GRCh38 coordinates. Comparing the
new coordinates, 47 of the 66 HERVs from Mayer et al. were present in the list of 3173. Coordinates of all the
unique to convert annotated GRCh38⁵⁷. For this custom annotation, different regions of the same provirus (e.g. the LTR and internal genes) were annotated separately, these regions were merged to allow accurate quantitation.
LTR new coordinates, 47 of the 66 HERVs from Mayer et al. Weighted in the list of services in an injure elements were then compared to a custom repeat region annotation previously built using the Dfam
2.0 library (v150923) for 2.0 library (v150923) for GRCh38⁵⁷. For this custom annotation, different regions of the same provirus (e.g. the
LTR and internal genes) were annotated separately, these regions were merged to allow accurate quantitation LTR and internal genes) were annotated separately, these regions were merged to allow accurate quantitation
of reads from the same provirus⁵⁷. LTR-containing repeat regions from the custom annotation had to begin,
end, of reads from the same provirus⁵⁷. LTR-containing repeat regions from the custom annotation had to begin, end, or be fully contained within previously annotated loci to be considered a match, a buffer of 5 bases either e end, or be fully contained within previously annotated loci to be considered a match, a buffer of 5 bases either
end of the locus was included. Previously annotated HERV loci from Mayer et al. and Vargiu et al. were found
 end of the locus was included. Previously annotated HERV loci from Mayer et al. and Vargiu et al. were found
to overlap multiple repeat regions per locus in our custom annotations, or were found to overlap no repeat
region to overlap multiple repeat regions per locus in our custom annotations, or were found to overlap no repeat
regions at all. Some loci also overlapped other endogenous retroelement types such as LINEs and SINEs, as
well as o to overlap multiple repeat regions per locus in our custom annotation, it that to overlap me repeat regions at all. Some loci also overlapped other endogenous retroelement types such as LINEs and SINEs, as
well as overlapp regions at all some loci all all some loci all all some loci all some loci all some loci all all something elements was considered rather than expression of all repeats and genes overlapping previously annotated loci. Expr elements was considered rather than expression of all repeats and genes overlapping previously annotated
loci. Expression was measured using read counts calculated by the featureCounts function from the Subread
25 loci. Expression was measured using read counts calculated by the feature Counts function from the Subread loci. Expression was measured using read counts calculated by the featureCounts function from the Subread

package²⁰⁶ (with parameters -p -C -B -f -T 2), multi-mapping reads were not counted. Analysis for purified
immune cell subset expression were performed on publicly available datasets from Linsley et al. ¹⁰⁷ (accession
 immune cell subset expression were performed on publicly available datasets from Linsley et al. ²⁰⁷ (accession
no. GSE60424 (GEO)) and Kazachenka et al.¹⁰⁸ (E-MTAB-8208 (EMBL-EBI)). LTR-overlapping transcripts
expresse expressed highly specifically in ccRCC were previously described⁵⁷. These transcripts were identified through *de novo* transcriptome assembly and their expression quantified in by transcript per million calculations, a expressed highly specifically in ccRCC were previously described³⁷. These transcripts were identified through de novo transcriptome assembly and their expression quantified in by transcript per million calculations, as p

de novo transcriptome assembly and their expression quantified in by transcript per million calculations, as
previously described⁵⁷.
Differential gene expression analysis, pathway analysis and gene set enrichment. DESe previously described".
Differential gene expredifferential expression
dispersion. To identify g Differential gene expression analysis, pathway analysis and gene set enrichment. DESeq2²⁰⁹ was used for differential expression analysis, using the binomial Wald test after estimation of size factors and estimation of di only transcripts with normalized count number >5 in at least 5 patients. Pathway analysis was performed using
the R package XGR¹⁰⁸ using the gene ontology biological process (GOBP) databases. Induced and suppressed
trans only the R package XGR¹⁰⁸ using the gene ontology biological process (GOBP) databases. Induced and suppressed
transcripts were analysed separately against the background of all tested transcripts. The "lea" ontology
algo transcripts were analysed separately against the background of all tested transcripts. The "lea" ontology
algorithm was used.
T-cell subset gene signature. Gene signature or single gene enrichment was evaluated using RSEM

T-cell subset gene signature. Gene signature or single gene enrichment was evaluated using RSEM abundance, ی
T-<mark>cell subset gene si</mark>
z score scaled across
immune-related sign Z score scaled across all samples for which RNA-Seq was available. Signature analysis was performed using 22 immune-related signatures listed below: i) the Danaher immune score is a 60-marker gene signature derived from p from pan-cancer RNAseq analysis for 14 immune cell populations, where marker genes have been
benchmarked against histological tumour-infiltrating lymphocyte (TIL) estimates and flow cytometry data^{58, 111};
ii) IMmotion150 from pan-cancer RNAseq analysis for 14 immune cell populations, where manne generator details
benchmarked against histological tumour-infiltrating lymphocyte (TIL) estimates and flow cytometry data^{58, 111};
ii) IMmotion1 benchmarked against histological tumour-infiltrating lymphocyte (TIL) estimates and flow cytometry data^{30, 111};
ii) |Mmotion150 ²⁰; iii) Javelin101²¹.
(1) Danaher Tcells : CD3D, CD3E, CD3G, CD6, SH2D1A, TRAT1
(2) Dan ii) IMmotion150 20 ; iii) Javelin101 21 .
(1) Danaher Tcells : CD3D, CD3E, CD3G, CD6, SH2D1A, TRAT1
(2) Danaher CD8 : CD8A, CD8B

-
-
- (
(
((2) Danaher CD8 : CD8A, CD8B
(3) Danaher Cytotoxic : CTSW, GNLY, GZMA, GZMB, GZMH, KI
(4) Danaher Bcells : BLK, CD19, MS4A1, TNFRSF17, FCRL2, KIA
(5) Danaher NKcells : NCR1, XCL2, XCL1 (3) Danaher Cytotoxic : CTSW, (3)
(4) Danaher Bcells : BLK, CD19,
(5) Danaher NKcells : NCR1, XC
(6) Danaher CD45 : PTPRC
- (4) Danaher Bcells : BLK, CD19, MS4A1, TNFRSF17, FCRL2, KIAA0125, PNOC, SPIB, TCL1A
(5) Danaher NKcells : NCR1, XCL2, XCL1
(6) Danaher CD45 : PTPRC
(7) Danaher DC : CCL13, CD209, HSD11B1
-
-
- (6) Danaher CD45 : PTPRC
(6) Danaher DC : CCL13, CD209, HSD11E
(8) Danaher CD8Ex : CD244, EOMES, LA
(9) Danaher Mac : CD163 ,CD68 , CD (7) Danaher DC : CCL13, CI
(8) Danaher CD8Ex : CD244
(9) Danaher Mac : CD163 ,
(10) Danaher Mast : MS4A
- (5) Danaher NKcells : NCR1, XCL2, XCL1
(6) Danaher CD45 : PTPRC
(7) Danaher DC : CCL13, CD209, HSD11B1
(8) Danaher CD8Ex : CD244, EOMES, LAG3, PTGER4 (8) Danaher CD8Ex : CD244, EOMES, LAG3
(9) Danaher Mac : CD163 ,CD68 , CD84
(10) Danaher Mast : MS4A2,TPSAB1,CPA3
(11) Danaher Neut : CSF3R, S100A12, CEA
-
-
- (9) Danaher Mac : CD163 ,CD68 , CD84, MS4A4A
(10) Danaher Mast : MS4A2,TPSAB1,CPA3,HDC,TPSB2
(11) Danaher Neut : CSF3R, S100A12, CEACAM3, FCAR, FC
(12) Danaher NKCD56 : IL21R, KIR2DL3, KIR3DL1, KIR3DL2 (11) Danaher Neut : CSF3R, S100A12, CEACAM3, FCAR, FCGR3B, FPR1, SIGLEC5
- (10) Danaher Mast : MS4A2,TPSAB1,CPA3,HDC,TPSB2
(11) Danaher Neut : CSF3R, S100A12, CEACAM3, FCAR
(12) Danaher NKCD56 : IL21R, KIR2DL3, KIR3DL1, KIR3I
(13) Danaher Th1 : TBX21 (12) Danaher NKCD56 : IL21R, KIR2DL3, KIR3DL1, KIR3DL2
(13) Danaher Th1 : TBX21
(14) Danaher Treg : FOXP3

 (16) immotion 160 (16) (16) (16) (16) (16) (16) (16)

-
-

(13) Danaher Th1 : TBX21
(13) Danaher Th1 : TBX21
(14) Danaher Treg : FOXP3
(15) IMmotion150 Angio : VEGFA, KDR, ESM1, PECAM1, AI (14) Danaher Treg : FOXP3
(15) IMmotion150 Angio : VEGFA, KDR, ESM1, PECAM1, AN
(16) IMmotion150 Teff : CD8A, IFNG, PRF1, EOMES, CD274 (15) IMmotion150 Angio : \
(15) IMmotion150 Angio : \
(16) IMmotion150 Teff : CD $\frac{1}{2}$ (16) IMmotion150 Teff : CD8A, IFNG, PRF1, EOMES, CD274

(17) IMmotion150 Myeloid : CXCL1, CXCL2, CXCL3, CXCL8, IL6, PTGS2
(18) Javelin101 TCR : CD3G, CD3E, CD8B, THEMIS, TRAT1, GRAP2, CD247
(19) Javelin101 TCell : CD2, CD96, PRF1, CD6, IL7R, ITK, GPR18, EOMES, S
(20) Javelin101 (
(
((19) Javelin101 TCell : CD2, CD96, PRF1, CD6, IL7R, ITK, GPR18, EOMES, SIT1, NLRC3
(20) Javelin101 NK : CD2, CD96, PRF1, CD244, KLRD1, SH2D1A
(21) Javelin101 chemo : CCL5, XCL2 (20) Javelin101 NK : CD2, CD96, PRF1, CD244, KLRD1, SH2D1A
(21) Javelin101 chemo : CCL5, XCL2
(22) Javelin101 other : CST7, GFI1, KCNA3, PSTPIP1 (21) Javelin101 chemo : CCL5, XCL2
(22) Javelin101 chemo : CCL5, XCL2
The signature score was calculated as the arithmetic mean of :

(22) Javelin101 other : CST7, GFI1, KCNA3, PSTPIP1
The signature score was calculated as the arithmet
signature for each sample. (22) Javelinnian Control of The signature score was calculated as the arithmetical signature for each sample. $\begin{array}{c}\n1 \\
2\n\end{array}$

TCR sequencing. TCR β -chain sequencing was performed by utilizing whole RNA extracted from tissue samples
or from cryopreserved PBMC samples, by using a quantitative experimental and computational TCR sequencing pipeline described previously¹¹²⁻¹¹⁵. An important feature of this protocol is the incorporation of a ٦
د د or from cryopreserved PBMC samples, by using a quantitative experimental and computational TCR
sequencing pipeline described previously¹¹²⁻¹¹⁵. An important feature of this protocol is the incorporation of a
UMI attache sequencing pipeline described previously¹¹²⁻¹¹³. An important feature of this protocol is the incorporation of a
UMI attached to each cDNA TCR molecule that enables correction for PCR and sequencing errors, which allows
 Higher quantitative precision compared to alternate protocols in the TCR sequences retrieved^{113, 116}. The suite
of tools used for TCR identification, error correction and CDR3 extraction is freely available at
https://gi of tools used for TCR identification, error correction and CDR3 extraction is freely available at
https://github.com/innate2adaptive/Decombinator.
For each TCR, we computed the abundance as the count of UMIs mapping to thi

of tools used for the computed for the dimensioners in the correction and CDR3 extractions.

For each TCR, we computed the abundance as the count of UMIs mapping to this TCR divided by the total

number of UMIs in the samp For each TCR, we computed the abundance as the
number of UMIs in the sample. If several sample
resulting abundance was calculated as the sum of co - 「 「 「 」
| For each TCR, we computed the abundance as the count of UMIS mapping to this TCR annual and the mapping number
number of UMIs in the sample. If several samples were available at a given patient-timepoint pair, the
resultin resulting abundance was calculated as the sum of counts for this TCR across the available samples divided by the sum of total counts across these samples.

Repertoire similarity measure. The similarity between two TCR repertoires was assessed with the normalised
dot product (also known as the cosine similarity) between the vectors of TCR abundance. This measure is a well-established metric widely used in machine learning to compare numerical vectors and gives a value $\frac{1}{2}$ Repertoire similarity, including the similarity pertoires the vectors of TCR abundance. This measure is a well-established metric widely used in machine learning to compare numerical vectors and gives a value between 0 (no well-established metric metric metric metric with metric with metric with an identical
between 0 (no similarity, that is, orthogonal vectors) and 1 (complete similarity, from vectors with an identical
magnitude and directi between 1 (no similarity, massis) and is strong similarity, mind a periphere similarity, from vectors of equal
length, indexed by the union of TCRs found in both repertoires and containing the number of times each TCR is
d length, indexed by the union of TCRs found in both repertoires and containing the number of times each TCR is
detected in each of the two repertoires (each position contains an integer \geq 0). The similarity between the detected in each of the two repertoires (each position contains an integer \geq 0). The similarity between the two detected in each of the two repertoires (each position contains an integer ≥0). The similarity between the two
similarity $=$ $\frac{TCR1 \cdot TCR2}{\parallel TCR1 \parallel * \parallel TCR2 \parallel}$

$$
Similarity = \frac{TCR1 \cdot TCR2}{\parallel TCR1 \parallel \text{*} \parallel TCR2 \parallel}
$$

where and are the abundance vectors, represents the vector product and paired vertical bars represent the $\frac{1}{2}$ \ddot{a} where and are the abundance vectors, represents the vector product and paired vertical bars representations.
Euclidean norm of the vector.

For spatial similarity (Figure 513), the similarity measure was performed on the TCR abundance vector
For spatial similarity (Figure 513), the similarity measure was performed on the TCR abundance vector
from each sample w abundance vectors derived from _(patient) and pairs, pairs.
For spatial similarity (Figure S13), the similarity measure wa
from each sample within a (patient, timepoint) pair. For this
not compared. - 「

— 「

 from each sample within a (patient, timepoint) pair. For this analysis, samples from different timepoints were
not compared.

Repertoire clonality index. The clonality index was estimated for each sample by using the command entropy from the entropy R package, on the basis of the observed frequency of the TCRs in that sample $\frac{1}{1}$ From the entropy R package, on the basis of the observed frequency of the TCRs in that sample
 $\frac{1}{2} \int \frac{1}{2} \$

$$
Clonality = 1 - \left(\sum p_i \times \log p_i\right) / \ln N
$$

where p_i is the frequency of the ith TCR in the repertoire and is the number of TCRs in that repertoire. \overline{a}

 $\ddot{}$ **Classification of expanded, contracted and persistent TCRs**. The difference in abundance between Pretreatment and On-treatment was calculated with the poisson test function in R, as the data were counts. TCRs with P value $\frac{1}{1}$

frequency thresholds in the tumour repertoires. To measure how such defined expanded TCRs were treatment and On-treatment was calculated with the poisson.
With P values above 0.01 were labelled as persistent.
Classification of expanded TCRs. We counted the number of TCRs detected with frequencies above a range of
fr MAN PARCE ALTERTAR ALTERTAR APPERTURN
Classification of expanded TCRs. We counted the num
frequency thresholds in the tumour repertoires.
representative of the shape of the TCR distribution $\frac{1}{2}$ frequency thresholds in the tumour repertoires. To measure how such defined expanded TCRs were
representative of the shape of the TCR distribution captured by the clonality score, we computed the
prevalence of the expanded representative of the shape of the TCR distribution captured by the clonality score, we computed the prevalence of the expanded population amongst the entire repertoire, for each threshold. To do so, we took the sum of cou prevalence of the expanded population amongst the entire repertoire, for each threshold. To do so, we took prevalence of the sum of counts for expanded TCRs and divided it by the sum of all counts in the sample. The proportion
obtained was then correlated to the matched clonality score with the Spearman's rank correlation.
To f

the sum of counts for expanded to the matched clonality score with the Spearman's rank correlation.
To focus on the most expanded TCRs (Figures 4E-4F and S15-S16), we examined those present above a
threshold frequency of 2 To focus on the most expanded TCRs (Figures 4E-4F and S15-S16), we examined those prese
threshold frequency of 2/1,000 (corresponding to the top 1% of the empirical TCR frequency distri
this threshold, which we already des threshold frequency of 2/1,000 (corresponding to the top 1% of the empirical TCR frequency distribution). At
this threshold, which we already described in previously published work ⁶¹, the correlation between clonality
a this threshold, which we already described in previously published work ⁶¹, the correlation between clonality
and proportion of repertoire occupied by expanded TCRs is very strong and the number of TCRs labelled as
expan and proportion of repertoire occupied by expanded TCRs is very strong and the number of TCRs labelled as
expanded is greater than for higher thresholds for which this correlation is also significant, which enables to
keep

CDR3 amino acid clustering. The pairwise similarity between pairs of TCRs was measured on the basis of expanded to greatest amount of data whilst still applying a stringent filtering step.
 CDR3 amino acid clustering. The pairwise similarity between pairs of TCRs was measured on the basis of

amino acid triplet sharing. S constanting the greater of the greater of the greater of data whilst consider the greater of data whilst amino acid triplet sharing. Sharing was quantified using the normalized string parameters string dot (type = 'spectru amino acid triplet sharing. Sharing was quantified using the normalized string kernel function stringdot (with
parameters stringdot (type = 'spectrum', length = 3, normalized = TRUE) from the Kernlab package. The kernel
is parameters stringer in the consecutive amino acids) shared by two CDR3s,
normalized by the number of triplets in each CDR3 being compared. The TCR similarity matrix was converted
into a network diagram by using the iGraph is commalized by the number of triplets in each CDR3 being compared. The TCR similarity matrix was converted
into a network diagram by using the iGraph package in R. Two TCRs were considered connected if the
similarity ind into a network diagram by using the iGraph package in R. Two TCRs were considered connected if the similarity index was >0.82 (threshold previously optimised in a separate study).
28 into a network diagram by using the iGraph package in R. Two TCRs were considered in the international international international consideration in the international consideration in the considered in a separate study). similarity index was >0.82 (threshold previously optimised in a separate study).

The counts of clusters obtained (*Nreal*) for the input size, for each sample, we randomly selected, outside of
the real clustering structure, a number of CDR3s equal to the number of expanded CDR3s in that sample and
look the real clustering structure, a number of CDR3s equal to the number of expanded CDR3s in that sample and
looked for clusters around those. This control step was repeated 10 times for each (patient, timepoint) pair
and we looked for clusters around those. This control step was repeated 10 times for each (patient, timepoint) pair
and we computed the average number of clusters obtained for those control (*Ncon*) and used *Nreal* /*Ncon* as
t and we computed the average number of clusters obtained for those control $(Ncon)$ and used $Nreal/Ncon$ as
the normalised cluster count value (Figure 4F, Figure S15F).
For Figure S15D, as depicted in Figure S15E, we used the clus

and we computed the average number of clusters obtained for those control (*NCON*) and used *NTeut/NCON* as
the normalised cluster count value (Figure 4F, Figure S15F).
For Figure S15D, as depicted in Figure S15E, we used the normalised cluster count value (Figure 41, Figure 214, Figure 41, Figure 41, Figure 41, Figure 41, Figure
The normalised cluster count value of the cluster count value of the cluster also expanded post-treatment or as initial count of maintained (resp. replaced) expanded clones present in that sample to obtain the proportion treatment samples and retrospectively labelled appearance at the atom point of the number of Pre-
treatment clusters containing maintained (resp. replaced) expanded clones which was then divided by the
initial count of mai trival count of maintained (resp. replaced) expanded clones present in that sample to obtain the proportion
displayed in FigureS15D.
Frequency ratio. We wanted to capture the rate of clonal replacement that occurs in the

infinition of maintained (resp. replaced) expanded clones present in that sample to obtain the proportion
Frequency ratio. We wanted to capture the rate of clonal replacement that occurs in the tumour repertoires.
To do so Example, Summigue

Frequency ratio. We walk

To do so, for each exparentio of the observed fre To do so, for each expanded TCR at baseline that could also be detected after treatment, we computed the ratio of the observed frequency at baseline divided by the observed frequency after-treatment. To derive a metric for To do so, for each expanded TCR at baseline that could also be detected after treatment, we computed the ratio of the observed frequency at baseline divided by the observed frequency after-treatment. To derive a metric for

Multiplex Immunofluorescence Staining and Image Analysis. FFPE blocks were cut in 2 micron thick slides. metric for each patient, we computed the average of ratio scores of ratio scores of the average in a second
(those that could not be detected after treatment were excluded).
Multiplex Immunofluorescence Staining and Image (the construction after the detection of the detection of the detection of Multiplex Immunofluorescence Staining and Image Analysis. FFF
The slides were baked for 60 minutes and stained using the anti-
Leica Bond III machi Multiplex Immunofluorescence Staining Image Analysis. The state interest in 2 micron multiplex and the slides were
Leica Bond III machine was used for the immunofluorescence staining. Images of the stained slides were
acqu The slides were baked for the immunofluorescence staining. Images of the stained slides were
acquired by using the Vectra 3 automated quantitative pathology imaging system (Akoya Biosciences).
Matching H&E image of each sl EFTE FERT III in the interact of the interact for the immunity formulations, and are stationary and accuracy acquired by using the Vectra 3 automated quantitative pathology imaging system (Akoya Biosciences).
Matching H&E Matching H&E image of each slide was reviewed by a pathologist and areas to annotate on the
immunofluorescent images for analysis were identified. Necrotic and stromal areas as well as non-tumour
areas were excluded and tu Mattemage of each slide was reviewed. Slides for pathologist and areas as well as non-tumour
areas were excluded and tumour areas were scored. Slides for patient ADR009 were not evaluable due to
necrosis. Total of 61 sampl in a manuscript in analysis of analysis were scored. Slides for patient ADR009 were not evaluable due to
necrosis. Total of 61 samples (41 pre-treatment and 20 on treatment samples) for the first mIF panel and 60
samples (areas were excluded and tumour areas were excluded and 20 on treatment samples) for the first mIF panel and 60
samples (40 pre-treatment and 20 on treatment samples) were for the second IF panel were used for analysis.
The necrosity of the First manner and 20 on treatment samples) were for the second IF panel were used for analysis.
The following antibodies were used for mIF staining: CD3 (Mouse monoclonal, LN10, 1:100 dilution on Opal
520 i samples (40 pre-treatment and 20 on treatment samples) were for the second I, LN10, 1:100 dilution on Opal 520 in 1:50 dilution), CD4 (Mouse monoclonal, 4B12, 1:50 dilution on Opal 540 in 1:100 dilution), CD8 (Mouse monocl The following antibodies were used for mini-elaming: CD3 (model interaction) and 540 in 1:100 dilution), CD8 (Mouse monoclonal, 4B11, 1:100 dilution on Opal 540 in 1:150 dilution on Opal 620 in 1:150 dilution), FoxP3 (Mous 520 monoclonal, 4B11, 1:100 dilution on Opal 540 in 1:150 dilution and on Opal 620 in 1:150 dilution), FoxP3
(Mouse Monoclonal, 236A/E7, 1:80 dilution on Opal 570 in 1:150 dilution), CD163 (Mouse monoclonal, 10D6,
1:100 di (Mouse Monoclonal, 236A/E7, 1:80 dilution on Opal 570 in 1:150 dilution), CD163 (Mouse monoclonal, 10D6,
1:100 dilution on Opal 690 in 1:50 dilution), Granzyme B (Mouse monoclonal, 11F1, 1:80 dilution, on Opal 620
in 1:150 (Mouse Monoclonal, 236A/E7, 237 2128 inhabite on open one can be considered in the consistency 236A
1:100 dilution on Opal 690 in 1:50 dilution), Granzyme B (Mouse monoclonal, 11F1, 1:80 dilution, on Opal 620
1.150 dilutio

1:150 dilution)
1:150 dilution)
Up to 25 multispectral images (MSI) were acquired per slide depending on the size of the tumour to include all
1:150 dilution, text monoclonal, increase acquired per slide depending on the s in
Up to 25 multispe
representative ar
algorithms for ea representative areas of the tumour. Representative MSIs from different slides were used while training the algorithms for each marker. Scoring of each slide was performed using the inForm software on Vectra. The
Z9 algorithms for each marker. Scoring of each slide was performed using the information on Vectra. The information $\frac{1}{2}$

with poor tissue quality were excluded from the analysis. Merged data obtained by using the inForm software
was analysed using the phenoptrReports tool (Akoya Biosciences) on R. T-cells subsets (CD8⁺, CD4⁺ effectors,
T was analysed using the phenoptrReports tool (Akoya Biosciences) on R. T-cells subsets (CD8⁺, CD4⁺ effectors,
Tregs and CD8⁺CD4⁺ double positive cells) were scored both out of total cells counted on each slide and o was analysed using the phenoptrReports tool (Akoya Biosciences) on R. T-cells subsets (CD8⁺, CD4⁺ effectors,
Tregs and CD8⁺CD4⁺ double positive cells) were scored both out of total cells counted on each slide and o Tregs and CD8'CD4' double positive cells) were scored both out of total cells counted on each slide and out of
the total T cells counted. CD163 cells were scored out of total cells counted per slide. Overall granzyme
expre expression was scored in relation to the total T-cell and CD163⁺ cell count. Granzyme B expression on CD8⁺
cells was scored out of the total CD8⁺ cells. Median scoring value was used for each patient per time point a expression was scored in relation to the total T-cell and CD163' cell count. Granzyme B expression on CD8'
cells was scored out of the total CD8⁺ cells. Median scoring value was used for each patient per time point and
t

cells was scored out of the total CD8" cells. Median scoring value was used for each patient per time point and
two-sided Mann-Whitney U test was used for statistical analysis of the data.
The mIF and mIHC antibody panels the mistable Mann-White Mann-White
The miF and miHC antibody panels were designed to evaluate T-cell subsets
expression. This was conducted given 1) double positive (CD8⁺CD4⁺) T-cells
have previously been described in $\begin{array}{c} \mathbf{1} \\ \mathbf{1} \\ \mathbf{2} \end{array}$ Expression. This was conducted given 1) double positive (CD8⁺CD4⁺) T-cells with high degrees of TCR clonality
have previously been described in $ccRCC^{117}$; 2) myeloid inflammation has been associated with blunting of expression. This was conducted given 1) double positive (CD8⁺CD4⁺
have previously been described in ccRCC¹¹⁷; 2) myeloid inflammat
anti-tumour T-cell activity in metastatic ccRCC²⁰; and 3) high tumot
have previousl Fraction has been associated with blunting of the infiltration with B-cells and plasma cells comes across cancer types $118-120$. have previously been described in ccRCC²⁰; 2) myeloid inflammation has been associated with blunting of
anti-tumour T-cell activity in metastatic ccRCC²⁰; and 3) high tumour infiltration with B-cells and plasma cells
h

anti-tumour T-cell activity in metastatic ccRCC²⁰; and 3) high tumour infiltration with B-cells and plasma cells
have previously been shown to correlate with favourable clinical outcomes across cancer types ¹¹⁸⁻¹²⁰.
Im Immunohistochemistry. Formalin-fixed paraffin-embedded tissue sections of clear-cell renal cell carcinoma
and normal tonsil tissues were subjected to haematoxylin and eosin and multiplex immunostaining. The
primary antibod $\begin{array}{c} \mathbf{I} \\ \mathbf{I} \end{array}$ Immunological parafilm-embedded tissues were subjected to haematoxylin and eosin and multiplex immunostaining. The
primary antibodies used for multiplex immunolabeling are as follows: CD19 (Rabbit monoclonal, SP291,
1:1000 primary antition distributed for multiplex in the formulation of the formulation), PD-1 (Mouse Monoclonal, NAT105/E3,
1:2 dilution).
To establish optimal staining conditions each antibody was tested and optimized on 2-4 um

1:2 dilution).
1:2 dilution).
To establish optimal staining conditions each antibody was tested and optimized on 2-4 um cut tissue sections
of human reactive tonsil and normal kidney by applying conventional single immunoh 1:2 manus,
To establish
of human rea
sections were ٦
>
< of human reactive tonsil and normal kidney by applying conventional single immunohistochemistry. In brief
sections were de-waxed and re-hydrated prior to the multiplex immunolabeling whose procedure was adapted
and perform sections were de-waxed and re-hydrated prior to the multiplex immunolabeling whose procedure was adapted
and performed according to the established protocol described elsewhere¹²¹. Total of 59 samples (40 pre-
treatment and performed according to the established protocol described elsewhere¹²¹. Total of 59 samples (40 pre-
treatment and 19 on treatment samples) for the mIHC panel.
Staining assessment and data handling. Specificity of th

treatment and 19 on treatment samples) for the mIHC panel.
Staining assessment and data handling. Specificity of the staining was assessed by a haematopathologist with
expertise in multiplex-immunostaining. Scanned slide **THE TREATMENT SAMPLES (THE MITCH PANEL**
Staining assessment and data handling. Specificity of the sta
expertise in multiplex-immunostaining. Scanned slide image
Digital Pathology System (Hamamatsu, Japan). Total of 60 $\frac{1}{2}$ Expertise in multiplex-immunostaining. Scanned slide images were obtained with the use of NanoZoomer
Digital Pathology System (Hamamatsu, Japan). Total of 60 samples (41 pre-treatment and 19 on treatment
samples) were used

samples) were used for analysis.
Flow cytometry. Renal tumour resections and normal tissue were cut into small pieces (2-3mm) by using
sterile disposable scalpel plus forceps in RPMI (Sigma-Aldrich) with Collagenase I (S tumour and normal tissue), Liberase (for ADR001 tumour tissue) and DNAse I (Roche) and was digested for 1 **|**
ミ �� First disposable scalpel plus forceps in RPMI (Sigma-Aldrich) with Collagenase I (Sigma-Aldrich) (for ADR013

tumour and normal tissue), Liberase (for ADR001 tumour tissue) and DNAse I (Roche) and was digested for 1

hour the art and normal tissues), Liberal (for ADROC 1 tumour and tissue) and DNAS liberal tissues and through
ha 70-µm cell strainer by using 5-10 ml of RPMI containing 2% fetal bovine serum (FBS) to obtain a single cell
suspe a 70-µm cell strainer by using 5-10 ml of RPMI containing 2% fetal bovine serum (FBS) to obtain a single cell
suspension. Lymphocytes were obtained from the single cell suspension by using Ficoll Paque Plus (GE
30 suspension. Lymphocytes were obtained from the single cell suspension by using Ficoll Paque Plus (GE suspension. Lymphocytes were obtained from the single cell suspension by using Ficoll Paque Plus (GE and 2%FBS and cryopreserved in 90% FBS with 10% dimethyl sulfoxide (Sigma-Aldrich). PBMCs were isolated
from blood samples collected in Vacutainer EDTA blood collection tubes (BD) using Ficoll Paque Plus (GE
Healthcare) de and 2002 and 2003 angles collected in Vacutainer EDTA blood collection tubes (BD) using Ficoll Paque Plus (GE
Healthcare) density gradient centrifugation and cryopreserved in in 90% FBS with 10% dimethyl sulfoxide
(Sigma–A Healthcare) density gradient centrifugation and cryopreserved in in 90% FBS with 10% dimethyl sulfoxide
(Sigma–Aldrich).
Thawed lymphocytes were washed with 1x phosphate-buffered saline (PBS) and were stained with the

 $\frac{1}{2}$
Thawed lymphocytes were washed with 1x phosphate-buffered saline (PBS) and were stained with the
antibodies listed below. Antibody mastermixes were prepared in Brilliant Staining Buffer (BD). eBioscience™ (Sigma–Aldrich).
Thawed lympho:
antibodies listed
Foxp3 / Transcrip $\begin{array}{ccc} \mathbf{1} & \mathbf{1} & \mathbf{1} \\ \mathbf{1} & \mathbf{1} & \mathbf{1} \\ \mathbf{1} & \mathbf{1} & \mathbf{1} \end{array}$ antibodies listed below. Antibody mastermixes were prepared in Brilliant Staining Buffer (BD). eBioscience™
Foxp3 / Transcription Factor Staining Buffer Set was used for the intracellular staining. Samples were stained
us Fluorescent reactive dye, BV570), CD57 (QA17A04, BV605), Ki67(B56, BV650), CD39 (TU66, BV711), CCR7 Forps) / Transcription Factor Staining Buffer Set was used for the intracellular staming. Samples were standing
using the following antibodies: CD8 (RPA-T8, BUV496), CD45RA (HI100, BUV563), CD4 (SK3, BUV615), CD38
(HIT2, B using the following antibodies: CD (MTTF) DDTPMP (MDDF) DDTPMP (MDDF) DDTPMP (PMP) DDTPMP (PDDF)
(HIT2, BUV737), CD3 (SK7, BUV705), CD57 (QA17A04, BV605), Ki67(B56, BV650), CD39 (TU66, BV711), CCR7
(G043H7, BV750), CD69(FN Fluorescent reactive dye, BV570), CD57 (QA17A04, BV605), Ki67(B56, BV650), CD39 (TU66, BV711), CCR7
(G043H7, BV750), CD69(FN50, BV785), CD103 (Ber-ACT8, BB515), CXR5 (RF8B2, PerCp-Cy5-5), TCF-7 (7F11A10,
PE), Granzyme B (G (G043H7, BV750), CD69(FN50, BV785), CD103 (Ber-ACT8, BB515), CXR5 (RF8B2, PerCp-Cy5-5), TCF-7 (7F11A10,
PE), Granzyme B (GB11, PE-CF594), CD25 (M-A251, PE-Cy5), PD-1 (EH12.2H7, PE-Cy7), TOX (REA473, APC),
HLA-DR (LN3, AF70 PE), Granzyme B (GB11, PE-CF594), CD25 (M-A251, PE-Cy5), PD-1 (EH12.2H7, PE-Cy7), TOX (REA473, APC),
HLA-DR (LN3, AF700), IgG4(Biotin), 4-1BB (4B4-1, BUV661), TIM3 (7D3, BV650), KLRG1 (13F12F2,
Superbright702), CD27 (O323, HLA-DR (LN3, AF700), IgG4(Biotin), 4-1BB (4B4-1, BUV661), TIM3 (7D3, BV650), KLRG1 (13F12F2,
Superbright702), CD27 (O323, BV750), ICOS (C398.4A, BV785), EOMES (WD1928, Percp-eFlour710), CTLA-4
(L3D10, APC), GITR (108-17, A HEAR-DR (END) MATED, NEW CORRECTING, THE CONSUMING THE CONSUMING SUPERDITION, CONSUMING SUPERDITION, CONSUMING
Superbright702), CD27 (O323, BV750), ICOS (C398.4A, BV785), EOMES (WD1928, Percp-eFlour710), CTLA-4
(L3D10, APC Supermances, CD27, CD27, 2022, CO224, APC, CO224, APC, Percep-et-examples were acquired on the BD
Symphony flow cytometer. Data was analysed using the FlowJo (version 10).
PD-1 competition binding assay to evaluate anti-PD

PBMC isolated from healthy individuals were activated in vitro using plate coated anti-CD3 and soluble anti-PD-1 competition binding assay to evaluate anti-PD1 monoclonal antibody binding
PBMC isolated from healthy individuals were activated in vitro using plate coated anti-CD3 and soluble anti-
CD28 with 100IU IL-2 per well. 50 ーー・リー was kept at 4°C overnight. Two washes using 200ul of PBS were performed to remove unbound antibodies the
next day. Subsequently, 2 x 10^5 PBMC were added into each well with subsequent addition of soluble anti- $CD28$ (2ug/ mL). The plate was placed into a humidified 37°C incubator for 72 hours. Following this period, the was kept at 4° C overnight. Two washes using 200ul of PBS were performed to remove unbound antibodies the
next day. Subsequently, 2 x 10^5 PBMC were added into each well with subsequent addition of soluble anti-
CD2 was kept at 48°C over a dated into each well with subsequent addition of soluble anti-
CD28 (2ug/ mL). The plate was placed into a humidified 37°C incubator for 72 hours. Following this period, the
wells containing activat next day. Subsequently, 2 x 10° PBMC were added into each well with subsequent addition of soluble anti-
CD28 (2ug/ mL). The plate was placed into a humidified 37°C incubator for 72 hours. Following this period, the
wells CD28 (2007) MLP and plate was placed into a humidiated 37°C included into a humidiated into a humidiated view the plane, the plane, the plane, we
discontinuities. PBS washes were used to remove unbound therapeutic antibodi wells containing activated Pamc were either included with 50ul (2.5mg) pembronizumated with 500 minutes. PBS washes were used to remove unbound therapeutic antibodies. Flow cytometric staining of CD3, PD-1 and anti-lgG4 wa 30 CD3, PD-1 and anti-IgG4 was performed thereafter.
31 Single-cell RNA/TCR Sequencing
Tumour infiltrating lymphocytes from ADR001 and AD013 were stained with CD3 (PE, SK7 clone), IgG4

(Biotinylated) and Streptavidin (BV650) antibodies for flow cytometry. Stained cells were FACS sorted as $\frac{3}{1}$ Tumour infiltrating lymphocytes from ADR001 and AD013 were stained with CD3 (PE, SK7 clone), IgG4
(Biotinylated) and Streptavidin (BV650) antibodies for flow cytometry. Stained cells were FACS sorted as
CD3⁺IgG4⁻ (40,0 CD3⁺IgG4⁻ (40,000 cells) and CD3⁺IgG4⁺ (20,000 cells) for ADR001 and CD3⁺IgG4⁻ (50,000 cells) and CD3⁺IgG4⁺
(90,000 cells) for ADR013. FACS sorted cells were single cell sorted using the 10X Genomic machine CD3'|gG4 (40,000 cells) and CD3'|gG4' (20,000 cells) for ADR001 and CD3'|gG4 (50,000 cells) and CD3'|gG4'
(90,000 cells) for ADR013. FACS sorted cells were single cell sorted using the 10X Genomic machine. The sorted
cells (90,000 cells) were processed using the 10X Genomic Chromium Next GEM Single Cell 5' Reagents Kit V2 (dual index)
for 5'gene expression library construction and V(D)J library construction. The samples were sequenced on the for 5'gene expression library construction and V(D)J library construction. The samples were sequenced on the Next Genomic Chromium Next Genomic Next Genomic Chromium Next Genomic don the Nigh Output Kit v2.5 (150 Cycles). for 5'gene expression library construction and V(D) library construction and samples were sequenced on the samples were setting to the samples were setting to the samples were sequenced on the samples were sequenced on the Next Sequence is the High Output Kit v2.5 (150 Cycles).
The High Output Kit v2.5 (150 Cycles).

Genomics). GEX reads were aligned to GRCh38 and counted using cellranger count, VDJ reads were aligned to cellranger's GRCh38 VDJ reference dataset using cellranger vdj. Expression matrices were analysed using the Seurat p Gellranger's GRCh38 VDJ reference dataset using cellranger vdj. Expression matrices were analysed using the Seurat package¹²². To remove technical variation in the data, TCR, ribosomal and heat-shock protein genes were r Seurat package¹²². To remove technical variation in the data, TCR, ribosomal and heat-shock protein genes
were removed from the analysis, also cells with mitochondrial reads making up >10% total read content were
remove Seurat package²²². To remove technical variation in the data, TCR, ribosomal and heat-shock protein genes
were removed from the analysis, also cells with mitochondrial reads making up >10% total read content were
removed removed. 8382 CD3⁺IgG4⁺ and 10083 CD3⁺IgG4⁺ cells in ADR013; and 4648 CD3⁺IgG4⁺ and 3343 CD3⁺IgG4⁺ cells
in ADR001 were retained after quality control filtering. Datasets were integrated using SCTransform
i removed. 8382 CD3'|gG4 and 10083 CD3'|gG4' cells in ADR013; and 4648 CD3'|gG4 and 3343 CD3'|gG4' cells
in ADR001 were retained after quality control filtering. Datasets were integrated using SCTransform
integration¹²³ us integration¹²³ using the recommended parameters and regressing the % mitochondrial read content. PCA and
UMAP dimensional reduction (dims = 1:30) and clustering (res = 0.3) was then performed using RunPCA,
RunUMAP, Find integration¹²³ using the recommended parameters and regressing the % mitochondrial read content. PCA and
UMAP dimensional reduction (dims = 1:30) and clustering (res = 0.3) was then performed using RunPCA,
RunUMAP, Find RunUMAP, FindNeighbours, and FindClusters. Publicly available gene signatures for T cell states were obtained
from the following publications: Schietinger et al.¹²⁴, Thommen et al.¹²⁵, Guo et al.¹²⁶, Li et al.¹²⁷, from the following publications: Schietinger et al.¹²⁴, Thommen et al.¹²⁵, Guo et al.¹²⁶, Li et al.¹²⁷, Yost et al.¹²⁸, Miller et al.⁸⁹, Zhou et al.¹²⁹, and Litchfield et al.¹³⁰ (Supplemental Data Table 3) from the following publications: Schietinger et al.¹²⁴, Thommen et al.¹²⁵, Guo et al.¹²⁶, Li et al.¹²⁴, Yost et al.¹²⁸,
Miller et al.⁶⁹, Zhou et al.¹²⁹, and Litchfield et al.¹³⁰ (**Supplemental Data Table 3** Miller et al.⁹⁹, Zhou et al.⁴⁹⁹, and Litchfield et al.⁴³⁰ (Supplemental Data Table 3). The proportion of reads
mapping to the genes in each signature for each cell was then calculated using PercentageFeatureSet. All
 NormalizeData, default parameters) using the MAST algorithm¹³¹ within FindMarkers. GOBP analysis was
carried out using the XGR package¹¹⁰ using the "lea" algorithm. scTCR data was analysed using scRepertoire¹³².
Cell carried out using the XGR package¹¹⁰ using the "lea" algorithm. scTCR data was analysed using scRepertoire¹³². Cells were considered of the same clone if they contained a matching TRB sequence and CDR3 gene.
QUANTIFICATION AND STATISTICAL ANALYSIS

CHE CHE CELLS WERE CONSIDERED ON THE SAME CONSIDERED ON THE SAME
CONDITIES CONTAINS AND STATISTICAL ANALYSIS
Statistical analysis was performed in P, and CoaphPad Prism 8. Correlation was earned out with the

 $\frac{1}{2}$ $\frac{1}{2}$ Statistical analysis was performed in R and GraphPad Prism 8. Correlation was carried out with the Spearman
nonparametric rank correlation test. We used mixed effect modelling when appropriate. We used the Mann–
Whitney tw Whitney two-tailed paired or non- paired nonparametric tests (as appropriate) to determine whether two
independent samples were selected from the same populations. P values were considered significant if less
than 0.05, an Independent samples were selected from the same populations. P values were considered significant if less
than 0.05, and significance values were corrected for multiple testing by Bonferroni correction when
appropriate. Hi than 0.05, and significance values were corrected for multiple testing by Bonferroni correction when
appropriate. High dimensional flow cytometry analysis was performed using FlowJo 10. Analyses and
visualization of HERV e appropriate. High dimensional flow cytometry analysis was performed using FlowJo 10. Analyses and
visualization of HERV expression were additionally performed in Qlucore Omics Explorer (Qlucore, Lund,
Sweden). Data visuali visualization of HERV expression were additionally performed in Qlucore Omics Explorer (Qlucore, Lund, Sweden). Data visualization was performed in BioRender, R and GraphPad Prism 8.
ADDITIONAL RESOURCES visualization of HERV expression with additionally performed in Question explorer (Question) and
Sweden). Data visualization was performed in BioRender, R and GraphPad Prism 8.
ADDITIONAL RESOURCES

SWEDEN). DATA VISUALIZATION WAS PERFORMED IN BIOREAD IN BIOREM 2.
Supportional registry numbers:
ADAPTeR: https://clinicaltrials.gov/ct2/show/NCT02446860
TRACERY Renal: https://clinicaltrials.gov/ct2/show/NCT03226886 $\begin{array}{c} \n\lambda \n\end{array}$ Clinical trial registry numbers:
ADAPTeR: https://clinicaltrials.gov/ct2/show/NCT024468
TRACERx Renal: https://clinicaltrials.gov/ct2/show/NCT03
PEACE: https://clinicaltrials.gov/ct2/show/NCT03004755 ADAPTeR: https://clinicaltrials.gov/ct2/show/NCT02446860 TRACERx Renal: https://clinicaltrials.gov/ct2/show/NCT03226886 PEACE: https://clinicaltrials.gov/ct2/show/NCT03004755 PEACE: https://clinicaltrials.gov/ct2/show/NCT03004755

Figure S1. Samples overview, a
(A) Consort diagrams for samplimmunofluorescence or immun
between TMB, fsINDEL load, ar
Genomic contraction analysis re Figure S1. Samples overview, and correlations and muscle income sequencing, RNAseq, TCRseq, and muscle immunofluorescence or immunohistochemistry analyses. (B) Boxplots showing no significant corre
between TMB, fsINDEL loa (A) Consort diagrams for the multiplexity analyses. (B) Boxplots showing no significant correlations
between TMB, fsINDEL load, and wGII to nivolumab response. Median pre-treatment values are shown. (C)
Genomic contraction in the contraction analysis results including neoantigens. Two-sided Mann-Whitney test was performed. *P*
Genomic contraction analysis results including neoantigens. Two-sided Mann-Whitney test was performed. *P*
Value >0. between they charge to all interest in the contractions of provisions in the experiment value of the thin (c)
Genomic contraction analysis results including neoantigens. Two-sided Mann-Whitney test was performed. P
value >

Genomic contraction analysis results including neoantigens. Two-sided Mann–Whitney test was performed. The value >0.05 considered not significant.
Figure S2. Schematic diagrams of ADR015 and ADR005 showing pre-/post-treatm Figure S2. Schematic diagrams of
Sampling, and evolution of metastatic
(A) Clinical timeline for ADR015, and (

ー s (「
「 (Figure S2. Schemation of metastatic disease

(A) Clinical timeline for ADR015, and (B) genomic data are shown. (C) Clinical timeline for ADR005, and (D)

PEACE samples with available TCRseq data. (E) The proportion of TCRs (A) Clinical timeline for ADR015, and (B) geno
PEACE samples with available TCRseq data. (E)
and Post-treatment during life (n=5) detected i
rate is greater than 0 are displayed. 3/5 were detected in region 1, region 2, re (A) Clientia, the proportion of TCRs that were expanded both Pre-treatment
PEACE samples with available TCRseq data. (E) The proportion of TCRs that were expanded both Pre-treatment
and Post-treatment during life (n=5) det and Post-treatment during life (n=5) detected in each post-mortem sample, only samples where the detection rate is greater than 0 are displayed. $3/5$ were detected in the lung metastatic and $1/5$, $1/5$, $2/5$ and $3/5$ rate is greater than 0 are displayed. 3/5 were detected in the lung metastatic and 1/5, 1/5, 2/5 and 3/5 were detected in region 1, region 2, region 3 and region 4 of the primary site, respectively. The median number of TCR sequences retrieved per post-mortem sample was 163 (range: 20-1340), and immune infiltration across sites we detected in region 2, region 2, region 2 and region 4 of the primary site, respectively. The median number of
TCR sequences retrieved per post-mortem sample was 163 (range: 20-1340), and immune infiltration across
sites we TER SERVICE PER TENDEM SAMPLE WAS 1999 TO 2014), and immune infinition across sites were uniformly low in all regions, as scored by expert pathologist review of haematoxylin and eosin stain slides (data not shown).
Slides

(A) Comparison of HERV annotations by Attig et al., Vargiu et al. and Mayer et al. Three examples are shown, Figure S3. Correspondence of HERV annotation and expression in immune cell types
(A) Comparison of HERV annotations by Attig et al., Vargiu et al. and Mayer et al. Three examples are shown,
depicting the position of GENCOD Figure Saret Correspondence of HERV annotations by Attig et al., Vargiu et al. and Mayer et al. This
depicting the position of GENCODE annotated genes, Dfam 2.0 annotated repear
RNAseq read pileup. (B) Expression of HERVs (A) Comparison of MERV annotations by Attigations and Mayer et al., Mayer et al., Martin Baranther are shown,

RNAseq read pileup. (B) Expression of HERVs previously associated with ccRCC or with nivolumab response, in

th The indicated purified immune cell types from public RNAseq datasets GSE60424 (top) and E-MTAB-8208
(bottom). Note the expression of LTR/ERVK|HERVK9-int~MER9a1|6|29876165|29881829 integration within
the HLA locus in most i (bottom). Note the expression of expression of the LTR/ERV1|LTR7|1|207633751|207634199 integration in
the HLA locus in most immune cell subsets and of the LTR/ERV1|LTR7|1|207633751|207634199 integration in
Figure S4. Violi

the HLA local monocration in most in most in the LTR, ERTL, ERTL, ERTL, ERTL, ERTL, IMES, IMMOTION
The Huatophils.
The S4. Violin plots comparing response groups at both timepoints by Danaher, IMMOTION150,
Javelin 101 sign

neutrophils.
Figure S4.
Javelin 101 si
See STAR M ーリー・シー Figure S1. The S1. Violity of the S1. Violity of the S1. State of spanning and the S1. See STAR Methods for details of signature analysis. The two-sided Mann-Whitney test performed on one value per patient (score averaged See **STAR Methods** for details of signature analysis. The
value per patient (score averaged by median value acros
significant P value are indicated (*: P<0.05; **: P<0.01). R
Figure S5. Immune cells subset comparisons of p See Proton Methods for accuration for agreement analysis. The two-sided Mann-White, the performed on one value per patient (score averaged by median value across biopsies if several available at a given time point), signif

significant P value are indicated (*: P <0.05). P P vol.01). R - responders, N-R - hon-responders.
Figure S5. Immune cells subset comparisons of pre- and post-treatment samples
(A) Immune cell subset expression levels in n Figure SS immune Call subset expression levels in non-responders and responders of Expression level of T-cell subsets out of total cells counted is shown. (C) Ration responders and responders at baseline and on treatment; Expression level of T-cell subsets out of total cells counted is shown. (C) Ratio of T-cells subsets in non-
responders and responders at baseline and on treatment; CD3⁺ T-cells to CD163⁺ myeloid cells, and CD8⁺ T-
3 responders and responders at baseline and on treatment; CD3+ T-cells to CD163⁺

T-cells to CD163⁺ myeloid cells, and CD8+

cells to CD163⁺ myeloid cell ratios between responders and non-responders on treatment is shown. (D)
Change in total GZMB expression and on CD8⁺ T cells from pre-treatment (six patients) to post-treatment
(week-9) is GZMB expression and on CD8⁺ T cells from pre-treatment (six patients) to post-treatment
vn (three patients).
htype dynamics in PBMC and intra- and inter-patient TCR repertoire heterogeneity
pertoires of multiple biopsi

Figure S6. Clonotype dynamics in PBMC and intra- and inter-patient TCR repertoire heterogeneity

(A) The TCR repertoires of multiple biopsies from a patient's tumour were sequenced and a pairwise (example)
Figure S6. Clonotype dynamics in P
(A) The TCR repertoires of multi
comparison of the repertoires of |
|
|
| Figure Section 20. The TCR repertoires of multiple biopsies from a patient's tumour were sequenced and
comparison of the repertoires of different biopsies from the same timepoint was performed by
cosine metric (STAR Method (A) The TCR repertoires of different biopsies from the same timepoint was performed by using the cosine metric (STAR Methods). The pairwise intratumoural TCR repertoire similarity is shown for each patient.
Each circle rep cosine metric (**STAR Methods**). The pairwise intratumoural TCR repertoire similarity is shown for each patient.
Each circle represents a comparison between two samples from the same patient $(n = 87 \text{ total comparisons})$ from 12 patients) Each circle represents a comparison between two samples from the same patient (*n* = 87 total comparisons from 12 patients). Red (resp. blue) circles indicate a pair of biopsies originating from the same site (resp. differ different metastatic sites). (B) Heat maps showing the pairwise similarities of a selection of 5 biopsies in the post-treatment nephrectomy for ADR001 (top) and ADR013 (bottom). Biopsies were selected based on comparable T post-treatment nephrectomy for ADR001 (top) and ADR013 (bottom). Biopsies were selected based on
comparable TCR counts. (C) Correlated clone sizes in blood samples. Scatter plots of blood clone size after
treatment and bef comparable TCR counts. (C) Correlated clone sizes in blood samples. Scatter plots of blood clone size after
treatment and before treatment are shown for all patients. Clones are colored by expansion/contraction
status (STA treatment and before treatment are shown for all patients. Clones are colored by expansion/contraction
status (STAR Methods). (D) The peripheral TCR repertoire clonality score pre-treatment and on-treatment is
shown for ea status (STAR Methods). (D) The peripheral TCR repertoire clonality score pre-treatment and on-treatment is
shown for each patient. Patients are split between responders and non-responders. Mixed-effect model P
value shown. shown for each patient. Patients are split between responders and non-responders. Mixed-effect model P
value shown. (E) The number of intratumoural (left panel) and peripheral (right panel) clones labelled as
expanded or c expanded or contracted between timepoints, per patient, normalized for the total number of clones tested.
Two-sided Mann-Whitney tests P value shown. (F) The peripheral cosine score between pre-treatment and
on-treatment i Two-sided Mann–Whitney tests P value shown. (F) The peripheral cosine score between pre-treatment and
on-treatment is shown for each patient. Patients are split between responders and non-responders. Two-sided
Mann–Whitney on-treatment is shown for each patient. Patient are split between response is an included that the state
Mann–Whitney test P value shown; n=12 patients.
Figure S7. Additional expanded TCRs metrics
(A) The arithmetic mean o

Mann–Whitney test P value shown; n=12 patients.
Figure S7. Additional expanded TCRs metrics
(A) The arithmetic mean of Pre/Post frequency raided Mann–Whitney test P value shown. (B) The |
|
|
| (A) The arithmetic mean of Pre/Post frequer
sided Mann–Whitney test P value shown. (B)
above each point; n=14 patients) for the rela
intratumoural repertoire pre-treatment occ
thresholds (ranging from all TCRs (threshold Representative network diagrams of pre-treatment intratumoural CDR3 β -chain sequences for patient sided Mann–Whitley test P value shown. (B) The Spearman's rank correlation coefficient and P value (shown
above each point; n=14 patients) for the relationship between the clonality score and the proportion of the
intratu thresholds (ranging from all TCRs (threshold of zero) up to those found at a frequency of $\geq 8/1,000$). (C)
Representative network diagrams of pre-treatment intratumoural CDR3 β -chain sequences for patient
ADR008. Th the superior (ranging from all TCRs (methods of zero) up to the superiorman at a frequences for patient
ADR008. The network shows sequences that are connected to at least one other TCR within the tumour.
Clustering was pe ADR008. The network shows sequences that are connected to at least one other TCR within the tumour.
Clustering was performed around expanded intratumoural TCRs (red circles). (D) The proportion of pre-
treatment expanded T circles). Paired two-sided Mann-Whitney test P value shown. (E) Pre-treatment clustering around maintained are also detected as expanded post-treatment and the ones that are not (respectively red circles and grey
circles). Paired two-sided Mann–Whitney test P value shown. (E) Pre-treatment clustering around maintained
and repla circles). Paired two-sided Mann–Whitney test P value shown. (E) Pre-treatment clustering around maintained
and replaced expanded clones for ADR008. (F) The post-treatment normalised number of clusters for the
networks c circles). Faired two-sided Mann–Whitney test P value shown. (L) The-treatment clustering around maintained
and replaced expanded clones for ADR008. (F) The post-treatment normalised number of clusters for the
networks con and replaced and replaced sequences is shown. Two-sided Mann-Whitney test P value shown; n=11
patients. (G) Representative network diagrams of post-treatment intratumoural CDR3 β -chain sequences for
patient ADR001 (lef patients. **(G)** Representative network diagrams of post-treatment intratumoural CDR3 β -chain sequences for
patient ADR001 (left) and for patient ADR013 (right). Clusters containing expanded sequences are shown.
34 patient ADR001 (left) and for patient ADR013 (right). Clusters containing expanded sequences are shown.
34 patient ADR001 (left) and for patient ADR013 (right). Clusters containing expanded sequences are shown.

 $\frac{1}{\epsilon}$ **Figure S8. scRNA- and TCRseq of ADR013 (responder) and ADR001 (non-responder)**

(A) UMAP of merged ADR001 (non-responder) and ADR013 (responder) scRNA data, coloured by cell type

definition (CD8 = CD8+/CD4-/FOXP3-, CD4 (A) UMAP of merged ADR001 (CD8 = CD8+/CD4-/FOXP3-, CD4 effector = CD8-/CD4+/FOXP3-, Treg = CD8-/FOXP3+). (B) Proportions
of each cell type recovered in each patient. (C) Differential gene expression analysis performed betw definition (CD) Differential gene expression analysis performed between IgG4⁺
and IgG4 cells in each cell type for each patient, average logFC then plotted for responder vs non-responder.
Regression line plotted using a of each cell type recovered in each patient. (C) Differential gene expression analysis performed between IgG4
and IgG4⁻ cells in each cell type for each patient, average logFC then plotted for responder vs non-responder. and |gG4 cells in each cell type for each patient, average |ogFC then plotted for responder vs non-responder.

Regression line plotted using a linear model, colours indicate whether a logFC change was found significant in
 either or both patients. (D) Heatmaps showing top genes which positively correlated (Pearson's correlation)
with TCR expansion in the non-responder (NR) patient. (E) Signature expression levels (calculated as the
proportio either or both patients. (D) Heatmaps showing top genes internation positively correlated (calculated as the proportion of cell transcript mapping to genes in signature) by non-responder (NR) and responder (R) and lgG4 bin with TCR expansion in the non-responder (NR) patients (2) signature expression level (calculated as the proportion of cell transcript mapping to genes in signature) by non-responder (NR) and responder (R) and lgG4 binding. binding. Significance levels show the result of Wilcox test between |gG4 bound and unbound cells. binding. Significance levels show the result of Wilcox test between IgG4 bound and unbound cells.

Supplementary Table

Table S1. Baseline demographics and patient characteristics and correlations with nivolumab response, and

sample annotations.

OS, months (median)
*Significance tests: Ch
median values (respoi ----
tego 12.
les ar ----
:ney l ----
rison c the dian values (responders vs. non-responders).
Percentages may not total 100 because of rounding.

median values (response to the control of the control of the Percentages may not total 100 because of round
NA - not applicable; ECOG - Eastern Cooperative NA - not applicable; ECOG - Eastern Cooperative Oncology Group performance scale; IMDC - International
Metastatic Renal-Cell Carcinoma Database Consortium; RECIST - Response Evaluation Criteria In Solid Tumours;
PFS - prog Netastatic Renal-Cell Carcinoma Database Consortium; RECIST - Response Evaluation Criteria In Solid Tum
Metastatic Renal-Cell Carcinoma Database Consortium; RECIST - Response Evaluation Criteria In Solid Tum
PFS - progress PFS - progression free survival; OS - overall survival
 \mathcal{L}^{max} - Recist - Recist - Recist of Tumours; Recist - Recist of Tumours; Recist - Recist of Tumours; Recist of Tumours; Recist of Tumours; Recist of Tumours; PFS - progression free survival; OS - overall survival

Supplemental Data Items

Supplemental Data Figure 1. Competition assay with anti-PD1 antibody (pembrolizumab). In vitro
assessment of activated PBMC demonstrates that PD-1 on T cells can be detected following pembrolizumab incubation using anti-human IgG4. (A) Incubation of activated PBMC with pembrolizumab blocks PD-1 flow cytometry staining (EH12.2 clone). (B) Pembrolizumab binding to PD-1 can be detected using an anti-IgG4 flow cytometry staining antibody. All dot plots are pre-gated on live single cells.

cytometry staining antibody. All dot plots are pre-gated on live single cells. Supplemental Data Hgure 2. Single-cell gene expression analysis of CD8 and IgG4 CD8 Supplemental Data Higgari RNAseq expression of Granzyme B, TCF7, TOX, HAVCR2 (TIM-3), CD38, ENTPD1(CD39) and PDCD1(PD-1) on (A) RNASeq expression of Granzyme B, TCF7, TOX, HAVCR2 (TIM-5), CD30, ENTED1(CD35) and PDCD1(PD-1) on (A)
CD8⁺ and (B) |gG4⁺CD8⁺ T-cells in ADR013 (responder) and ADR001 (non-responder) are shown. CD8 and (B) igG4 CD8
CD8

 T-cells in ADR013 (responder) and ADR001 (non-responder) are shown. Supplemental Data Table 1. Sample characteristics for: whole exome sequencing (including sequencing metrics, TMB, INDEL and neoantigen burden, purity and cancer cell fraction); RNA sequencing; TCR sequencing; and mIF/IHC.

 $\ddot{}$ Supplemental Data Table 2. Previously annotated HERV loci matched to custom repeat region annotations.
Previously annotated HERV loci from Mayer et al. and Vargui et al. and the matching loci from the custom repeat region annotation. The start and end buffer columns show the full region used for matching to the custom annotations, with 5 bases added or taken from the end or start of previously annotated loci positions
respectively. custom annotations, with 5 bases added or taken from the end or start of previously annotated loci positions.
respectively. respectively.

 $\ddot{\cdot}$ Supplemental Data Table 3. List of genes in T-cell specific expression signatures.

References

of Cancer, 2016. 115(9): p. 1147-1155.
3. Cole, W.H. and T.C. Everson, *Spontaneous regression of cancer: preliminary report.* Ann Surg, 1956.
144(3): p. 366-83.

4. Janiszewska, A.D., S. Poletajew, and A. Wasiutyński, Spontaneous regression of renal cell carcinoma.
Contemp Oncol (Pozn), 2013. 17(2): p. 123-7.

2. Carcinoma. Cell Rep, 2018. 23(1): p. 313-326 e5.

2. Smittenaar, C.R., et al., Cancer incidence and mortality projections in the UK until 2035. British Journal

of Cancer, 2016. 115(9): p. 1147-1155.

3. Cole, W.H. and 5. Show, R.M. and P.F. Schellhammer, Spontaneous regression of metastatic renal cell carcinoma.
Urology, 1982. **20**(2): p. 177-81.

Carcinoma. Cell Rep, 2018. 23(1). p. 313-326 e5.

2. Smittenaar, C.R., et al., Cancer incidence

of Cancer, 2016. 115(9): p. 1147-1155.

3. Cole, W.H. and T.C. Everson, Spontaneo.

144(3): p. 366-83.

4. Janiszewska, A.D., 2. Smittenaar, 2016. 115(9): p. 1147-1155.

2. Cole, W.H. and T.C. Everson, *Spontaneous regression of cancer: preliminary report.* Ann Surg, 1956.

144(3): p. 366-83.

4. Janiszewska, A.D., S. Poletajew, and A. Wasiutyńsk 3. Janiszewska, A.D., S. Poletajew, and A. Wasiutyński, Spontaneous regression of renal cell carcinoma

3. Janiszewska, A.D., S. Poletajew, and A. Wasiutyński, Spontaneous regression of renal cell carcinoma

3. Contemp Onc Example 1. January 1. J

5. Snow, R.M. and P.F. Schellhammer, *Spontaneous regression of metastatic renal cell carcinoma.*

Urology, 1 5. Show, 1982. 20(2): p. 177-81.

5. Klapper, J.A., et al., *High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma*
 retrospective analysis of response and survival in patients treated in the surger 6. Klapper, J.A., et al., High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a
retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer retrospective analysis of response and survival in patients treated in the surgery branch at the National Cance

Institute between 1986 and 2006. Cancer, 2008. 113(2): p. 293-301.

7. Rosenberg, S.A., et al., *Experience w*

2015. **373**(19): p. 1803-13.
9. Motzer, R.J., et al., *Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.* N
Engl J Med, 2018. **378**(14): p. 1277-1290.

retritute between 1986 and 2006. Cancer, 2008. 113(2): p. 293-301.

7. Rosenberg, S.A., et al., *Experience with the use of high-dose interleukin-2 in the treatment of 652*

cancer patients. Ann Surg, 1989. 210(4): p. 474-10. Xu, W., M.B. Atkins, and D.F. McDermott, Checkpoint inhibitor immunotherapy in kidney cancer.
Nature Reviews Urology, 2020. 17(3): p. 137-150.

Institute between 1986 and 2000: Cancer, 2000. 113(2): p. 293-301.

7. Rosenberg, S.A., et al., Experience with the use of high-dose

cancer patients. Ann Surg, 1989. 210(4): p. 474-84; discussion 484-5

8. Motzer, R.J., e 7. Rosenberg, S.A., 2010, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1920, 1

8. Motzer, R.J., et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med

2015. **3** cancer patients. Ann Surg, 1989. 210(4): p. 474-04, discussion 484-9.

8. Motzer, R.J., et al., *Nivolumab versus Everolimus in Advance*

2015. **373**(19): p. 1803-13.

9. Motzer, R.J., et al., *Nivolumab plus Ipilimumab ve* 8. Motzer, R.J., et al., *Nivolumab plus i pilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma*.

19. Motzer, R.J., et al., *Nivolumab plus i pilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.*

10. Xu, W 9. Motal, 2018. **378**(14): p. 1277-1290.

9. Mu, W., M.B. Atkins, and D.F. McDermott, *Checkpoint inhibitor immunotherapy in kidney cancer.*

Nature Reviews Urology, 2020. **17**(3): p. 137-150.

11. Albiges, L., et al., *Up* 11. Atkins, and Delta Carcinoma, 20. 17(3): p. 137-150.

11. Albiges, L., et al., Updated European Association of Urology Guidelines on Renal Cell Carcinoma:

11. Albiges, L., et al., Updated European Association of Urolog Nature Reviews Urology, 2020. 17(3): p. 137-150. 11. Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Carcinoma. Eur Urol, 2019. **76**(2): p. 151-156.

12. de Velasco, G., et al., Tumor Mutational Load and Immune Para

Carcinoma. Eur Urol, 2019. **76**(2): p. 151-156.

12. de Velasco, G., et al., *Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell*

Carcinoma Risk Groups. Cancer Immunol Res, 2016. 4(10): p. 820-822.

.
14. Sr

Journal of Medicine, 2014. **371**(23): p. 2189-2199.
15. Rizvi, N.A., et al., *Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade*
in non-small cell lung cancer. Science, 2015. **348**(623

Euremoma. Eur Olol, 2019. 76(2): p. 151-156.

12. de Velasco, G., et al., *Tumor Mutatiol*

Carcinoma Risk Groups. Cancer Immunol Res,

13. Alexandrov, L.B., et al., *Signatures of*

p. 415-21.

14. Snyder, A., et al., *Ge* 12. Alexandrov, L.B., et al., *Signatures of mutational processes in human cancer*. Nature, 2013. 500(746;

13. Alexandrov, L.B., et al., *Signatures of mutational processes in human cancer*. Nature, 2013. 500(746;

14. Sn Carcinoma Risk Groups. Cancer Immanor Res, 2010. 4(10): p. 820-822.

13. Alexandrov, L.B., et al., *Signatures of mutational processes in*.

14. Snyder, A., et al., *Genetic Basis for Clinical Response to CTLA-4*

14. Snyd 13. Alexandrov, L.B., et al., Signatures of mutational processes in numari cancer. Nature, 2013. 300(7463).

14. Sinyder, A., et al., *Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England*

14. S 14. Solution of Medicine, 2014. **371**(23): p. 2189-2199.

15. Rizvi, N.A., et al., *Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade

16. Hellmann, M.D., et al., Tumor Mutational Burden and E* 15. In the Indian of the Mathematical Burden in the S. A. (15. Relimann, M.D., et al., Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in
15. Hellmann, M.D., et al., Tumor Mutational Burden and Efficacy o in non-small cell lung cancer. Science, 2015. 348(6230): p. 124-6.
16. Hellmann, M.D., et al., Tumor Mutational Burden and Efj
Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer C
17. Aggen, D.H. and C.G. Drake,

11. Hellmann, M.D., Carly Californian Burden and Efficiency of Dynamical Monotherapy and in

16. Combination with lpilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 853-861.e4.

17. Aggen, D.H. and C.G. Dra Combination with ipinimumab in Small-Cell Lung Cancer. Cancer Cell, 2018. 33(5): p. 853-861.e4.
17. Aggen, D.H. and C.G. Drake, *Biomarkers for immunotherapy in bladder cancer: a moving*
Immunother Cancer, 2017. 5(1): p. 9 17. Aggen, D.H. and C.G. Drawing J. Andreas for interesting in bladder cancer, 2017. 5(1): p. 94. Immunother Cancer, 2017. 5(1): p. 94.

372(26): p. 2509-20.
19. Braun, D.A., et al., Interplay of somatic alterations and immune infiltration modulates response to PD-
1 blockade in advanced clear cell renal cell carcinoma. Nat Med, 2020. **26**(6): p. 90

19. Braun, D.A., et al., *Interplay of somatic alterations and immune infiltration modulates response*

19. Braun, D.A., et al., *Interplay of somatic alterations and immune infiltration modulates response*

1*blockade in* 19. McDermott, D.F., et al., *Clinical activity and molecular correlates of response to atezolizumab alone of*
19. a., interpretation with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med, 2018. **24**(6): p. 74 1 blockade in advanced clear cell rennal cell carcinioma. Net Wied, 2020. 26(6): p. 909-910.

20. McDermott, D.F., et al., *Clinical activity and molecular correlates of response to un*

21. Motzer, R.J., et al., *Avelumab*

20. McDermotter, D.F., et al., Avelumab versus sunitinib in renal cell carcinoma. Nat Med, 2018. 24(6): p. 749-757.
21. Motzer, R.J., et al., Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma:
22. Tu in combination with bevacizamab versus sumtimb in entirent central combine. Nat Niet, 2018. 24(6): p. 749-757.
21. Motzer, R.J., et al., Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma:
22. Turajli imptomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine, 2020.
22. Turajlic, S., et al., Insertion-and-deletion-derived tumour-specific neoantigens and the immur
phenotype: a pan-cancer analysis. Lance biomarcial analysis of the phase 3 Java Turajlic, S., et al., Insertion-and-deletion-derived tumour-specific neoantige
phenotype: a pan-cancer analysis. Lancet Oncol, 2017. **18(**8): p. 1009-1021.
23. Litchfield, K., et al.

phenotype: a pan-cancer analysis. Lancet Oncol, 2017. 18(6): p. 1009-1021.
23. Litchfield, K., et al., *Escape from nonsense-mediated decay associat*
immunogenicity. Nat Commun, 2020. 11(1): p. 3800.
24. Braun, D.A., et al immunogenicity. Nat Commun, 2020. 11(1): p. 3800.
24. Braun, D.A., et al., *Clinical Validation of PBRM1 Alterations as a Marker of Immune Che*
Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol, 2019.
25. Miao, D., et

22. Litchfield, K., et al., *Escape from nonsense-mediated decay associates with anti-tumor*

23. Litchfield, K., et al., *Escape from nonsense-mediated decay associates with anti-tumor*

22. Litchfield, K., et al., *Escap*

minimizogementy. Nat Community 2020. 11(1): p. 3800.

24. Braun, D.A., et al., *Clinical Validation of PBRI*

Inhibitor Response in Renal Cell Carcinoma. JAMA On

25. Miao, D., et al., *Genomic correlates of response arcin* 25. Miao, D., et al., *Genomic correlates of response to immune checkpoint therapies in clear cell relational*
26. Miao, D., et al., *Genomic correlates of response to immune checkpoint therapies in clear cell relations an* Valian, D., et al., *Genomic correlates of response to imm*

carcinoma. Science, 2018. **359**(6377): p. 801-806.

26. Abou Alaiwi, S., et al., *Mammalian SWI/SNF complex g*

blockade in solid tumors. Cancer Immunol Res, 202 carcinoma. Science, 2018. 335(6377): p. 801-806.
26. Abou Alaiwi, S., et al., *Mammalian SWI/S*
blockade in solid tumors. Cancer Immunol Res, 20.
27. Motzer, R.J., et al., *Molecular Subsets in H*
Angiogenesis Blockade. Ca 27. Motzer, R.J., et al., *Molecular Subsets in Rend*

Angiogenesis Blockade. Cancer Cell, 2020.

28. Rooney, M.S., et al., *Molecular and genetic p*

cytolytic activity. Cell, 2015. **160**(1-2): p. 48-61.

29. Fridman, W.H 27. Monometrical Cancer Cell, 2020.
28. Rooney, M.S., et al., *Molecular and genetic properties of tumors associated with local immune*
cytolytic activity. Cell, 2015. **160**(1-2): p. 48-61.
29. Fridman, W.H., et al., *The* Angle general exemption of the and cytolytic activity. Cell, 2015. **160**(1-2): p. 48
29. Fridman, W.H., et al., *The immune*
2017. **14**(12): p. 717-734.
30. Helmink, B.A., et al., *B cells and te*
Nature, 2020.
31. Miao, D

26. Moontage 2018. 359(6377): p. 801-806.
25. Abou Alaiwi, S., et al., *Mammalian SWI/SNF complex genomic alterations and immune checkpoint*
blockade in solid tumors. Cancer Immunol Res, 2020.
27. Motzer, R.J., et al., *Mo* 26. Aboutable in solid tumors. Cancer Immunol Res, 2020.

27. Motzer, R.J., et al., Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and

Angiogenesis Blockade. Cancer Cell, 2020.

28. Rooney, M.S., et al.

2017. **14**(12): p. 717-734.
30. Helmink, B.A., et al., *B cells and tertiary lymphoid structures promote immunotherapy response.*
Nature, 2020.

31. Miao, D., et al., *Genomic correlates of response to immune checkpoint blockade in microsatellite-*
stable solid tumors. Nature Genetics, 2018. **50**(9): p. 1271-1281.

28. Rooting, 198. Rooting, 198. 160(1-2): p. 48-61.
29. Rooting, Cell, 2015. 160(1-2): p. 48-61.
29. Rooting, W.H., et al., *The immune contexture in cancer prognosis and treatment*. Nat Rev Clin 1
2017. 14(12): p. 717-734 cytolytic activity. Cell, 2015. 160(1-2): p. 48-61.
2017. 14(12): p. 717-734.
30. Helmink, B.A., et al., *B cells and tertiary*
Nature, 2020.
31. Miao, D., et al., *Genomic correlates of istable solid tumors.* Nature Genet 2017. **14**(12): p. 717-734.

30. Helmink, B.A., et al., *B cells and tertiary lymphoid structures promote immunotherapy response.*

Nature, 2020.

21. Miao, D., et al., *Genomic correlates of response to immune checkpoint* 31. Miao, D., et al., *Genomic correlates of response to immune checkpoint blockade in microsatellite*
31. Miao, D., et al., *Genomic correlates of response to immune checkpoint blockade in microsatellite*
32. McGranahan,

2019. **179**(1): p. 219-235 e21.
34. Gerlinger, M., et al., *Genomic architecture and evolution of clear cell renal cell carcinomas defined by*
mu*ltiregion sequencing.* Nat Genet, 2014. **46**(3): p. 225-233.

32. McGranahan, N., et al., *Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immun*
checkpoint blockade. Science, 2016. **351**(6280): p. 1463-9.
33. Wolf, Y., et al., *UVB-Induced Tumor Heterogeneity Di* stable solid tumors. Nature Genetics, 2018. 30(9): p. 1271-1201.

32. McGranahan, N., et al., *Clonal neoantigens elicit T cell in*

checkpoint blockade. Science, 2016. **351**(6280): p. 1463-9.

33. Wolf, Y., et al., *UVB-I* checkpoint blockade. Science, 2016. **351**(6280): p. 1463-9.

33. Wolf, Y., et al., *UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.* Cell

2019. **179**(1): p. 219-235 e21.

34. Gerlinger, M., et al., checkpoint blockdate. Science, 2016. 351(0200): p. 1463-9.

33. Wolf, Y., et al., *UVB-Induced Tumor Heterogeneity*

2019. **179**(1): p. 219-235 e21.

34. Gerlinger, M., et al., *Genomic architecture and evaluating on seque* 33. Serlinger, M., et al., *Genomic architecture and evolution of clear cell renal cell carcinomas defined by*
33. Gerlinger, M., et al., *Genomic architecture and evolution of clear cell renal cell carcinomas defined by*
 multiregion sequencing. Nat Genet, 2014. **46**(3): p. 225-233.
35. Turajlic, S., et al., *Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx*
Renal. Cell, 2018. **173**(3): p. 595-610 e11.
36. Tur multiregion sequencing. Nat Genet, 2014. 46(3): p. 225-233.
35. Turajlic, S., et al., *Deterministic Evolutionary Traject*
Renal. Cell, 2018. **173**(3): p. 595-610 e11.
36. Turajlic, S., et al., *Tracking Cancer Evolution R*

35. Turajlic, S., et al., Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx
Renal. Cell, 2018. 173(3): p. 595-610 e11.
Renal. Cell, 2018. 173(3): p. 581-594 e12. Renal. Cell, 2018. 173(3). p. 333-610 e11.
36. Turajlic, S., et al., *Tracking Cance*
Renal. Cell, 2018. 173(3): p. 581-594 e12. 36. Turajlic, S., et al., Tracking Cancer Evolution Reveals Constrained Routes to Metastases: Tracking Reveals
Reveal. Cell, 2018. 173(3): p. 581-594 e12. Renal. Cell, 2018. 173(3): p. 581-594 e12.

37. Garcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multistudy. J Clin Oncol, 2009. 27(34): p. 5794-9.
38. McDermott, D.F., et al., Open-Label, Single-Arm, Phase II Study of carcinoma treated with a statem in the statem of the statem of the statem of the statem of the SRS.

38. McDermott, D.F., et al., *Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as*

First-Line Therapy study. J Clin Oncol, 2009. 27(34): p. 3734-9.

38. McDermott, D.F., et al., *Open-Labe*

First-Line Therapy in Patients With Advances

1002002365.

39. Riaz, N., et al., Tumor and Microen

2017. **171(**4): p. 934-949 e16.
 First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol, 2021: p.
1002002365.
39. Riaz, N., et al., Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cel
2017.

First-Line Therapy in Patition Advanced Non-Clear Cell Carcinomatic Patition (1000002365.

First, Rine, N., et al., Tumor and Microenvironment Evolution during immunotherapy with Nivolumab

2017. 171(4): p. 934-949 e16.

4 39. Riaz, N., et al., Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017. **171**(4): p. 934-949 e16.

39. 17. 171(4): p. 934-949 e16.

40. Gorelick, A.N., et al., *Phase and context shape the function of composite oncogenic mutations.* Nature

2020. **582**(7810): p. 100-103.

41. Birkeland, E., et al., *Patterns of genomic* 40. Gorelick, A.N., et al., *Phase and context shape the function of composite oncogenic mutations.* Nature, 2020. **582**(7810): p. 100-103.

41. Birkeland, E., et al., *Patterns of genomic evolution in advanced melanoma*. Nat Commun, 2018. **9**(1): p. 2665.

42. Sakamoto, H., et al., *The Evolutionary Origins of Recurrent Pancreatic Cancer*. Cancer Discov, 2020.
10(6): p. 792-805.

43. Sveen, A., et al., Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key
Determinant of Survival after Curative Liver Resection. PLoS Genet, 2016. 12(7): p. e1006225.

2020. **582**(7810): p. 100-103.

41. Birkeland, E., et al., *Patterns of genomic evolution in advanced melanoma*. Nat Commun, 2018. **9**(1):

p. 2665.

42. Sakamoto, H., et al., *The Evolutionary Origins of Recurrent Pancrea* 41. Birkeland, E., et al., *The Evolutionary Origins of Recurrent Pancreatic Cancer.* Cancer Discov, 2020.

10(6): p. 792-805.

10(6): p. 792-805.

43. Seven, A., et al., *Intra-patient Inter-metastatic Genetic Heterogenei* 10(6): p. 792-805.

43. Sveen, A., et al., *Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key*

Determinant of Survival after Curative Liver Resection. PLoS Genet, 2016. 12(7): p. e1006225. Determinant of Survival after Curative Liver Resection. PLoS Genet, 2016. 12(7): p. e1006225.

44. Sebagh, M., et al., Evidence of intermetastatic heterogeneity for pathological response and genetic

mutations within color Determinant of Survival after Curative Ever Resection. PLOS Genet, 2016. 12(7): p. e1000225.

44. Sebagh, M., et al., *Evidence of intermetastatic heterogeneity for pathological respons*

mutations within colorectal liver 44. Sebaga, M., et al., Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors. Oncompany 24. Altavilla, G., et al., Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors. Oncompany 2

2222 223
45. Clin

45. Kloor, M. and M. von Knebel Doeberitz, The Immune Biology of Microsatellite-Unstable Cand
46. Kloor, M. and M. von Knebel Doeberitz, The Immune Biology of Microsatellite-Unstable Cand
17 Trends Cancer, 2016. 2(3): p. 1 https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000089857.8.
46. Kloor, M. and M. von Knebel Doeberitz, The Immune Biology of Microsatellite-Unstable Cancer.
Trends Cancer, 2016. **2**(3): p. 121-133.

47. Doherty, P.C., The 1995 Albert Lasker Medical Research Award. The keys to cell-mediated immunity.
Jama, 1995. **274**(13): p. 1067-8.

mutations within colorectal liver metastases following presperative chemotherapy. Oncotarget, 2016. 7(16): p.
21591-600.
45. ClinVar; IVCV000089857.8]. National Center for Biotechnology Information; Available from:
https:/ 48. Altavilla, G., et al., *Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors.* Oncol
Rep, 2010. **24**(4): p. 927-32.

49. Zaretsky, J.M., et al., *Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.*
N Engl J Med, 2016. **375**(9): p. 819-29.

Trends Cancer, 2016. **2**(3): p. 121-133.
47. Doherty, P.C., *The 1995 Albert Lasker Medical Research Award. The keys to cell-mediated immulama, 1995. 274(13): p. 1067-8.
48. Altavilla, G., et al., <i>Microsatellite instabi* 93. Altavilla, G., et al., *Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors.* Onco

1997. 2010. 24(4): p. 927-32.

1997. 2010. 24(4): p. 927-32.

1998. Are al., *Mutations Associated with Acquired* 50. Panda, A., et al., Endogenous retrovirus expression is associated with response to immune checkpoint
blockade in clear cell renal cell carcinoma. JCI Insight, 2018. **3**(16).

19. Altar, Altar, G., 2012. 2013. 128(11): p. 4804-4820.

Altar, Altar, G., et al., Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

N Engl J Med, 2016. 375(9): p. 819-29.

Fanda, A., et al., En 49. The matrix of the state 51. Smith, C.C., et al., Endogenous retrovirul signatures predict immunotherapy response in clear cell renancell arcinoma. J Clin Invest, 2018. 128(11): p. 4804-4820.
52. Ficial, M., et al., Endogenous retrovirul signature blockade in clear cell rendi cell carcinoma. Scrimsight, 2016. 3(16).

51. Smith, C.C., et al., *Endogenous retroviral signatures predic*

cell carcinoma. J Clin Invest, 2018. **128**(11): p. 4804-4820.

52. Ficial, M., et a stell carcinoma. J Clin Invest, 2018. **128**(11): p. 4804-4820.

52. Ficial, M., et al., *Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as*
 Predictive Biomarkers for Response to Nivolumab in cen carcinoma. J Clin Invest, 2018. 128(11): p. 4804-4820.
52. Ficial, M., et al., *Expression of T-Cell Exhaustion M*
Predictive Biomarkers for Response to Nivolumab in Metas
Research, 2020.
53. Mayer, J., J. Blomberg, an Firedictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancel
Research, 2020.
53. Mayer, J., J. Blomberg, and R.L. Seal, *A revised nomenclature for transcribed human endog*

Premium Premiumate Johnsponse to Microbian and Metastatic Clear Cell Research, 2020.
Research, 2020.
53. Mayer, J., J. Blomberg, and R.L. Seal, *A revised nomenclature for transcribed human endogenous*
retroviral loci. Mob Research, 2020.
53. Mayer, J., J. Blomberg, and R.L. Seal, *A revised nomenclature for transcribed human endogenous*
retroviral loci. Mob DNA, 2011. **2**(1): p. 7. 53.7 May \sim J., J., J. Blomberg, and R.L. Seal, A revised normalized in the seal of transcribed human endogenous
retroviral loci. Mob DNA, 2011. 2(1): p. 7. retroviration. Wob DNA, 2011. $2(1)$: p. 7.

or common. Retrovirology, 2016. 13: p. 7.

55. Attig, J., et al., *Physiological and Pathological Transcriptional Activation of Endogenous Retroelements*

Assessed by RNA-Sequencing of B Lymphocytes. Front Microbiol, 2017.

are common. Retrovirology, 2010. 13: p. 7.

55. Attig, J., et al., *Physiological and Pc*

Assessed by RNA-Sequencing of B Lymphocy

56. Takahashi, Y., et al., *Regression of*

is associated with recognition of an HERV-E
 Assessed by RNA-Sequencing of B Lymphocytes. Front Microbiol, 2017. 8: p. 2489.
56. Takahashi, Y., et al., Regression of human kidney cancer following allogeneic stem cell transplantation
is associated with recognition of Assessed by NNA-Sequencing of B Lymphocytes. Front Microbiol, 2017. 8: p. 2489.

56. Takahashi, Y., et al., Regression of human kidney cancer following allogen

is associated with recognition of an HERV-E antigen by T cell is associated with recognition of an HERV-E antigen by T cells. J Clin Invest, 2008. **118**(3): p. 1099-109.

57. Attig, J., et al., LTR retroelement expansion of the human cancer transcriptome and

immunopeptidome revealed is associated with recognition by an HERV-E antigen by T cells. 3 Christiest, 2000. 118(3): p. 1035-103.

57. Attig, J., et al., LTR retroelement expansion of the human cancer transcriptome and

immunopeptidome revealed by 57. Immunopeptidome revealed by de novo transcript assembly. Genome Res, 2019. 29(10): p. 1

58. Danaher, P., et al., Gene expression markers of Tumor Infiltrating Leukocytes. J Imm

57. Dignon, J.C., et al., *irRECIST for* immunopeptidome revealed by de novo transcript assembly. Genome Res, 2019. 29(10): p. 1578-1590.

58. Danaher, P., et al., *Gene expression markers of Tumor Infiltrating Leukocytes.* J Immunother Ca

2017. 5: p. 18.

Pigno 58. Pignon, J.C., et al., *irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in*
59. Pignon, J.C., et al., *irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in*
59. Pi 2017. 5: p. 18.
59. Pignon, J.C., et al., irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in
Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinica Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res,
2019. 25(7): p. 2174-2184.
60. Newman, A.M., et al., Robust enumeration of cell subsets from tissue expression

2019. 25(7): p. 2174-2184.
60. Newman, A.M., et al., *Robust enumeration of cell subsets from tissue expression profiles.* Nat
Methods, 2015. 12(5): p. 453-7.

61. Joshi, K., et al., *Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape*
in lung cancer. Nat Med, 2019. **25**(10): p. 1549-1559.

1. Joshim Indian Matter, Spatial Heterogeneity of the mutational heterogeneity of the mutational heterogeneity

62. Zhang, A.W., et al., Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell,

61. 2018. **173**(7): p. 1755-1769.e22.
63. Angelova, M., et al., *Evolution of Metastases in Space and Time under Immune Selection. Cell, 2018.*
64. Dash, P., et al., Quantifiable predictive features define e

2019. 25(7): p. 2174-2184.

60. Newman, A.M., et al., *Robust enumeration of cell subsets from tissue expression profiles*. Nat

Methods, 2015. 12(5): p. 453-7.

10shi, K., et al., *Spatial heterogeneity of the T cell rece* Methods, 2015. 12(5): p. 453-7.

61. Shi, K., et al., *Spatial heterogeneity of the T cell receptor repertoire reflects the mutational lin*

in lung cancer. Nat Med, 2019. 25(10): p. 1549-1559.

62. Zhang, A.W., et al., *I* in lung cancer. Nat Wed, 2019. 25(10): p. 1545-1555.

62. Zhang, A.W., et al., Interfaces of Malignant a

2018. 173(7): p. 1755-1769.e22.

63. Angelova, M., et al., *Evolution of Metastases*

64. Dash, P., et al., *Quantif* 63. Angelova, M., et al., *Evolution of Metastases in Space and Time under Immune Selection.* Cell, 2018.
64. Dash, P., et al., *Quantifiable predictive features define epitope-specific T cell receptor repertoires.*
Nature Fact The Selection of Hernard Controller and the Selection of The Cell receptor repertoires.

Nature, 2017. 547(7661): p. 89-93.

65. Glanville, J., et al., *Identifying specificity groups in the T* cell receptor repertoir

Nature, 2017. 547(7661): p. 89-93.
65. Glanville, J., et al., *Identifying specificity groups in the T cell receptor repertoire.* Nature, 2017.
547(7661): p. 94-98.

Facture, 2017. 547(7661): p. 89-93.

65. Gianville, J., et al., *Identifying specificity groups in the T* cell receptor repertoire. Nature, 2017.

547(7661): p. 94-98.

66. Chang, J.T., E.J. Wherry, and A.W. Goldrath, *Mol* **547**(7661): p. 94-98.

66. Chang, J.T., E.J. Wherry, and A.W. Goldrath, *Molecular regulation of effector and memory Tce*
 differentiation. Nat Immunol, 2014. **15**(12): p. 1104-15.

67. Ghorani, E., et al., *The T cell* 66. Chang, J.T., E.J. Wherry, and A.W. Goldrath, *Molecular regulation of effector and memory T cell*
differentiation. Nat Immunol, 2014. **15**(12): p. 1104-15.

Nat Cancer, 2020. 1(5): p. 546-561.
68. Reading, J.L., et al., *The function and dysfunction of memory CD8(+)* T *cells in tumor immunity.*
Immunol Rev, 2018. 283(1): p. 194-212.

69. Sade-Feldman, M., et al., *Defining T Cell States Associated with Response to Checkpoint*
Immunotherapy in Melanoma. Cell, 2018. **175**(4): p. 998-1013 e20.

66. Chang, J.H., H. H. (1912): 19. 1104-15.
67. Chang, J.P., et al., *The Tcell differentiation landscape is shaped by tumour mutations in lung car*
Nat Cancer, 2020. 1(5): p. 546-561.
68. Reading, J.L., et al., *The funct* differentiation. Nat Immunol, 2014. 15(12): p. 1104-15.

67. Ghorani, E., et al., The Tcell differentiation land

Nat Cancer, 2020. 1(5): p. 546-561.

68. Reading, J.L., et al., The function and dysfunctic

Immunol Rev, 20 Finmunol Rev, 2018. **283**(1): p. 194-212.

69. Sade-Feldman, M., et al., *Defining TCell States Associated with Response to Checkpoint*

Immunotherapy in Melanoma. Cell, 2018. **175**(4): p. 998-1013 e20.

70. Miller, B.C., Frame Call, 2018. 175(4): p. 998-1013 e20.

70. Miller, B.C., et al., *Subsets of exhausted CD8(+)* T cells differentially mediate tumor contr

respond to checkpoint blockade. Nat Immunol, 2019. 20(3): p. 326-336.

71. Wan Immunotherapy in Melanoma. Cell, 2018. 175(4): p. 998-1013 e20.

70. Miller, B.C., et al., *Subsets of exhausted CD8(+) T cells diffe*

respond to checkpoint blockade. Nat Immunol, 2019. **20**(3): p. 326-3

71. Wang, Y., et

Fraction 1972. The Transmitted Manuteum of the Theory CD8(+) T cells in tumor immunity.

68. Reading, J.L., et al., The function and dysfunction of memory CD8(+) T cells in tumor immunity.

Immunol Rev, 2018. 283(1): p. 19 respond to checkpoint blockade. Nat Immunol, 2019. 20(3): p. 326-336.
71. Wang, Y., et al., *The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8*
During Chronic Viral Infection. Front Immunol, 20 respond to checkpoint blockdue. Nat Immunol, 2015. 20(3): p. 326-336.

71. Wang, Y., et al., The Transcription Factor TCF1 Preserves the Eff

During Chronic Viral Infection. Front Immunol, 2019. 10: p. 169.

72. Kallies,

72. Kallies, A., D. Zehn, and D.T. Utzschneider, *Precursor exhausted T cells: key to successful*
72. Kallies, A., D. Zehn, and D.T. Utzschneider, *Precursor exhausted T cells: key to successful*
7. Kallies, A., D. Zehn, a During Chronic Viral Injection. Front Immunol, 2019. **10.** p. 109.

72. Kallies, A., D. Zehn, and D.T. Utzschneider, *Precursor ex*
 immunotherapy? Nat Rev Immunol, 2020. **20**(2): p. 128-136. $\frac{1}{2}$. Kallies, A., D. Zehn, and D.T. December, Precursor exhausted T channels, Precursor exhausted T cells: key to successfully and D.T. Utamin and D.T. immunotherapy? Nat Rev Immunol, 2020. 20(2): p. 128-136.

2019. 5**71**(7764): p. 211-218.
74. Sekine, T., et al., *TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T*
cells. Sci Immunol, 2020. 5(49).

1991 2019. **571**(7764): p. 211-218.

74. Sekine, T., et al., *TOX is expressed by exhausted and polyfunctional human effector memory CD8(+)*

1991 cells. Sci Immunol, 2020. 5(49).

75. Yao, C., et al., *Single-cell RNA-seq*

19. Sci Immunol, 2020. 5(49).

75. Yao, C., et al., *Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic

infection. Nature Immunology, 2019. 20(7): p. 890-901.

76. Duhen, T., et al.,* 75. Yao, C., et al., *Single-ce*
 infection. Nature Immunology, 76. Duhen, T., et al., *Co-ex*,
 tumors. Nat Commun, 2018. 9(1

77. Simoni, Y., et al., *Bysta*
 infiltrates. Nature, 2018. 557(77

78. Im, S.J., et al. 1977. The Immunology, 2019. 2017): p. 890-901.

76. Duhen, T., et al., Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human sol.

198. Nat Commun, 2018. 9(1): p. 2724.

77. Simoni, Y., et al., *By*

2016. 537(7620): p. 417-421.
79. Scott, A.C., et al., *TOX is a critical regulator of tumour-specific T cell differentiation.* Nature, 2019.
71. Nature, 2019. 270-274.

infection. Nature Immunology, 2015. 20(7): p. 858-501.

76. Duhen, T., et al., *Co-expression of CD39 and CD*

tumors. Nat Commun, 2018. 9(1): p. 2724.

77. Simoni, Y., et al., *Bystander CD8(+) T cells are a*
 infiltrate tumors. Nat Commun, 2018. 9(1): p. 2724.

77. Simoni, Y., et al., *Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour*
 infiltrates. Nature, 2018. 557(7706): p. 575-579.

78. Im, S.J., et a 17. Simoni, Y., et al., *Bystander CD8(+*
 infiltrates. Nature, 2018. 557(7706): p. 575

78. Im, S.J., et al., *Defining CD8+ T cel.*

2016. 537(7620): p. 417-421.

79. Scott, A.C., et al., *TOX is a critical i*

571(776 17. Infiltrates. Nature, 2018. 557(7706): p. 575-579.

179. Im, S.J., et al., *Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.* Nature,

2016. 537(7620): p. 417-421.

30. Scott, A.C., et al., infiltrates. Nature, 2018. 357(7700). p. 375-579.

78. Im, S.J., et al., Defining CD8+ T cells that

2016. 537(7620): p. 417-421.

79. Scott, A.C., et al., TOX is a critical regula

571(7764): p. 270-274.

80. Brahmer, J.R 2016. 537(7620): p. 417-421.

79. Scott, A.C., et al., *TOX is a critical regulator of tumour-specific T cell differentiation*. Nature, 2019.

571(7764): p. 270-274.

80. Brahmer, J.R., et al., *Phase 1 study of single-age* 19. ST1(7764): p. 270-274.

19. Scotter, A.C., et al., *Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractional diamors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J C* 80. Brahmer, J.R., et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory
solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 2010. 80. Brahmer, J.R., et al., T.C. III invigoration to tumour burden ratio associated with anti-PD-1 response.
28(19): p. 3167-75.
81. Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1

28(19): p. 3167-75.
81. Huang, A.C., et al., *T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.*
Nature, 2017. 545(7652): p. 60-65.

solid tumors: safety, clinical activity, pharmacodynamics, and interactive correlation of activity 2013.

18. Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Nature, 201 82. Dong, H., et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and
interleukin-10 secretion. Nat Med, 1999. 5(12): p. 1365-9.

82. Dong, H., et al., *B-141, a third member of the B7 family, co-stimulates T-cell proliferation and*
1991. Bong, H., et al., *B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and*
1992. Barber, 82. Barber, D.L., et al., Restoring function in exhausted CD8 T cells during chronic viral infection. N
83. Barber, D.L., et al., Restoring function in exhausted CD8 T cells during chronic viral infection. N
84. Cherkasova merieukin-10 secretion. Nat Med, 1999. 3(12): p. 1369-9.

83. Barber, D.L., et al., *Restoring function in exhauste*

2006. **439**(7077): p. 682-7.

84. Cherkasova, E., et al., *Detection of an Immunogei*
 Clear Cell Kidne

2006. 439(7077): p. 682-7.
84. Cherkasova, E., et al., Detection of an Immunogenic HERV-E Envelope with Selective Expression in
Clear Cell Kidney Cancer. Cancer Res, 2016. 76(8): p. 2177-85.

Clear Cell Kidney Cancer. Cancer Res, 2016. **76**(8): p. 2177-85.

85. Powles, T., et al., Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable

urothelial carcinoma in the ABACUS trial. Nat Med,

2006. **439**(7077): p. 682-7.

84. Cherkasova, E., et al., *Detection of an Immunogenic HERV-E Envelope with Selective Expression in*
 Clear Cell Kidney Cancer. Cancer Res, 2016. **76**(8): p. 2177-85.

85. Powles, T., et a

2019. 5**76**(7787): p. 465-470.
87. Merritt, C.R., et al., *Multiplex digital spatial profiling of proteins and RNA in fixed tissue.* Nat
Biotechnol, 2020. **38**(5): p. 586-599.

88. Rodriques, S.G., et al., Slide-seq: A scalable technology for measuring genome-wide expression at high
spatial resolution. Science, 2019. **363**(6434): p. 1463-1467.

Earl Cell Kinney Cancer. Cancer Res, 2010. 76(6): p. 2177-05.

85. Powles, T., et al., *Clinical efficacy and biomarker anal*

urothelial carcinoma in the ABACUS trial. Nat Med, 2019. **25**(1

186. Iansen, C.S., et al., *An* 88. Institute of the ABACUS trial. Nat Med, 2019. 25(11): p. 1706-1714.
86. Insen, C.S., et al., An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature
2019. 576(7787): p. 465-470.
87. Merritt, C urothelial carcinoma in the ABACOS trial. Nat Med, 2015. 25(11): p. 1700-1714.

86. Jansen, C.S., et al., An intra-tumoral niche maintains and differentiates

2019. 576(7787): p. 465-470.

87. Merritt, C.R., et al., Multip 88. Marritt, C.R., et al., *Multiplex digital spatial profiling of proteins and RNA in fixed tissue.* Nat
Biotechnol, 2020. **38**(5): p. 586-599.
B3. Rodriques, S.G., et al., *Slide-seq: A scalable technology for measuring* Biotechnol, 2020. **38**(5): p. 586-599.

88. Rodriques, S.G., et al., *Slide-seq: A scalable technology for measuring genome-wide expressis*
 spatial resolution. Science, 2019. **363**(6434): p. 1463-1467.

89. Wong, Y.N.S. 88. Spatial resolution. Science, 2019. **363**(6434): p. 1463-1467.

89. Wong, Y.N.S., et al., *Evolving adoptive cellular therapies in urological malignancies*. Lancet Oncol,

2017. **18**(6): p. e341-e353.

90. Li, H. and R. spatial resolution. Science, 2019. 363(6434): p. 1463-1467.
89. Wong, Y.N.S., et al., *Evolving adoptive cellular ther*
2017. **18**(6): p. e341-e353.
90. Li, H. and R. Durbin, *Fast and accurate short read a*
Bioinformatics 2017. **18**(6): p. e341-e353.
90. Li, H. and R. Durbin, *Fast and accurate short read alignment with Burrows-Wheeler transform.*

89. Wong, Y.N.S., P. Wong, Y.N.S., Principal malignation in the presentation in urological malignancies. Lance
2017. 18(6): p. e341-e353.
Bioinformatics, 2009. 25(14): p. 1754-60.
Bioinformatics, 2009. 25(14): p. 1754-60. 90. Li, H. and R. D. Durante short read accurate short read alignment with Burrows-Wheeler transformation, 2009. 25(14): p. 1754-60. Bioinformatics, 2009. 25(14): p. 1754-60.

11(12): p. 2529-2548.
93. Koboldt, D.C., et al., *VarScan: variant detection in massively parallel sequencing of individual and*
pooled samples. Bioinformatics, 2009. **25**(17): p. 2283-5.

samples. Nat Biotechnol, 2013. 31(3): p. 213-9.
92. Fang, H., et al., *Indel variant analysis of short-read sequencing data with Scalpel.* Nat Protoc, 2016.
11(12): p. 2529-2548.
93. Koboldt, D.C., et al., *VarScan: varian* 11(12): p. 2529-2548.

93. Koboldt, D.C., et al., *VarScan: variant detection in massively parallel sequencing of individual and*

pooled samples. Bioinformatics, 2009. 25(17): p. 2283-5.

94. Wang, K., M. Li, and H. Hakon 93. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high
194. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high
194. Shukla, S.A.,

samples. Nat Biotechnol, 2013. 31(3). p. 213-9.

92. Fang, H., et al., *Indel variant analysis o*,

11(12): p. 2529-2548.

93. Koboldt, D.C., et al., *VarScan: variant d*
 pooled samples. Bioinformatics, 2009. 25(17): p
 pooled samples. Bioinformatics, 2009. 23(17): p. 2283-5.
94. Wang, K., M. Li, and H. Hakonarson, ANNOVAR:
throughput sequencing data. Nucleic Acids Res, 2010. **38**
95. Shukla, S.A., et al., Comprehensive analysis of ca
gen throughput sequenting data. Nucleic Acids Res, 2010. 36(16): p. e164.
95. Shukla, S.A., et al., *Comprehensive analysis of cancer-associat*.
96. Hoof, I., et al., *NetMHCpan*, *a method for MHC class I binding*
Immunogenet genes. Nat Biotechnol, 2015. 33(11): p. 1152-8.
96. Hoof, I., et al., NetMHCpan, a method J
Immunogenetics, 2008. 61(1): p. 1.
97. Andreatta, M. and M. Nielsen, *Gapped
application to the MHC class I system.* Bioinform
98.

97. Madreatta, M. and M. Nielsen, *Gapped sequence alignment using artificial neural network*
197. Andreatta, M. and M. Nielsen, *Gapped sequence alignment using artificial neural network*
199. Talevich, E., et al., *CNVki* Immunogenetics, 2008. **61**(1): p. 1.
97. Andreatta, M. and M. Nielsen, *Gapped sequence alignment using artificial neural networks:*
application to the MHC class I system. Bioinformatics, 2016. **32**(4): p. 511-7.

95. Shukla, S.A., et al., *Comprehensive analysis of cancer-associated somatic mutations in class | HLA*
9e*nes.* Nat Biotechnol, 2015. **33**(11): p. 1152-8.
96. Hoof, I., et al., *NetMHCpan, a method for MHC class | bindin* 99. Shukla, S.A., 199. S.A., 199.
96. Hoof, I., et al., *NetMHCpan, a method for MHC class I binding prediction beyond humans.*
1mmunogenetics, 2

application to the MHC class I system. Bioinformatics, 2016. **32**(4): p. 511-7.
98. Talevich, E., et al., CNVkit: Genome-Wide Copy Number Detection and Visualization from Tar
DNA Sequencing. PLoS Comput Biol, 2016. **12**(4) application to the MHC class I system. Biomioninatics, 2010. 32(4): p. 311-7.

98. Talevich, E., et al., CNVkit: Genome-Wide Copy Number Detection a.

90. Nilsen, G., et al., Copynumber: Efficient algorithms for single- an 98. Milsen, G., et al., Copynumber: Efficient algorithms for single- and multi-track copy number
99. Milsen, G., et al., Copynumber: Efficient algorithms for single- and multi-track copy number
99. Milsen, G., et al., Copy DNA Sequencing. PLoS Comput Biol, 2010. 12(4): p. e1004873.

99. Nilsen, G., et al., Copynumber: Efficient algorithms for

segmentation. BMC Genomics, 2012. 13: p. 591.

100. Beroukhim, R., et al., Patterns of gene express 99. Segmentation. BMC Genomics, 2012. 13: p. 591.

100. Beroukhim, R., et al., Patterns of gene expression and copy-number alterations in von-hippe

disease-associated and sporadic clear cell carcinoma of the kidney. Cance segmentation. BMC Genomics, 2012. 13: p. 591.
100. Beroukhim, R., et al., *Patterns of gene e.*
disease-associated and sporadic clear cell carcino
101. Olshen, A.B., et al., *Parent-specific copy*
segmentation. Bioinformat 100. Beroukhim, R., et al., *Patterns of the kidney.* Cancer Res, 2009. **69**(11): p. 4674-81.

101. Olshen, A.B., et al., *Parent-specific copy number in paired tumor-normal studies using circular binan*
 segmentation. B disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res, 2009. 69(11): p. 4674-61.

101. Olshen, A.B., et al., *Parent-specific copy number in paired tumor-normal studies using circular bin*
 segmen

101. Carter, S.L., et al., Absolute quantification of somatic DNA alterations in human cancer. Nat

102. Carter, S.L., et al., Absolute quantification of somatic DNA alterations in human cancer. Nat

103. Rosenthal, R., et segmentation. Biomomiaties, 2011. 27(15): p. 2050-46.

102. Carter, S.L., et al., *Absolute quantification of sor*

Biotechnol, 2012. **30**(5): p. 413-21.

103. Rosenthal, R., et al., *DeconstructSigs: delineatin*

DNA repa Biotechnol, 2012. **30**(5): p. 413-21.

103. Rosenthal, R., et al., *DeconstructSigs: delineating mutational processes in single tumors dist*

DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol, 2016. Biotechnol, 2012. **30**(5): p. 413-21.
103. Rosenthal, R., et al., *DeconstructSigs: delineating mutational processes in single tumors distinguishes*
DNA repair deficiencies and patterns of carcinoma evolution. Genome

103. Rosenthal, R., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. 29(1): p. 15-21.

104. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics, 2013. 29(1): p. 15-21.
 DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol, 2010. 17: p. 31.

104. Dobin, A., et al., STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013. 29

105. Li, B. and C.N. Dewey, RSEM: acc 104. Boom, A., et al., STAR: univigate universal RNA-seq aligner. Biomomialities, 2013. 2014. p. 13-21.
105. Li, B. and C.N. Dewey, *RSEM: accurate transcript quantification from RNA-Seq data with or witho*
106. Liao, Y., 1982. Liao, Y., G.K. Smyth, and W. Shi, featureCounts: an efficient general purpose program for assigning
106. Liao, Y., G.K. Smyth, and W. Shi, featureCounts: an efficient general purpose program for assigning
107. Linsle reference genome. BMC Biomic mattes, 2011. 12: p. 323.
106. Liao, Y., G.K. Smyth, and W. Shi, *featureCounts: a*
sequence reads to genomic features. Bioinformatics, 2014
107. Linsley, P.S., et al., *Copy number loss of the* sequence reads to genomic features. Bioinformatics, 2014. 30(7): p. 923-30.

107. Linsley, P.S., et al., Copy number loss of the interferon gene cluster in melanomas is linked to reduce

T cell infiltrate and poor patient sequence reads to genomic jequences. Biomotimatics, 2014. 30(7): p. 923-30.
107. Linsley, P.S., et al., Copy number loss of the interferon gene cluster if
T cell infiltrate and poor patient prognosis. PLoS One, 2014. 9(10) Teell infiltrate and poor patient prognosis. PLoS One, 2014. 9(10): p. e109760.
108. Kazachenka, A., et al., Epigenetic therapy of myelodysplastic syndromes connects to cellular
differentiation independently of endogenous Then infinities and poor patient prognosis. PLOS One, 2014. 9(10): p. e109760.
108. Kazachenka, A., et al., *Epigenetic therapy of myelodysplastic syndromialfferentiation independently of endogenous retroelement derepressi*

1112. *Kazachenka, A., et al., _Epigenetic therapy of myelodysplastic syndromes connected to change*
differentiation independently of endogenous retroelement derepression. Genome Med, 2019. 11(1):
109. Love, M.I., W. Hube differentiation independently of endogenous retroelement derepression. Genome Med, 2019. 11(1): p. 86.
109. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA*
data with DESeq2 1119. Love, M.I., d_{total} with DESeq2. Genome Biol, 2014. $\textbf{15}$ (12). p. 550.

567(7749): p. 479-485.
112. Best, K., et al., Computational analysis of stochastic heterogeneity in PCR amplification efficiency
revealed by single molecule barcoding. Sci Rep, 2015. 5: p. 14629.

application to immunological traits. Genome Med, 2016. 8(1): p. 129.

111. Rosenthal, R., et al., Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019.

567(7749): p. 479-485.

112. Best, K., et al., Co application to immunological traits. Genome wied, 2010. 6(1): p. 129.

111. Rosenthal, R., et al., *Neoantigen-directed immune escape in l.*

567(7749): p. 479-485.

112. Best, K., et al., *Computational analysis of stocha* 112. Best, K., et al., *Computational analysis of stochastic heterogeneity in PCR amplification efficiency*
112. Best, K., et al., *Computational analysis of stochastic heterogeneity in PCR amplification efficiency*
113. O 113. Best, T., et al., Quantitative Characterization of the T Cell Receptor Repertoire of Naïve and Mer
Subsets Using an Integrated Experimental and Computational Pipeline Which Is Robust, Economical, and
Versatile. Front revealed by single molecule barcoding. Sci Rep, 2015. 3: p. 14025.

113. Oakes, T., et al., Quantitative Characterization of the T Ce

Subsets Using an Integrated Experimental and Computational Pipe

Versatile. Front Immun Subsets Using an Integrated Experimental and Computational Pipeline Which Is Robust, Economical, and
Versatile. Front Immunol, 2017. 8: p. 1267.
114. Thomas, N., et al., Decombinator: a tool for fast, efficient gene assign

Subsets Using an Integrated Pressure Pressure Pressure International Person Versatile. Front Immunol, 2017. 8: p. 1267.

114. Thomas, N., et al., *Decombinator: a tool for fast, efficient gene assignment in T-cell receptor* versatile. Front Immunol, 2017. 8: p. 1267.

114. Thomas, N., et al., *Decombinator: c*

sequences using a finite state machine. Bioi

115. Uddin, I., et al., *Quantitative analy.*

465-492.

116. Barennes, P., et al., *Be* 115. Uddin, I., et al., *Quantitative analysis of the T cell receptor repertoire.* Methods Enzymol, 201465-492.
115. Uddin, I., et al., *Quantitative analysis of the T cell receptor repertoire*. Methods Enzymol, 201465-492

116. Barennes, P., et al., *Benchmarking of T cell receptor repertoire profiling methods reveals large*
systematic biases. Nature Biotechnology, 2020.

sequences using a finite state machine. Biomomiatics, 2013. 29(5): p. 542-50.
115. Uddin, I., et al., Quantitative analysis of the T cell receptor repertoire.
465-492.
116. Barennes, P., et al., Benchmarking of T cell rece 119. Uddin, I., et al., *Quantitative analysis of the T cell receptor repertoire. Wethods the Newton, 2013. 023: p.*
116. Barennes, P., et al., *Benchmarking of T cell receptor repertoire profiling methods reveals large*
s systematic biases. Nature Biotechnology, 2020.

117. Menard, L.C., et al., *Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Pos*

(*DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers. Front Immu* systematic biases. Processive Biotechnology, 2021

(DP) CD4+CD8+ T Cells With Expression of Exhau

118. Berntsson, J., et al., Prognostic impact

cancer. Int J Cancer, 2016. 139(5): p. 1129-39.

119. Kroeger, D.R., K. Miln 118. Berntsson, J., et al., *Proposic impact of tumour-infiltrating B cells and plasma cells in colorectal*
118. Berntsson, J., et al., *Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal*
118. (DP) CD4+CD8+ T Cells With Expression of Exhibition Markers. Front Immanol, 2010. 3: p. 2720.

118. Berntsson, J., et al., *Prognostic impact of tumour-infiltrating B cells and plasma cells in c*

2016. 22(12): p. R., K. M cancer. Int J Cancer, 2016. **139**(5): p. 1129-39.

119. Kroeger, D.R., K. Milne, and B.H. Nelson, *Tumor-Infiltrating Plasma Cells Are Associated with Tert.*

119. Kroeger, D.R., K. Milne, and B.H. Nelson, *Tumor-Infiltrat* cancer. Int J cancer, 2010. 139(9): p. 1129-59.
119. Kroeger, D.R., K. Milne, and B.H. Nelse
Lymphoid Structures, Cytolytic T-Cell Response
2016. 22(12): p. 3005-15.
120. Yeong, J., et al., High Densities of Turn
Negative 11982), The Mass Controller, The Happenses, and Superior Prognosis in Ovarian Cancer. Clin Cancer Res,
1916. 22(12): p. 3005-15.
120. Neong, J., et al., High Densities of Tumor-Associated Plasma Cells Predict Improved Prog

Example 2013): Program and Canadaguari and Canadaguari and Superior Program and Superior Programs in Trip Negative Breast Cancer. Front Immunol, 2018. 9: p. 1209.

120. Yeong, J., et al., *High Densities of Tumor-Associate* 2016. **22**(12): p. 3005-15.
120. Yeong, J., et al., High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple
Negative Breast Cancer. Front Immunol, 2018. **9**: p. 1209.

Negative Breast Cancer. Front Immunol, 2018. 9: p. 1209.

121. Marafioti, T., et al., Phenotype and genotype of interfollicular large B cells, a subpopulation of

120. Marafioti, T., et al., Comprehensive Integration of Si Negative Breast Cancer. From Immunol, 2010. 9: p. 1209.
121. Marafioti, T., et al., *Phenotype and genotype of ir*
lymphocytes often with dendritic morphology. Blood, 2003
122. Stuart, T., et al., *Comprehensive Integrat* 121. Martin 121. Marchines, presenting processes of the system and general marge B cells, parally phenotytes often with dendritic morphology. Blood, 2003. 102(8): p. 2868-76.

122. Stuart, T., et al., Comprehensive Integra gymphocytes often with dentantic morphology. Blood, 2003. 102(8): p. 2868-76.

122. Stuart, T., et al., *Comprehensive Integration of Single-Cell Data.* Cell, 20

123. Hafemeister, C. and R. Satija, *Normalization and var* 122. Stuart, T., et al., et al., and R. Satija, Normalization of Single-Cell Data. Cell, 2019. 177(7): p. 1888-1902.

123. Hafemeister, C. and R. Satija, Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol, 2019. 20(1): p. 296.

124. Schietinger, A., et al., Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiatio

Program Initiated Early during using regularized inegative binomial regression. Genome Biol, 2019. 20(1): p. 296.

124. Schietinger, A., et al., Tumor-Specific T Cell Dysfunction Is a Dynamic Anti

Program Initiated Early during Tumorigenesis. Immunity, Program Initiated Early during Tumorigenesis. Immunity, 2016. **45**(2): p. 389-401.
125. Thommen, D.S., et al., *A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with*
predictive potential in non-sma Program Initiated Early during Fumorigenesis. Immunity, 2010. 45(2): p. 383-401.
125. Thommen, D.S., et al., *A transcriptionally and functionally distinct PD-1* (*+*
predictive potential in non-small-cell lung cancer trea predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med, 2018. **24**(7): p. 994
1004.
126. Guo, X., et al., *Global characterization of T cells in non-small-cell lung cancer by single-cell seq*

predictive potential in non-small-cell lung cancer treated with PD-1 blockdae. Nat Med, 2018. 24(7): p. 994-
1004.
126. Guo, X., et al., *Global characterization of T cells in non-small-cell lung cancer by single-cell sequ* 1004.
126. Guo, X., et al., *Global cha*
Nat Med, 2018. **24**(7): p. 978-985.

126. Guo, 2018. 24(7): p. 978-985.

127. Li, H., et al., *Dysfunctional CD8 T Cells Form a Proliferative*, *Dynamically Regulated Compartment*

within Human Melanoma. Cell, 2019. **176**(4): p. 775-789 e18.

44 127. Li, H., et al., Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment
within Human Melanoma. Cell, 2019. **176**(4): p. 775-789 e18. 121. Li, H., Et al., Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Comparative
Within Human Melanoma. Cell, 2019. 176(4): p. 775-789 e18. within Human Melanoma. Cell, 2019. 176(4): p. 775-789 e18.

219. Zhou, X., et al., *Differentiation and persistence of memory CD8*(+) T cells depend on T cell factor 1.

Immunity, 2010. 33(2): p. 229-40.

130. Litchfield, K., et al., *Meta-analysis of tumor- and T cell-intrinsic me*

Immunity, 2010. **33**(2): p. 229-40.
130. Litchfield, K., et al., *Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to*
checkpoint inhibition. Cell, 2021. **184**(3): p. 596-614 e14.

129. 2010. 33(2): p. 229-40.

129. Immunity, 2010. 33(2): p. 229-40.

130. Litchfield, K., et al., Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to

checkpoint inhibition. Cell, 2021. 184(3): p. checkpoint inhibition. Cell, 2021. **184**(3): p. 596-614 e14.
131. Finak, G., et al., MAST: a flexible statistical framework for assessing transcriptional changes an
characterizing heterogeneity in single-cell RNA sequencin checkpoint inhibition. Cell, 2021. 184(3): p. 596-614 e14.
131. Finak, G., et al., MAST: a flexible statistical frame
characterizing heterogeneity in single-cell RNA sequencin
132. Borcherding, N., N.L. Bormann, and G. Kra

131. Financeterizing heterogeneity in single-cell RNA sequencing data. Genome Biol, 2015. **16**: p. 278.
Characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol, 2015. **16**: p. 278.
132. Borcherding, N. characterizing heterogeneity in single-certifiers agreemently data. Genome Biol, 2015. 16: p. 278.
132. Borcherding, N., N.L. Bormann, and G. Kraus, *scRepertoire: An R-based toolkit for single*
receptor analysis. F1000Res 132. Borcherding, N., N.L. Borcherding, and G. Kraus, screpertor analysis, F1000Res, 2020. 9: p. 47.
Teceptor analysis. F1000Res, 2020. 9: p. 47. receptor analysis. F1000Res, 2020. 9: p. 47.

Figure 1. Experimental workflow, patients and samples overview, and genomic characteristics of the ADAPTeR cohort

Tumour purity vs Transcript expression (TPM)

Figure 2. Expression of human endogenous viruses (HERVs) and LTR-overlapping transcripts in ccRCC according to tumour purity

Figure 3. GSEA and immune deconvolution by RNAseq shows higher levels of immune infiltration and activation in responders compared to non-responders under nivolumab

R Grzm and PD-1 Expression in Immune Subsets at Baseline **Grzm and PD-1** Ex

Grzm and PD-1 Expression in Immune Subsets on Treatment

C.

B.

Figure 4. Quantification and immunophenotyping of pre- and post-treatment infiltrating immune cells by IHC and mIF

Figure 5. TCR sequencing demonstrates maintained clonal expansion through persistent antigenic stimulation associate with nivolumab response

Figure 6. Flow cytometry-based analysis of ADR013 (responder) and ADR001 (non-responder) evaluating posttreatment total and nivolumab-bound CD8+ T-cells

Figure 7. Nivolumab binding correlates with upregulation of T-cell activation genes and clones expanded through persistent antigenic stimulation

Figure 8. Longitudinal profiling by bulk and single-cell RNA/TCRseq reveal dynamic immune correlates of response and resistance to nivolumab

